Autoimmune Pancreatitis by Buijs, J. (Jorie)
Autoimmune Pancreatitis
Novel Insights on Diagnosis, Treatment and Outcome
Jorie Buijs
COLOFON
© Jorie Buijs, The Netherlands, 2015
ISBN: 978-94-6182-621-3
All rights reserved. No parts of this thesis may be reproduced or transmitted in any form or by 
any means, without prior written permission of the author.
Layout and printing: Off Page, Amsterdam, The Netherlands
The work presented in this thesis was conducted at the department of Gastroenterology and
Hepatology, Erasmus MC University Medical Center Rotterdam, the Netherlands.
Financial support for printing this thesis was kindly given by:
Covidien B.V.; Dr. Falk Pharma Benelux B.V.; Olympus Nederland B.V.; Pentax Medical B.V.; 
Sysmex Nederland B.V.; Tramedico B.V.; Zambon Nederland B.V.; ERBE Nederland B.V.; 
Nederlandse Vereniging voor Gastroenterologie; Department of Gastroenterology and 
Hepatology, Erasmus University Medical Center Rotterdam; Erasmus University Rotterdam.
Autoimmune Pancreatitis 
Novel Insights on Diagnosis, Treatment and Outcome 
Autoimmuun pancreatitis 
Nieuwe inzichten in diagnose, behandeling en uitkomst 
Proefschrift 
ter verkrijging van de graad van doctor aan de 
Erasmus Universiteit Rotterdam 
op gezag van de 
rector magnificus 
prof.dr. H.A.P. Pols  
en volgens besluit van het College voor Promoties. 
De openbare verdediging zal plaatsvinden op  
woensdag 16 december 2015 om 15.30 uur 
Jorie Buijs 
geboren te Driehuizen, Schermer 
Autoimmune Pancreatitis
Novel Insights on Diag t and Outcome
ut i  i is
ieu e inzic te  i  ia se, e a eli  e  uitk st
Proefschrift
 ij ing va       
Erasmus Universiteit Rotterdam
op gezag van de
rector magnificus
prof.dr. H.A.P. Pols 
en volgens besluit van het College voor Promoties.
De openbare verdediging zal plaatsvinden op 
woensdag 16 december 2015 om 15.30 uur
door
Jorie Buijs
geboren te Driehuizen, Schermer
PrOmOTIeCOmmIssIe :
Promotor:  Prof.dr. m.J. Bruno
Overige leden: Prof.dr. C.H.J.van eijck
 Prof.dr. U.H.W. Beuers
 Prof.dr. P.m. van Hagen
Copromotoren: Dr. H.r. van Buuren
 Dr. D.L. Cahen
Paranimfen:  mara Buijs
 Vivian e. ekkelenkamp
5CONTeNTs
Chapter 1A Introduction 7
Chapter 1B Aims and outline of the thesis 19
Chapter 2 A comparative study of diagnostic scoring systems 
for autoimmune pancreatitis 25
Chapter 3 Serum level of Ca 19-9 increases ability of IgG4 test to distinguish patients  
with autoimmune pancreatitis from those with pancreatic carcinoma 39
Chapter 4 The value of elevated serum IgG4 and IgG4/IgG2 ratio in autoimmune,  
acute and chronic pancreatitis 53
Chapter 5 Testing for anti-PBP antibody is not useful in diagnosing 
autoimmune pancreatitis 67
Chapter 6 IgG4-related prostatitis: a case-control study focusing on clinical 
and pathologic characteristics 79
Chapter 7 Comparable efficacy of low- versus high-dose induction corticosteroid 
treatment in autoimmune pancreatitis 93
Chapter 8 The long-term impact of autoimmune pancreatitis on pancreatic function, 
quality of life, and life expectancy 109
Chapter 9 Summary and general discussion 125
Appendix Nederlandse samenvatting 137
List of co-authors 141
PhD portfolio 145
List of publications 149
Dankwoord 153
Curriculum vitae 157

AUTOImmUNe PANCreATITIs 
A reVIeW OF THe LITerATUre 
C H A P T E R  1 A
Jorie Buijs, Marianne J. van Heerde, 
Henk R. van Buuren, Marco J. Bruno, Djuna L. Cahen
Submitted

9INTRODUCTION
1INTrODUCTION
Autoimmune pancreatitis was first described in 19611. It was not before 1995 that Yoshida2 
introduced the term autoimmune pancreatitis (AIP) for this rare form of pancreatitis. In 2001, 
a milestone was reached, when Hamano3 discovered that serum IgG4 levels are elevated in AIP 
patients, providing a diagnostic marker to distinguish AIP from other pancreatobiliary disorders. 
Since then, this benign fibro-inflammatory disorder has been increasingly recognized4-6.
Clinically, AIP mimics pancreatic cancer, with painless obstructive jaundice and weight loss 
as most common symptoms. Unlike other types of pancreatitis, AIP responds dramatically to 
steroid therapy7,8. Therefore, a correct and timely diagnosis is of utmost importance, to provide 
proper treatment and avoid complications and unnecessary interventions. Despite a strikingly 
favorable treatment response, initially, relapses are common, and maintenance therapy may be 
necessary to control the disease9. 
AIP has two subtypes10,11. Type 1 represents the pancreatic manifestation of an IgG4-related 
systemic disease (IgG4-RD), which can involve several other organs, such as the biliary tree, 
kidneys, and salivary glands12. It is the most common form, associated with elevated levels of 
serum IgG4, and relapses are frequently observed. Type 2 is pancreas-specific, not associated 
with elevated serum IgG4, and rarely causes relapse13.
ePIDemIOLOGY 
Data on the incidence and prevalence of AIP are scarce and most studies originate from 
Japan14,15. There, a nationwide survey showed an overall prevalence of 2.2 per 100.000, with 
an annual incidence rate of 0.9/100.000. Worldwide, the distribution between type 1 and 2 AIP 
varies. In general, type 1 is more common, but this predominance is much more evident in Asia 
than in the USA or Europe16-18. Type 1 and 2 AIP have different demographics. Type 1 concerns 
mostly male patients, with a peak age of onset between 60 and 70 years15. Type 2 develops at a 
younger age (40, on average), and affects both sexes equally16.
PATHOGeNesIs
The pathogenesis of AIP is largely unknown. Although the presenting symptoms and response to 
therapy in type 1 and 2 AIP are similar, the two diseases have unique pancreatic histopathologic 
patterns, and, in contrast to type 2, type 1 AIP is part of a systemic disease. Therefore, despite 
their nomenclature, a distinct pathogenesis is suspected.
An immune mediated disorder was soon considered for both types, given the infiltration of 
plasma cells in the pancreas and the excellent response to steroid therapy. A likely mechanism 
in such disorders is that the disease develops in genetic susceptible persons after exposure to 
certain triggers. Different genetic associations have been reported for AIP, which suggest a 
genetic susceptibility for AIP19-23. Also, a relation with H.pylori infection was postulated, which 
assumes an autoimmune response via molecular mimicry in genetically predisposed persons25,26. 
However, these studies need confirmation. Because most causative studies focussed on the 
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more prevalent type 1 AIP, even less is known about the aetiology of type 2 AIP, which may be 
completely different.
A variety of autoantibodies have been demonstrated in sera of AIP patients, although, up to 
now, none appear to be disease specific24. For type 1 AIP and IgG4-RD, the role of IgG4 antibodies 
is still poorly understood. Whether elevated serum IgG4 is pathogenic or an innocent bystander 
of the inflammatory response remains unclear. Traditionally, IgG4 represents the least abundant 
subclass of IgG, typically less than 5% in healthy individuals. Although the normal value varies, 
it remains stable in healthy individuals27. IgG4 is regarded as a regulatory antibody, rather 
than fulfilling an inflammatory role. There are several other clinical conditions associated with 
elevated serum IgG4. In some, a protective effect is suggested, like maintenance of tolerance 
to cow’s milk in atopic individuals, and in patients who underwent bee-venom immunotherapy 
after severe anaphylactic reactions28,29. There is one clinical condition described, pemphigoid 
diseases, where a clear pathologic role of IgG4 is described, as an IgG4 antibody to the epithelial 
antigen desmoglein causes blister formation27.
HIsTOLOGY
When two distinct histological patterns were recognized, it became clear that AIP concerns 
different subtypes13,27. Type 1 is characterized by a lymphoplasmacytic sclerosing pancreatitis 
Figure 1. Histological features of IgG4-RD, showing 
(A) infiltration with IgG4-positive staining cells, 
(B) storiform fibrosis and (C) obliterative phlebitis.
A B
C
11
INTRODUCTION
1
(LPSP), which comprises of a combination of periductal lymphoplasmacytic infiltration, rich 
in IgG4, storiform fibrosis, and obliterative phlebitis (Figure 1). In type 2 AIP, an idiopathic 
duct-centric pancreatitis (IDCP) is recognized, with granulocyte epithelial lesions (GEL’s). 
Obliterative phlebitis is less common in this type and IgG4-positive cells are scarce or absent. 
DIAGNOsTIC CrITerIA
Establishing the diagnosis of AIP can be difficult, as a single diagnostic test is lacking. Instead, 
several diagnostic scoring systems are used to confirm the diagnosis. In 2006, the HISORt 
criteria were proposed by Chari et al., which are based on a combination of Histology, Imaging, 
Serology, Other organ involvement, and Response to therapy6. These criteria categorize 
patients in three groups, according to the diagnosis being based on; histology (group A); 
radiology, in combination with IgG4 positivity or other organ involvement (Group B); or 
unexplained pancreatic disease, IgG4 positivity, and a positive response to steroid therapy 
(Group C). Either typical histology or IgG4 positivity is mandatory to fulfil these criteria.
Next, the Asian criteria were introduced in 200828. Compared to the HISORt criteria, they 
are more straightforward, requiring either a histological confirmation or typical radiological 
findings. Unfortunately, either way, invasive procedures are generally needed to provide 
certainty. First, to establish a histological diagnosis by fine needle biopsy (FNB) can be difficult, 
due to patchy distribution of the disease throughout the pancreas. Second, to establish a 
radiological diagnosis, an invasive endoscopic retrograde cholangio-pancreatography (ERCP) 
is often required to detect the subtle pancreatic duct changes. 
Recently, an international panel of experts developed the International Consensus 
Diagnostic Criteria (ICDC)29. These criteria combine aspects of the HISORt and Asian criteria 
and categorize features as level 1 and 2 findings, to specify the level of evidence for a diagnosis 
of AIP. Furthermore, these criteria are the first to distinguish type 1 and type 2 AIP. 
For clinical practice, the HISORt criteria are the most feasible. However, it is not possible 
to diagnose a subgroup of IgG4-negative AIP patients, in which histology is lacking. The 
ICDC overcome this problem and are the only diagnostic criteria that distinguish the two AIP 
subtypes. However, the ICDC are complex and therefore less suitable for daily practice. Also, as 
the definition of type 2 AIP is based solely on histology, which is not always available, they can 
lead to under-recognition of type 2 disease. 
CLINICAL FeATUres
The clinical presentation of AIP is the same for both subtypes, with obstructive jaundice and 
weight loss as most common symptoms. Steatorrhea and diabetes mellitus are also frequently 
seen. Consequently, these patients are often wrongly suspected of having pancreatic cancer, 
resulting in invasive procedures or even major surgery30. For example, in 2% of patients 
who underwent a pancreatoduodenectomy for presumed pancreatic cancer, histology 
revealed AIP31. 
In type 1 AIP, other organs are involved in 45-52% of patients, including the biliary tract, 
salivary glands, and kidneys9,12,17. These manifestations show the same, characteristic infiltration 
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of IgG4-positive cells, leading to the term IgG4 related disease (IgG4-RD). Over the years, 
many new organ manifestations of IgG4-RD have been recognized. Although the pancreas and 
bile ducts are most commonly involved, the disease has been described in nearly every organ 
system. Other organ involvement can precede, present simultaneously, or follow the presence 
of pancreatitis. It may help establish the diagnosis of AIP, when these manifestations are more 
accessible for tissue collection. In type 2 AIP, other organs are rarely affected, but this type 
is associated with inflammatory bowel disease (IBD). The reported prevalence of IBD in these 
patients varies from 16 to 31%9,18,32.
DIAGNOsIs 
serology 
Up to now, elevated serum IgG4 (>140 mg/dL) is the best diagnostic marker for AIP, with a 
sensitivity of 76% and specificity of 93%33. However, generally, type 2 AIP patients do not present 
with an elevated serum IgG4, while 5-10% of patients with pancreatic cancer, acute or chronic 
pancreatitis do9,34. Therefore, serum IgG4 alone cannot be used to diagnose AIP. 
Several other autoantibodies have been reported in AIP patients, and are even 
incorporated in the Asian diagnostic criteria. However, the clinical applicability of these 
antibodies in AIP has not been confirmed. A validation study in a Western population 
did not prove any of these autoantibodies useful in diagnosing AIP35. Recently, an Italian 
group identified a novel serologic antibody for AIP. This antibody, against H.pylori 
associated plasminogen-binding protein, yields a sensitivity of 94% and specificity of 95%, 
when comparing AIP with pancreatic carcinoma26. These promising results call for urgent 
validation in large (multicentre) cohorts. 
Figure 2. CT-scan showing (A) a diffusely enlarged pancreas with characteristic rim enhancement before 
steroid therapy and (B) response after steroid therapy. 
A B
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Imaging
Imaging plays an important role in diagnosing AIP. To investigate the cause of obstructive 
jaundice, cross-sectional imaging is performed with computed tomography (CT) or magnetic 
resonance imaging (MRI). In the active phase of the disease, a diffusely enlarged pancreas is 
often found, sometimes with a characteristic rim enhancement36 (Figure 2A). Some AIP patients 
present with a pancreatic mass, which obviously makes it more difficult to distinguish AIP from 
pancreatic cancer37. Furthermore, in patients who present late in the course of the disease, 
especially after multiple undiagnosed relapses, pancreatic atrophy can be found.
Histology
The gold standard to diagnose AIP is pancreatic histology. Histology can be obtained through 
biopsy or surgery. In resection specimens, a reliable diagnosis can be easily made. But given the 
excellent medical treatment response, surgery is to be avoided in patients with AIP. Fine needle 
aspiration (FNA) is a sensitive method to diagnose pancreatic cancer38, but the diagnostic value 
for AIP is less good39. Due to the patchy distribution of characteristic histological features, 
negative results are difficult to interpret40. However, the technique of pancreatic tissue 
acquisition is evolving and experienced endoscopists have reported to achieve better results 
with endoscopic ultrasonography (EUS)-guided biopsy (FNB) 41,42. Therefore, future studies 
should determine the use of FNB in autoimmune pancreatitis.  
Tre ATmeNT
Induction of remission
The first therapeutic step in AIP is to induce clinical remission with steroids. Up to now, there 
is no consensus on the precise definition of clinical response. Objective outcome measures 
such as resolution of jaundice, biochemical improvement of liver function tests, and resolution 
of pancreatic or biliary duct strictures, or other pancreatic abnormalities on cross-sectional 
imaging, should be carefully monitored. Often, the first response is striking, with jaundice 
resolving in days. However, normalisation of liver enzymes values can take longer and bile duct 
strictures and other morphologic abnormalities may take several months to subside (Figure 2). 
Furthermore, elevated levels of IgG4 often decrease, but fail to normalise in the majority 
of patients8. 
Both type 1 and 2 patients show a nearly 100% response to steroid therapy8,16,18. Therefore, 
response to steroids is even used as a diagnostic tool to differentiate AIP from pancreatic 
cancer, and is incorporated in most diagnostic criteria6,28,43. A 2-week steroid trial can be useful, 
without negative consequences for resectable pancreatic cancer, but predefined response 
criteria should be strictly applied44. 
The optimal steroid dosage for remission induction has not been established, as prospective 
studies are lacking. The most advocated treatment schedule consists of prednisone in a 
dosage of 30 to 40 mg per day for 2-4 weeks, after which steroids are tapered and stopped in 
2-3 months8,16. Comparable outcomes were reported with 25 to 50 mg of prednisone, although 
these studies were not primarily aimed to evaluate dose-response relationships8,45-47. Reports on 
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corticosteroid induction doses lower than 15 mg/d are scarce. One case report even described 
successful treatment with a prednisolone dosage of 5 mg/d48. Future studies are needed to 
define the optimal treatment regimen.
relapses and maintenance therapy
Despite a successful initial treatment response in the vast majority of patients, 27 to 47% of 
patients with AIP develop a recurrence8,9,18. Relapses typically occur in the pancreas and/or bile 
ducts, but can also arise in other involved organs. Recurrences are more common in type 1 
AIP patients and in patients with a concomitant IgG4-associated sclerosing cholangitis9,18. 
Generally, relapses are treated with a second course of steroids, to which most patients again 
respond favourably. 
To prevent relapses, low-dose steroids can be used for maintenance. However, long-term 
steroid treatment may result in significant side effects, especially in the elderly. As an 
alternative, immunomodulators, such as azathioprine, can be prescribed. Conflicting results 
of azathioprine have been reported, from treatment-limiting side effects to successful use 
without serious complications18,49-52. Therefore, future studies are needed to establish the role 
of azathioprine in AIP. 
An argument against maintenance therapy in general is that, although relapses frequently 
occur, the majority of patients never develop a recurrence. Furthermore, most recurrences 
are easy to treat. Therefore, the drawbacks of maintenance therapy may out way it’s benefits. 
Perhaps, maintenance therapy will eventually prove valuable only in a subgroup of patients with 
an already established (or increased risk for) relapse. Recently, rituximab has been suggested as 
an alternative for patients with difficult-to-treat, relapsing AIP49. An open label trial in the USA 
is presently undertaken53. 
LONG-Term OUTCOme
Little is known about the long-term outcome of AIP patients. Although AIP does not seem to 
affect overall survival9, several long-term consequences have been suggested. As patients are 
often wrongly suspected of pancreatic cancer, resulting in invasive (diagnostic) procedures 
or even major surgery, it is possible that AIP has a negative long-term influence on quality 
of life. Furthermore, a delayed diagnosis may lead to pancreatic function loss, because 
prolonged inflammation causes fibrosis and pancreatic acinar and islet cell loss18,54. Another 
possible, late complication is the development of cancer. Other forms of pancreatitis are 
known to increase the risk for pancreatic cancer and the same association was reported for 
AIP55,56. Recently, it was also suggested that AIP leads to an increased risk for cancer of any 
origin57. Therefore, long-term outcome studies are needed to establish whether AIP patients 
are truly at risk. 
In conclusion, AIP is a rare type of chronic pancreatitis, clinically mimicking pancreatic 
cancer, with a dramatic response to medical therapy, ic. steroids. In the last decade, AIP has 
been increasingly recognized, but despite recent advancements, there are still considerable 
gaps in our knowledge regarding its etiology, treatment, and long-term outcome.
15
INTRODUCTION
1reFereNCes
1. Sarles H, Sarles JC, Muratore R, Guien C. Chronic inflammatory sclerosis of the pancreas--an 
autonomous pancreatic disease? Am J Dig Dis. Jul 1961;6:688-698.
2. Yoshida K, Toki F, Takeuchi T, Watanabe S, Shiratori K, Hayashi N. Chronic pancreatitis caused by 
an autoimmune abnormality. Proposal of the concept of autoimmune pancreatitis. Dig Dis Sci. Jul 
1995;40(7):1561-1568.
3. Hamano H, Kawa S, Horiuchi A, et al. High serum IgG4 concentrations in patients with sclerosing 
pancreatitis. N Engl J Med. Mar 8 2001;344(10):732-738.
4. Kim KP, Kim MH, Lee SS, Seo DW, Lee SK. Autoimmune pancreatitis: it may be a worldwide entity. 
Gastroenterology. Apr 2004;126(4):1214.
5. Kamisawa T, Okamoto A. Autoimmune pancreatitis: proposal of IgG4-related sclerosing disease. J 
Gastroenterol. Jul 2006;41(7):613-625.
6. Chari ST, Smyrk TC, Levy MJ, et al. Diagnosis of autoimmune pancreatitis: the Mayo Clinic experience. 
Clin Gastroenterol Hepatol. Aug 2006;4(8):1010-1016; quiz 1934.
7. Erkelens G, Vleggaar F, Lesterhuis W, van Buuren H, van der Werf S. Sclerosing pancreato-cholangitis 
responsive to steroid therapy. Lancet. 1999;354:43-44.
8. Kamisawa T, Shimosegawa T, Okazaki K, et al. Standard steroid treatment for autoimmune pancreatitis. 
Gut. Nov 2009;58(11):1504-1507.
9. Sah RP, Chari ST, Pannala R, et al. Differences in clinical profile and relapse rate of type 1 versus type 2 
autoimmune pancreatitis. Gastroenterology. Jul 2010;139(1):140-148; quiz e112-143.
10. Kamisawa T, Notohara K, Shimosegawa T. Two clinicopathologic subtypes of autoimmune pancreatitis: 
LPSP and IDCP. Gastroenterology. Jul 2010;139(1):22-25.
11. Chari ST, Kloeppel G, Zhang L, Notohara K, Lerch MM, Shimosegawa T. Histopathologic and 
clinical subtypes of autoimmune pancreatitis: the honolulu consensus document. Pancreatology. 
2010;10(6):664-672.
12. Stone JH, Zen Y, Deshpande V. IgG4-related disease. N Engl J Med. Feb 9 2012;366(6):539-551.
13. Sugumar A, Kloppel G, Chari ST. Autoimmune pancreatitis: pathologic subtypes and their implications 
for its diagnosis. Am J Gastroenterol. Sep 2009;104(9):2308-2310; quiz 2311.
14. Nishimori I, Tamakoshi A, Otsuki M, Research Committee on Intractable Diseases of the Pancreas 
MoHL, Welfare of J. Prevalence of autoimmune pancreatitis in Japan from a nationwide survey in 2002. 
J Gastroenterol. May 2007;42 Suppl 18:6-8.
15. Kanno A, Nishimori I, Masamune A, et al. Nationwide epidemiological survey of autoimmune 
pancreatitis in Japan. Pancreas. Aug 2012;41(6):835-839.
16. Hart PA, Kamisawa T, Brugge WR, et al. Long-term outcomes of autoimmune pancreatitis: a multicentre, 
international analysis. Gut. Dec 11 2013;62(12):1771-1776.
17. Kamisawa T, Chari ST, Giday SA, et al. Clinical profile of autoimmune pancreatitis and its histological 
subtypes: an international multicenter survey. Pancreas. Aug 2011;40(6):809-814.
18. Maire F, Le Baleur Y, Rebours V, et al. Outcome of patients with type 1 or 2 autoimmune pancreatitis. Am 
J Gastroenterol. Jan 2011;106(1):151-156.
19. Kawa S, Ota M, Yoshizawa K, et al. HLA DRB10405-DQB10401 haplotype is associated with autoimmune 
pancreatitis in the Japanese population. Gastroenterology. May 2002;122(5):1264-1269.
20. Umemura T, Ota M, Hamano H, Katsuyama Y, Kiyosawa K, Kawa S. Genetic association of Fc receptor-
like 3 polymorphisms with autoimmune pancreatitis in Japanese patients. Gut. Sep 2006;55(9):1367-
1368.
21. Park do H, Kim MH, Oh HB, et al. Substitution of aspartic acid at position 57 of the DQbeta1 affects 
relapse of autoimmune pancreatitis. Gastroenterology. Feb 2008;134(2):440-446.
22. Chang MC, Chang YT, Tien YW, et al. T-cell regulatory gene CTLA-4 polymorphism/haplotype 
association with autoimmune pancreatitis. Clin Chem. Sep 2007;53(9):1700-1705.
16
Chapter 1a
23. Umemura T, Ota M, Hamano H, et al. Association of autoimmune pancreatitis with cytotoxic 
T-lymphocyte antigen 4 gene polymorphisms in Japanese patients. Am J Gastroenterol. Mar 
2008;103(3):588-594.
24. Smyk D, Rigopoulou E, Koutsoumpas A, Kriese S, Burroughs A, Bogdanos D. Autoantibodies in 
autoimmune pancreatitis. Int J Rheumatol. 2012;940831:Epub 2012 Jul 2012.
25. Guarneri F, Guarneri C, Benvenga S. Helicobacter pylori and autoimmune pancreatitis: role of carbonic 
anhydrase via molecular mimicry? J Cell Mol Med. Jul-Sep 2005;9(3):741-744.
26. Frulloni L, Lunardi C, Simone R, et al. Identification of a novel antibody associated with autoimmune 
pancreatitis. N Engl J Med. Nov 26 2009;361(22):2135-2142.
27. Aalberse RC, Stapel SO, Schuurman J, Rispens T. Immunoglobulin G4: an odd antibody. Clin Exp Allergy. 
Apr 2009;39(4):469-477.
28. Ruiter B, Knol EF, van Neerven RJ, et al. Maintenance of tolerance to cow’s milk in atopic individuals is 
characterized by high levels of specific immunoglobulin G4. Clin Exp Allergy. Jul 2007;37(7):1103-1110.
29. Wyss M, Scheitlin T, Stadler BM, Wuthrich B. Immunotherapy with aluminum hydroxide adsorbed 
insect venom extracts (Alutard SQ): immunologic and clinical results of a prospective study over 3 
years. Allergy. Feb 1993;48(2):81-86.
30. Zhang L, Notohara K, Levy MJ, Chari ST, Smyrk TC. IgG4-positive plasma cell infiltration in the diagnosis 
of autoimmune pancreatitis. Mod Pathol. Jan 2007;20(1):23-28.
31. Otsuki M, Chung JB, Okazaki K, et al. Asian diagnostic criteria for autoimmune pancreatitis: consensus 
of the Japan-Korea symposium on autoimmune panceatitis. J Gastroenterol. 2008;43:403-408.
32. Shimosegawa T, Chari ST, Frulloni L, et al. International consensus diagnostic criteria for autoimmune 
pancreatitis: guidelines of the International Association of Pancreatology. Pancreas. Apr 2011;40(3):352-
358.
33. van Heerde M, Biermann K, Zondervan P, et al. Prevalence of autoimmune pancreatitis and other 
benign disorders in pancreatoduodenectomy for presumed malignancy of the pancreatic head. Dig 
Dis Sci. 2012; 57(9):2458-2465.
34. van Heerde MJ, Biermann K, Zondervan PE, et al. Prevalence of autoimmune pancreatitis and other 
benign disorders in pancreatoduodenectomy for presumed malignancy of the pancreatic head. Dig 
Dis Sci. Sep 2012;57(9):2458-2465.
35. Detlefsen S, Zamboni G, Frulloni L, et al. Clinical features and relapse rates after surgery in type 1 
autoimmune pancreatitis differ from type 2: a study of 114 surgically treated European patients. 
Pancreatology. May-Jun 2012;12(3):276-283.
36. Ghazale A, Chari S, Smyrk T, et al. Value of serum IgG4 in the diagnosis of autoimmune pancreatitis and 
in distinguishing it from pancreatic cancer. Am J Gastroenterol 2007;102:1646-1653.
37. Raina A, Krasinskas AM, Greer JB, et al. Serum immunoglobulin G fraction 4 levels in pancreatic cancer: 
elevations not associated with autoimmune pancreatitis. Arch Pathol Lab Med. Jan 2008;132(1):48-53.
38. van Heerde M B-JL, Batstra M et al. Diagnostic value of multiple (auto)antibodies and Ca 19.9 in 
discriminating between autoimmune pancreatitis, malignancy and other disorders. Gut. 2012;61 
(Suppl 3) A77.
39. Proctor RD, Rofe CJ, Bryant TJ, Hacking CN, Stedman B. Autoimmune pancreatitis: an illustrated guide 
to diagnosis. Clin Radiol. Apr 2013;68(4):422-432.
40. Finkelberg DL, Sahani D, Deshpande V, Brugge WR. Autoimmune pancreatitis. N Engl J Med. Dec 21 
2006;355(25):2670-2676.
41. Erickson RA, Sayage-Rabie L, Beissner RS. Factors predicting the number of EUS-guided fine-needle 
passes for diagnosis of pancreatic malignancies. Gastrointest Endosc. Feb 2000;51(2):184-190.
42. Holmes BJ, Hruban RH, Wolfgang CL, Ali SZ. Fine needle aspirate of autoimmune pancreatitis 
(lymphoplasmacytic sclerosing pancreatitis): cytomorphologic characteristics and clinical correlates. 
Acta Cytol. 2012;56(3):228-232.
43. Hirano K, Fukushima N, Tada M, et al. Diagnostic utility of biopsy specimens for autoimmune 
pancreatitis. J Gastroenterol. 2009;44(7):765-773.
17
INTRODUCTION
1
44. Mizuno N, Bhatia V, Hosoda W, et al. Histological diagnosis of autoimmune pancreatitis using EUS-
guided trucut biopsy: a comparison study with EUS-FNA. J Gastroenterol. 2009;44(7):742-750.
45. Chari ST, Takahashi N, Levy MJ, et al. A diagnostic strategy to distinguish autoimmune pancreatitis from 
pancreatic cancer. Clin Gastroenterol Hepatol. Oct 2009;7(10):1097-1103.
46. Shimosegawa T, Chari ST, Frulloni L, et al. International consensus diagnostic criteria for autoimmune 
pancreatitis, guidelines of the international association of pancreatology. Pancreas. 2011;40(3):352-
358.
47. Moon SH, Kim MH, Park DH, et al. Is a 2-week steroid trial after initial negative investigation for 
malignancy useful in differentiating autoimmune pancreatitis from pancreatic cancer? A prospective 
outcome study. Gut. Dec 2008;57(12):1704-1712.
48. Hirano K, Tada M, Isayama H, et al. Long-term prognosis of autoimmune pancreatitis with and without 
corticosteroid treatment. Gut. Dec 2007;56(12):1719-1724.
49. Kamisawa T, Okamoto A, Wakabayashi T, Watanabe H, Sawabu N. Appropriate steroid therapy for 
autoimmune pancreatitis based on long-term outcome. Scand J Gastroenterol. 2008;43(5):609-613.
50. Ito T, Nishimori I, Inoue N, et al. Treatment for autoimmune pancreatitis: consensus on the treatment 
for patients with autoimmune pancreatitis in Japan. J Gastroenterol. May 2007;42 Suppl 18:50-58.
51. Watanabe M, Yamaguchi K, Kobayashi K, et al. Autoimmune pancreatitis diagnosed after 
pancreatoduodenectomy and successfully treated with low-dose steroid. J Hepatobiliary Pancreat 
Surg. 2007;14(4):397-400.
52. Hart PA, Topazian MD, Witzig TE, et al. Treatment of relapsing autoimmune pancreatitis with 
immunomodulators and rituximab: the Mayo Clinic experience. Gut. Sep 16 2012.
53. Church NI, Pereira SP, Deheragoda MG, et al. Autoimmune pancreatitis: clinical and radiological features 
and objective response to steroid therapy in a UK series. Am J Gastroenterol. Nov 2007;102(11):2417-
2425.
54. Sandanayake NS, Church NI, Chapman MH, et al. Presentation and management of post-treatment 
relapse in autoimmune pancreatitis/immunoglobulin G4-associated cholangitis. Clin Gastroenterol 
Hepatol. Oct 2009;7(10):1089-1096.
55. Matsushita M, Ikeura T, Fukui T, Uchida K, Okazaki K. Refractory autoimmune pancreatitis: azathioprine 
or steroid pulse therapy? Am J Gastroenterol. Jul 2008;103(7):1834; author reply 1834-1835.
56. Kamisawa T, Chari ST, Lerch MM, Kim MH, Gress TM, Shimosegawa T. Recent advances in autoimmune 
pancreatitis: type 1 and type 2. Gut. Sep 2013;62(9):1373-1380.
57. Nishimori I, Tamakoshi A, Kawa S, et al. Influence of steroid therapy on the course of diabetes mellitus 
in patients with autoimmune pancreatitis: findings from a nationwide survey in Japan. Pancreas. Apr 
2006;32(3):244-248.
58. Bracci PM, Wang F, Hassan MM, Gupta S, Li D, Holly EA. Pancreatitis and pancreatic cancer in two large 
pooled case-control studies. Cancer Causes Control. Nov 2009;20(9):1723-1731.
59. Gupta R, Khosroshahi A, Shinagare S, et al. Does autoimmune pancreatitis increase the risk of pancreatic 
carcinoma?: a retrospective analysis of pancreatic resections. Pancreas. Apr 2013;42(3):506-510.
60. Shiokawa M, Kodama Y, Yoshimura K, et al. Risk of cancer in patients with autoimmune pancreatitis. Am 
J Gastroenterol. Apr 2013;108(4):610-617.

AIms AND OUTLINe OF THe THesIs
C H A P T E R  1 B

21
Aims And outline
1AIms
In the past decades, knowledge regarding autoimmune pancreatitis (AIP) has been rapidly 
evolving. However, much remains to be discovered about this intriguing form of pancreatitis. 
The general aim of this thesis is to study the diagnostic process, treatment, and outcome 
of AIP. For this purpose, information is subtracted from an AIP database registry, that was 
established by three tertiary referral centers (Rotterdam, Amsterdam, Utrecht), in cooperation 
with several other hospitals. We describe the characteristics of this multicenter national cohort 
and evaluate outcomes. 
OUTLINe
Establishing the diagnosis of AIP can be difficult, as a single diagnostic test is lacking. Over 
the years, several diagnostic scoring systems have been proposed, based on a combination 
of histology, imaging, serology, other organ involvement and response to therapy. In chapter 
2 we evaluate the performance of the three major diagnostic AIP scoring systems in our AIP 
cohort of 114 patients.
Due to the clinical presentation of AIP, with obstructive jaundice, weight loss and diabetes 
mellitus, patients are often wrongly suspected of having pancreatic cancer. This frequently 
results in invasive procedures or even major surgery. The tumor marker carbohydrate antigen 
19-9 (Ca 19-9) is associated with pancreatic carcinoma, as elevated serum IgG4 is with AIP. In 
chapter 3 we evaluate the diagnostic use of Ca 19-9 and serum IgG4 levels, in differentiating 
between AIP and pancreatic carcinoma. Furthermore, the two outcomes are combined, to 
potentially improve diagnostic performance. 
Up to now, elevated serum IgG4 (>140mg/dL) is the best diagnostic marker for AIP. However, 
particular caution is needed when interpreting mildly elevated levels of IgG4, since they are 
also encountered in other pancreatobiliary disorders. In Chapter 4, we compare serum IgG4 
levels of patients with acute, chronic, and autoimmune pancreatitis, to assess the diagnostic 
value in differentiating between these three forms of pancreatitis. 
In 2009, an Italian group identified a novel serologic marker for AIP, with an outstanding 
sensitivity and specificity. The promising results of this marker, anti-PBP antibodies, have never 
been confirmed. In chapter 5 we aim to validate the usefulness of this novel marker in AIP and 
various other pancreatobiliary diseases. 
IgG4-related disease is a systemic disease and its manifestations have been described in 
nearly every organ system. Although the pancreas and bile ducts are most commonly involved, 
precise history taking is important to detect manifestations in other organs. In chapter 6 we 
describe the occurrence and histopathological characteristics of IgG4-related prostatitis in our 
cohort of AIP patients. 
The first therapeutic step in AIP is to induce clinical remission with steroids. Often, the first 
response is striking, with jaundice resolving in days. The optimal steroid dosage for remission 
induction has not been established, as prospective studies are lacking. Currently, a dosage of 
30-40 mg per day is commonly used, although a lower dose would potentially reduce side-
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effects. In chapter 7, we compare the efficacy of a high versus a low prednisone dose to induce 
disease remission. 
Little is known about the long-term outcome of AIP patients. A delayed diagnosis may 
lead to pancreatic function loss, and like chronic pancreatitis, pancreatic cancer may be a late 
complication. The influence of AIP on quality of life is unknown and whether AIP affects survival 
remains unclear. In chapter 8 we investigate the long-term impact of AIP, in terms of treatment 
response, pancreatic function, quality of life, incidence of malignancies, and mortality.
Finally, in chapter 9, we summarize and discuss the main findings of this thesis. In addition, 
we present directions for further research.
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ABsTrACT
Objective
Several diagnostic scoring systems for autoimmune pancreatitis (AIP) have been proposed 
including the Asian, HISORt (Histology, Imaging, Serology, Other organ involvement and 
Response to therapy) and International Consensus Diagnostic Criteria (ICDC), which have 
been compared by a few studies. We evaluated the diagnostic performance of these criteria in 
patients diagnosed with AIP between May 1992 and August 2011. 
methods
Scoring systems were applied retrospectively using data obtained in the initial evaluation 
period, before pancreatic resection was performed. 
results
114 cases with AIP were included. 82% met the diagnostic criteria for AIP according to either the 
Asian, HISORt or ICDC criteria. Only 33% met the Asian criteria, probably mainly related to a low 
rate of diagnostic pancreatography. In 18% all scoring systems failed to confirm the diagnosis, 
even though these patients were considered to have a firm diagnosis of AIP. 
Conclusions
In this cohort of AIP patients, the three major diagnostic scoring systems for AIP proved to be 
complementary rather than overlapping. Our data indicate that one-fifth of our AIP patients 
do not meet any of these scoring systems. The ICDC, Asian and HISORt criteria should be 
considered as useful clinical tools but not as gold standard for the diagnosis.
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INTrODUCTION
Autoimmune pancreatitis represents the pancreatic manifestation of IgG4-related sclerosing 
disease that may affect not only the pancreas but also other organs including the extrapancreatic 
biliary tract, salivary glands, retroperitoneal tissues, and kidneys1. Since AIP often presents in 
men in their 6th or 7th decade, with jaundice, weight loss and a pancreatic mass, the differential 
diagnosis is focused mainly on malignancy. Recently, the Honolulu consensus meeting agreed 
on the presence of two distinct histological and clinical types of AIP: lymphoplasmacytic 
sclerosing pancreatitis (LPSP) / type 1 and idiopathic duct-centric pancreatitis (IDCP) / type 22-4. 
Whereas type 1 represents the classical phenotype as described above, type 2 patients present 
younger (4th decade), without male preponderance. Abdominal pain and acute pancreatitis 
are observed more often. IgG4 elevation is rarely observed. Inflammatory bowel disease 
is often associated, other organ manifestations are rare. Response to steroids is good, with 
less recurrence (40-50% in type 1, 0-25% in type 2) 1,3-6. The histological hallmark of type 2 is 
destruction of ductal epithelium by GELs (granulocyte epithelial lesions). Fibrosis is less 
common and IgG4 positive cells are scant or absent. Since there is no serological marker and 
other organ involvement (OOI) is uncommon, the autoimmune nature of AIP type 2 is a matter 
of debate2.
There is no single diagnostic test to diagnose AIP, but diagnosis can be confirmed using 
diagnostic scores combining radiological (diffuse or focal enlargement, occasionally with rim 
enhancement, diffuse or segmental narrowing of the main pancreatic duct), histological (LPSP 
and IgG4 staining in type 1 AIP, GELs in type 2 AIP), serological (IgG4, IgG and the presence of 
autoantibodies) and other criteria such as involvement of other organs (sclerosing cholangitis, 
interstitial nephritis, retroperitoneal fibrosis or Sjögren-like syndrome) and response to steroid 
therapy7-9. The Asian criteria (2008)8 and HISORt criteria (acronym for Histology, Imaging, 
Serology, Other organ involvement and Response to therapy, Mayo Clinic, 20067, revised in 
200910) are used most frequently. The Asian criteria are relatively easy to apply but require 
diagnostic pancreatography. Diagnosis is made in combination with either serology, histology 
or response to therapy. The HISORt criteria, categorizing patients in three groups, enable 
diagnosis solely based on histology, which gives special significance to pancreatic core biopsy 
(group A). Other ways to make diagnosis are: radiology in combination with IgG4 positivity 
or other -histologically proven - OOI (group B), and unexplained pancreatic disease, IgG4 
positivity and response to therapy (group C). In group B and C, IgG4 positivity is mandatory. 
Recently, the ICDC were developed, based on aforementioned systems in combination with 
proposed Italian6 and German criteria11. 
For use in daily clinical practice, these systems harbor their own pros and cons. The Asian 
criteria are easy and straightforward to use but a pancreatogram is always required. This 
contrasts with common European and American gastroenterology practice in which in case of 
suspected pancreatic cancer, early surgery is preferred over endoscopic retrograde cholangio-
pancreatography (ERCP) / biliary drainage12. Moreover, to avoid post-ERCP pancreatitis, 
gastroenterologists usually do not attempt to deliberately cannulate and fill the pancreatic 
duct13. A non-invasive modality such as magnetic resonance cholangio-pancreatography 
(MRCP) is still inferior to ERCP in detecting the subtle ductal changes in AIP14. HISORt criteria 
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are somewhat more complicated but quite elegant, enabling a diagnosis of AIP from different 
angles. The ICDC are very elaborate. They encompass all kinds of difficult diagnostic situations 
which might improve sensitivity, but consequently complicate its application. This renders 
ICDC unsuitable for use in routine daily practice. The use of histology based criteria, part of 
all systems, poses some limitations and challenges. Histology obtained with resection is 
considered gold standard, but actually represents failure of the system to timely diagnose 
AIP, that is before resection. Histology obtained with endoscopic ultrasonography (EUS) 
core biopsy, although very attractive in expert hands15,16, is limited by sampling error, is not 
routinely available in daily gastroenterology practice and requires a pathologist familiar with 
the diagnosis and IgG4 staining.
For these reasons we aimed to investigate the diagnostic performance of all three scoring 
systems, using the data on initial clinical presentation, with emphasis on preoperative data.  
mATerIAL s AND meTHODs
Patients diagnosed with AIP between May 1992 and August 2011 were enrolled in this 
multicentre retrospective study. They were included if the ICDC, Asian or HISORt criteria were 
fulfilled. In addition, patients were eligible when (1) post-surgery pancreatic histology allowed 
an unequivocal diagnosis of AIP or when otherwise unexplained pancreato-biliary disease or 
extrapancreatic manifestations were diagnosed in combination with either (2) response to 
steroids or (3) IgG4-positive serology. Clinical data, laboratory and imaging findings, histology, 
response to treatment, and recurrence were studied to characterize the patient population. 
The radiological data were reviewed by a radiologist, expert pancreatologist and research fellow 
independently.  In case of disagreement, cases were reviewed by the entire panel. Histological 
evaluation was performed by two expert pathologists familiar with IgG4 staining and specialized 
in hepatic, pancreatic and biliary pathology. If not performed already, immunostaining was 
performed using a monoclonal mouse anti-human IgG4 (Zymed Laboratories, San Francisco, 
USA), with a working dilution of 1:100. IgG4 positivity was defined as the presence of >10 IgG4-
positive plasma cells in at least one HPF at a magnification of x400. Response to treatment was 
defined as resolution or marked (>50%) improvement of radiological, clinical and biochemical 
abnormalities, recurrence as reappearance of disease manifestations. Scoring systems were 
applied using data obtained during the initial evaluation period of six months. The onset of 
the initial evaluation period was defined as the presentation with major symptoms such as 
obstructive jaundice or overt pancreatic disease, prompting particular diagnostic activity. 
The clinical course of AIP may be protracted and highly variable, which may cause substantial 
diagnostic delay. Pancreatic resection because of presumed malignancy, although sometimes 
unavoidable, represents failure of timely diagnosis. None of the patients that underwent 
resection were operated later than six months after onset of jaundice or overt pancreatic 
disease. Therefore, data were used which were obtained during an initial evaluation period of 
six months, or until resection was performed.
One sample student t test and Fisher’s exact test were used to compare differences in 
means or frequencies. A two-sided p-value ≤ 0.05 was considered statistically significant.
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medical ethical concerns 
The study was approved by the institutional review board of the Erasmus University Medical 
Center, Rotterdam, the Netherlands.
resULTs
Patient characteristics and clinical presentation
A total of 114 patients were included (Table 1). The median age was 62 (IQR 51-69) years, 
99/114 (87%) were men. Females were diagnosed at a younger age than men (57, IQR 39-67 
years, p < 0.001). Obstructive jaundice and signs of pancreatic exocrine insufficiency 
(weight loss and steatorrhea) were the most frequent presenting symptoms, followed by 
abdominal pain (usually mild discomfort) and recent onset diabetes (six months prior to 
diagnosis). 
Other organ involvement (OOI) was present in two-thirds (78/114, 68%) of the patients. 
In two-thirds (52/78, 67%) of these patients one organ was affected, in one-third (26/78, 
33%), multiple systems were involved. Usually, OOI coincides with or follows the pancreatic 
manifestation (34/78, 44%; 30/78, 38% respectively). In 18% (14/78) however, OOI was heralding 
AIP. Sclerosing cholangitis (65/105, 62% of all recorded OOI), was by far the most frequent 
extrapancreatic manifestation, followed by salivary gland involvement (Sjögren like syndrome, 
9/105, 9%), retroperitoneal fibrosis (10/105, 10%), interstitial nephritis (5/105, 5%), localized 
or generalized lymphadenopathy (6/105, 6%), prostatitis (5/105, 5%), pulmonary involvement 
(4/105, 4%) and uveitis (1/105, 1%). 
Elevated IgG4 (>1.40 g/L) was present in 82% (85/104). Levels above 2.8 g/L, which 
is the recommended level to discriminate between AIP and pancreatic cancer10,17, were 
present in 60% (62/104). The tumor marker Ca 19-9 was elevated (>34 U/ml) in 58% (42/72). 
Levels above 300  U/ml, considered specific for pancreatic cancer10,18, were present in 18% 
(13/72). Autoantibodies (antinuclear antibody, rheumatoid factor, pANCA, anti lactoferrin or 
anticarbonic anhydrase II) were found in less than one-third of patients.  
radiological findings
Radiological findings at initial clinical presentation are shown in Table 2. On computed tomogram 
(CT), diffuse swelling of the pancreas was present in 56% (63/113), focal enlargement in 33% 
(37/113), of which 30% (34/113) in the head and  3% (3/113) in the tail. In 25% (28/113) there was no 
enlargement. Rim enhancement, an important criterion in the HISORt system, was present in 
24% (26/107). In 24% (27/113) regional adenopathy was noted, which could be misinterpreted as 
lymphatic metastases. In 24 patients (21%), abdominal CT showed no pancreatic abnormalities. 
Pancreatography (ERCP or MRCP) was performed in half of the patients (58/114, 51%). Diffuse 
stricturing of the main pancreatic duct was present in 66% (38/58), a segmental stricture in 
17% (10/58). Ten percent (6/58) showed a normal pancreatogram. Biliary strictures were very 
common, mostly strictures of the intrapancreatic part of the common bile duct (84/97, 87%). 
Proximal biliary strictures (proximal hepatocholedochal, hilar or intrahepatic) were present in 
34% (33/97). 
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Table 1. Baseline characteristics (Continued)
Patients
n = 114
Percentage 
%
Demographic findings
Male gender 99/114 87
Age, median (IQR), y* 62 (51-69)
    Male 62 (53-70)
    Female 75 (39-67)
Presenting symptoms
Obstructive jaundice 87/114 76
Abdominal pain 61/114 54
Weight loss 98/111 88
DM recent onset 40/113 35
Steatorrhea 77/103 75
Serological findings
IgG >18.0 g/L 38/103 37
IgG4 Median (IQR) g/L 5.01 (1.73-9.55)
Normal < 1.40 g/L 19/104 18
>1.40 g/L 85/104 82
>2.80 g/L 62/104 60
Ca 19.9 >34 U/ml 42/72 58
>100 U/ml 27/72 38
>300 U/ml 13/72 18
Rheumatoid factor + 11/39 28
Antinuclear antibody + 22/71 31
Other antibody ∆ 8/64 13
Other organ involvement
Presence None, n (%) 36/114 32
Single, n (%) 52/114 46
Multiple, n (%) 26/114 23
Timing ¥ Preceding, n (%) 14/78 18
Same time, n (%) 34/78 44
Later, n (%) 30/78 38
Prior treatment
Resection 18/114 16
Exploratory surgery † 16/114 14
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Table 1. Baseline characteristics (Continued)
Patients
n = 114
Percentage 
%
Biliodigestive anastomosis 2/114 2
Liver-kidney transplantation 1/114 1
Chemoradiation 1/114 1
Diagnostic delay 
median (IQR), months‡ 4.3 (2.0-18.8)
*Age at time of initial symptoms; ∆ pANCA, ALF or ACA-II; ¥with respect to  onset of  jaundice or overt pancreatic 
disease; †explorative laparotomy, diagnostic  laparoscopy; ‡time between date diagnosis and date symptoms
Table 2. CT and MRCP/ERCP findings of AIP
Patients 
n =114
Percentage 
%
CT
Swelling of the pancreas:
Diffuse 63/113 56
Segmental (head) 34/113 30
Segmental (body) 0/113 0
Segmental (tail) 3/113 3
No enlargement 28/113 25
Rim enhancement 26/107 24
Pancreatic atrophy 6/113 5
Pseudocyst 2/113 2
Calcifications 1/113 1
Regional adenopathy 27/113 24
erCP/mrCP
Pancreatic duct:
Normal 6/58 10
Stricture diffuse 38/58 66
Stricture segmental 10/58 17
Biliary ducts:
Normal 3/97 3
Stricture intrapancreatic 84/97 87
Proximal (extrapancr) strictures 33/97 34
Combined strictures 20/97 21
CT: computed tomogram; ERCP: endoscopic retrograde cholangio-pancreatography; MRCP: magnetic 
resonance cholangio-pancreatography
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Histopathological findings 
Histology was available in 35/114 patients (31%), mainly from resection specimens (17/114, 15%) 
and exploratory surgery biopsy (11/114, 10%). A diagnosis of AIP was histologically confirmed 
in all of them. In only 7/114 patients (6%) EUS fine needle biopsy (FNB) had been performed 
with lymphoplasmacytic sclerosing pancreatitis (LPSP) present in four and IgG4 positivity in 
two. FNB contributed to diagnosis in only one patient. AIP type 2 (reflected by idiopathic duct-
centric pancreatitis IDCP), was diagnosed in 3/114 patients (3% of the entire cohort), all of which 
underwent pancreatic resection. 
Therapy and prognosis
Steroid therapy was started in 95/114 (83%), with an excellent response rate of 98% (92/94). 
Reasons to refrain from steroids (19/114, 17%) were: resection without postoperative recurrence 
(n=7), spontaneous remission or relatively mild symptoms (n=8), or patient refusal (n=2). One 
patient died of cardiovascular disease before therapy was initiated. Recurrence was noted in 37% 
(41/111); after remission without treatment in 17% (19/111), during treatment (failure to wean) in 
11% (12/111) and after treatment in 9% (10/111). Death occurred in 14% (14/99). In 29% (4/14) of the 
deaths the cause was disease related (cholangitis / sepsis, hepatic or renal failure), 29% (4/14) 
cardiovascular and 36% (5/14) unknown. One case of malignancy was recorded (acute leukaemia). 
Performance of diagnostic scoring systems and basis diagnosis
Twenty of 114 patients (18%) met the diagnostic criteria for all three systems, 40/114 (35%) 
met criteria for two systems and 33/114 (29%) for one system (Table 3). In 18% (21/114) all 
three scoring systems failed to confirm the diagnosis of AIP, even though these patients had 
an unchallenged clinical diagnosis of AIP based on postoperative histology, a combination 
of unexplained pancreatic disease, biliary disease/extrapancreatic manifestations and either 
response to steroids or IgG4-positive serology.
Table 3. Basis on which diagnosis of AIP was confirmed
Percentage (%) No. patients 
Positive for AIP criteria 82 93/114
3x positive 18 20/114
2x positive 35 40/114
1x positive 29 33/114
Negative for AIP criteria 18 21/114
(1) Histology 33 7/21
(2) Unexplained pancreatic disease
+biliary disease/OOI + response to steroids
38 8/21
(3) Unexplained pancreatic disease + biliary disease/
OOI + IgG4 positive
38 8/21
OOI: other organ involvement
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The highest percentage of patients met the ICDC (77/114, 68%), followed by HISORt 
criteria (59/114, 52%, p=0.022) and Asian (37/114, 33%, p= 0.005, Table 4). The relatively poor 
performance of the Asian criteria in the entire cohort, was mainly due to a low percentage of 
diagnostic pancreatography in this series (58/114, 51%). If a pancreatogram was available, Asian, 
ICDC and HISORt criteria performed equally well (36/58, 62% vs 39/58, 67%, p=0.698 and 31/58, 
53%, p=0.452, respectively). If abdominal CT showed no pancreatic abnormalities (n=24, 21%), 
HISORt was the only scoring system that could establish a diagnosis of AIP (group C, which 
requires response to steroid therapy). If IgG4 levels were normal (19/104, 18%), AIP was never 
diagnosed according to the HISORt criteria, while the Asian criteria and ICDC established the 
diagnosis in 42% (8/19) and 58% (11/19), respectively (p=0.517). 
DIsCUssION
In this well-characterized cohort of AIP patients, the three major diagnostic criteria systems 
proved complementary rather than overlapping. At initial clinical presentation, the majority 
of patients with AIP was correctly identified by any of the three systems, without the need for 
histology. Our data further suggest that a small subset of patients does not meet the criteria of 
any of these systems. Therefore, these scores are valuable and helpful, particularly for defining 
populations, but should not be regarded as absolute, gold diagnostic standard. Based on our 
data and the clinical applicability of the respective systems, we recommend the use of HISORt 
criteria, and the Asian criteria if a pancreatogram is available (optional) or if IgG4 levels are 
normal (mandatory). If diagnosis is still not confirmed, the ICDC can be used.
Table 4. Performance of diagnostic scoring systems at initial presentation
Overall 
(n=114)
Pancreatogram† 
(n=58)
IgG4 negative 
(n=19)
Normal  CT‡
(n=24)
HIsOrt 52% 53% 0% 50%
Group A 1% 0% 0% 0%
Group B 6% 12% 0% 0%
Group C 45% 41% 0% 50%
Asian 33% 62% 42% 0%
ICDC 68% 67% 58% 0%
AIP type 1 definitive 60% 55% 26% 0%
AIP type 1 probable 2% 0% 0% 0%
AIP type 2 definitive 0% 0% 0% 0%
AIP type 2 probable 0% 0% 0% 0%
AIP not otherwise specified 6% 12% 32% 0%
Systems were scored with initial clinical  findings; that is, EUS FNA was included, histology obtained by resection 
or laparotomy biopsy was excluded. † Pancreatogram present; ‡Normal appearance of pancreas on CT.
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In our opinion, the intrinsic erratic nature of AIP, with its protracted and highly variable 
clinical course, forms the main drawback in the clinical applicability of any diagnostic criteria 
system in a given moment of the disease. Radiological, clinical and biochemical abnormalities 
may fluctuate in time. The 18% of patients in our cohort that did not meet any of these systems 
in the initial evaluation period, had a firm diagnosis of AIP. It was only a matter of timing, 
pancreatic resection or steroid trial, to finally make the diagnosis. The main differential 
diagnosis with malignancy however, prompts the clinician to minimize diagnostic delay. We 
believe it is highly unlikely that any diagnostic criteria system will totally cover this dilemma in 
a given short period of time with sufficient specificity. 
In general, our series resembles other large cohorts of AIP patients10,19-22. Since there were 
only three cases of histologically confirmed IDCP (type 2 AIP), our cohort reflects mainly the 
clinical spectrum of LPSP (type 1 AIP). Differences in disease characteristics between various 
cohorts are probably due to differences in the use of diagnostic criteria systems and their ability 
to differentiate between type 1 and type 2 AIP2,3. The Asian criteria and HISORt in particular 
highlight the features of AIP type 1. Italian6 and German criteria11 appear to be targeted at both 
types. Whether the good performance of the HISORt criteria in our cohort reflects selection 
bias or true low incidence of type 2 AIP in the Netherlands is not clear. 
We report a high percentage of elevated Ca 19-9 levels in 58% of cases compared to an 
average of 25% in other series6,10,21. Levels above 300 U/ml, considered specific for pancreatic 
cancer10,18, were present in 18%. This is not explained by a difference in the presence of proximal 
biliary involvement, which was similar (34%). We report five cases of AIP associated prostatitis, 
which is quite uncommon. No case of inflammatory bowel disease was noted, corresponding 
with virtual absence of type 2 AIP. Response and recurrence rates (98% and 37% respectively) 
match those reported in the literature.
To our knowledge, this is the first study that uses a well-defined cohort of AIP patients 
to head-to-head test the dominant and currently available diagnostic criteria systems for AIP. 
The strengths of our study include the large number of patients and the use of data at initial 
clinical presentation, which provides insight in the respective performance of these systems in 
common gastroenterology practice. Furthermore we provide specific clues for certain difficult 
diagnostic situations such as a normal CT (which was present in 21% of our cohort) and normal 
IgG4 levels (which were reported in 18%). One limitation of the current study is the retrospective 
nature and the use of HISORt and Asian criteria (that particularly highlight type 1), which might 
have introduced selection bias. Another limitation is the limited availability of pancreatic core 
biopsies, as they are only rarely obtained in the Netherlands. In only one of seven patients 
that underwent EUS fine needle biopsy (FNB) in our cohort did this contribute to diagnosis. 
Although the technique is increasingly feasible due to the development of flexible large bore 
EUS needles, the required histological expertise is not commonplace. This impairs a proper 
evaluation of its contribution to the diagnostic process in patients suspected of having AIP. 
However, the crucial role of EUS FNA (or FNB) in the diagnostic process of a pancreatic mass 
remains undisputed. Response to steroid therapy as a diagnostic tool to confirm AIP should 
only be used if malignancy is properly excluded10, that is by an attempt to confirm malignancy 
by tissue sampling. A final limitation in our study is the observer bias that might have been 
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introduced in the radiological revisions. Only the radiologist was blinded for the diagnosis. In 
daily practice, pancreatic enlargement and rim enhancement can be quite subtle. The quality 
of pancreatograms and cholangiograms varies considerably and they may be difficult to 
evaluate. The detection of the subtle changes associated with AIP is enhanced by knowledge 
and training23, which was likely to be the case in the revisions of the pancreatologists and 
research fellows. 
With this study, no conclusions can be made regarding the specificity of the diagnostic 
scoring systems, i.e. false positivity in differential diagnosis with malignancy or chronic 
pancreatitis. Reports on diagnostic scoring systems generally focus on capability of classifying 
the presence of disease. With each scoring system, corresponding diagnostic algorithms for 
differential diagnosis with malignancy were developed9,10,24,25. Extensive validation studies of all 
diagnostic criteria simultaneously are not reported yet. Because of the rarity of the disease, 
uniformity and international consensus should be pursued. The development of the ICDC was 
an important step as it combined several good aspects of various scoring systems. They are 
excellent for research purposes, but in our opinion their clinical use is limited because of their 
complexity. An international prospective trial, aimed at the optimal diagnostic algorithm for 
the diagnosis of AIP, is highly desirable. 
In conclusion, our data show that at initial clinical presentation, the majority of patients 
with AIP was correctly identified by any of the three major diagnostic criteria systems, without 
the need for histology. The systems proved to be complementary rather than overlapping. A 
small subset of patients did not fulfil the criteria of any of these systems. Though very useful in 
defining populations and confirming diagnosis of AIP, they should not be regarded as absolute, 
gold diagnostic standard. In daily practice, we recommend the use of HISORt criteria, and the 
Asian diagnostic scoring system if a pancreatogram is available (optional) or if IgG4 level is 
normal (mandatory). If diagnosis is still not confirmed, the ICDC can be used. 
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ABsTrACT
Background
Autoimmune pancreatitis (AIP) is often difficult to distinguish from pancreatic carcinoma or 
other pancreatobiliary diseases. High serum levels of carbohydrate antigen 19-9 (Ca 19-9) 
are indicative of malignancies, whereas high levels of immunoglobulin (Ig)G4 (>1.4 g/L) are 
characteristic of AIP. We investigated whether serum levels of these proteins can differentiate 
between these diseases. 
methods
We measured levels of Ca 19-9 and IgG4 in serum samples from 33 patients with AIP, 53 with 
pancreatic carcinoma, and 145 with other pancreatobiliary disorders. We determined cut-off 
levels for each assay. Logistic regression analysis was used to evaluate combined data on 
Ca 19-9, IgG4, and bilirubin levels. 
results
Low levels of Ca 19-9 were independently associated with AIP, compared with pancreatic 
adenocarcinoma (odds ratio [OR], 0.28; 95% confidence interval [CI], 0.13–0.59; P=.0001). 
Using an upper level of 74 U/ml, the assay for Ca 19-9 identified patients with AIP with 73% 
sensitivity and 74% specificity. Using a lower level of 2.6 g/L, the assay for IgG4 identified these 
patients with 70% sensitivity and 100% specificity. Combining data, levels of Ca 19-9 <74 U/ml 
and IgG4 >1.0 g/L identified patients with AIP with 94% sensitivity and 100% specificity. 
Conclusions 
Patients with AIP have lower levels of Ca 19-9 than those with pancreatic carcinoma. 
Measurement of either Ca 19-9 or IgG4 level alone are not accurate for diagnosis. However, the 
combination of Ca 19-9 <74 U/ml and IgG4 >1.0 g/L distinguish patients with AIP from those with 
pancreatic carcinoma with 94% sensitivity and 100% specificity.
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INTrODUCTION
Autoimmune pancreatitis (AIP) is a rare, distinct condition that often presents with a pancreatic 
mass, jaundice and weight loss, and thus may mimic pancreatic carcinoma. In a recent study, 
we described a 2.6% prevalence of AIP in patients undergoing pancreatoduodenectomy for 
presumed malignancy of the pancreatic head1. Biliary involvement is common in AIP, sometimes 
without overt pancreatic disease, and can be confused with cholangiocarcinoma or primary 
sclerosing cholangitis (PSC). Frequently AIP represents the pancreatic manifestation of IgG4-
related disease, a systemic disorder that may not only involve the pancreas but almost any 
other organ. AIP can be associated with disorders such as retroperitoneal fibrosis, sialadenitis, 
prostatitis, interstitial nephritis and inflammatory tumours in lungs, mediastinum or liver. The 
disease is highly responsive to steroids2 , a characteristic which can be helpful in establishing 
the diagnosis3. There is no single diagnostic test that reliably differentiates AIP from other 
disorders. IgG4 is the best single test to distinguish between AIP and malignancy, with an 
optimal cut-off level of 2.8 g/L (twice the upper limit of normal), yielding sensitivity of 65% and 
specificity of 98%4. Levels up to 2.8 g/L can also be found in patients with pancreatic carcinoma, 
PSC and other pancreatic disorders. Thereby, the specificity of slightly elevated levels is 
limited4-9. Several other serological markers - total IgG or autoantibodies like antinuclear 
antibody, rheumatoid factor, anti carbo anhydrase II and antilactoferrin - have been proposed 
as useful diagnostic tests10. However, most of the studies describing the value of these tests lack 
sufficient validation.
Ca 19-9 is a tumor associated antigen originally isolated from a human colorectal cancer cell 
line. The level is elevated in the majority of pancreatic carcinoma patients but it lacks diagnostic 
performance required for early detection or diagnosis due to substantial numbers of false 
positive and false negative readings11. High levels are also observed in other gastrointestinal 
malignancies including biliary, hepatocellular, colorectal and gastric cancer. A systemic review 
found an overall sensitivity of 81% and specificity of 90% for pancreatic carcinoma11. A value 
higher than 1000 U/mL usually indicates digestive cancer, with nearly 100% specificity for 
pancreatic carcinoma12. Investigators from India demonstrated that a level above 300 U/ml in 
mass lesions in chronic pancreatitis was always indicative of malignancy13. However, apart from 
chronic pancreatitis, Ca 19-9 can also be elevated in other benign GI diseases like cirrhosis, 
primary sclerosing cholangitis, bacterial cholangitis or choledocholithiasis, actually any 
condition associated with cholestasis14-16. 
In our national AIP cohort, elevated levels of Ca 19-9 were encountered in the majority of 
patients. Levels above 34 U/ml were found in 58%, above 100 U/ml in 38% and above 300 U/ml 
in 18% of cases. Several patients even had levels as high as 5000 to 23,000 U/ml17. Elevated levels 
in AIP were also reported in other cohorts18-23.
In this study, we aimed to evaluate Ca 19-9 levels in AIP, pancreatobiliary malignancies 
and benign diseases that show clinical similarity with AIP. Secondly we aimed to assess the 
performance of Ca 19-9 as a diagnostic test to differentiate between AIP and pancreatic 
carcinoma, single and in combination with IgG4.
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meTHODs
Patients 
Between March 2007 and May 2011 sera were prospectively obtained from consecutive 
patients presenting in a single, tertiary center with AIP (n=33), pancreatic carcinoma (n=53), 
cholangiocarcinoma (n=32), chronic pancreatitis (n=52), primary sclerosing cholangitis (n=30) 
and Sjögren’s syndrome (n=31). Sera were obtained with informed consent and were processed 
immediately, or stored at -80˚C. The diagnosis of AIP was made according to the International 
Consensus Diagnostic Criteria, Asian or HISORT criteria, or a combination of unexplained 
pancreatic disease, biliary disease/extrapancreatic manifestations and either response to 
steroids or IgG4-positive serology 17,24-26. Sera of chronic pancreatitis patients were collected 
from patients with chronic alcoholic, obstructive or idiopathic pancreatitis. Diagnostic criteria 
systems of AIP were systematically applied to all patients with chronic pancreatitis to exclude 
misclassification. Sera of pancreatic carcinoma or cholangiocarcinoma patients were included 
only if diagnosis was histologically confirmed. PSC and Sjögren’s syndrome patients were 
diagnosed according to accepted criteria27,28.
Laboratory measurements
Serum Ca 19-9 levels were measured using an electrochemiluminescense immunoassay (ECLIA) 
on a Modular Analytics E module (Roche Diagnostics Co, Tokyo, Japan). The upper limit provided 
by the manufacturer was 34 U/ml. IgG4 levels were determined on the Immage 800 Analyzer 
(Beckman Coulter, Mijdrecht, the Netherlands) using the Peliclass IgG subclass nephelometry 
kit according to manufacturer’s instructions (Sanquin, Amsterdam, the Netherlands). The 
upper limit of normal provided by the manufacturer was 1.40 g/l. Bilirubin levels were measured 
using the Diazo method on a Roche modular P analyser (Roche Diagnostics, Almere, The 
Netherlands). The upper limit of normal provided by the manufacturer was 16 µmol/L. Serum 
IgG4, bilirubin and Ca19.9 levels were measured simultaneously. 
statistical analysis
Ca 19-9, IgG4 and bilirubin levels were expressed as median value with interquartile range 
(IQR). One-way analysis and pairwise comparisons with Bonferroni correction for multiple 
testing were performed to detect significant differences between groups. P values < 0.05 were 
considered statistically significant. Mann Whitney U test was performed to detect differences 
in laboratory parameters in subgroups of AIP patients (with or without mass presentation, 
steroid use and proximal biliary involvement). Logistic regression analysis was applied to study 
the simultaneous effect of Ca 19-9, IgG4 and bilirubin. Receiver operating characteristic (ROC) 
analysis was performed to assess optimal cut-off levels. Test characteristics of  Ca 19-9, IgG4 
and combination were calculated. Statistical analysis was carried out using SPSS Statistics 20.0 
Software (IBM, New York, USA).
medical ethical concerns
The study was approved by the institutional review board of the Erasmus University Medical 
Center, Rotterdam, the Netherlands.
43
Serum Ca19-9 and Igg4 to dIStInguISh aIP from PanCreatIC CarCInoma
3
resULTs
Ca 19-9 as predictor of AIP
Patient characteristics and laboratory measurements are shown in Table 1. The distribution of Ca 
19-9 for the different groups is shown in Figure 1. Ca 19-9 was significantly higher in pancreatic 
carcinoma (median 349 U/ml, IQR 63 - 1588) and cholangiocarcinoma (median 247 U/ml, IQR 
41-2175) than in AIP (median 26 U/ml, IQR 12 - 108), p < 0.001. The level in AIP was significantly 
higher than in Sjögren’s syndrome (median 6 U/ml, IQR 4-15), p=0.009. In AIP, Ca 19-9 levels 
showed a wide distribution with minimum of 1 U/ml and maximum of 23283 U/ml. Moreover, 
in PSC markedly elevated levels were also observed (median 59 U/ml, IQR 23-154), minimum 6, 
maximum 885 U/ml. The median Ca19-9 level in PSC patients however was significantly lower 
than in patients suffering from cholangiocarcinoma (p=0.009). The unadjusted effect of Ca 19-9 
as a predictor of AIP against pancreatic carcinoma showed a strong association of low Ca 19-9 
with high probability of AIP (OR=0.42; 95%CI (0.25-0.70), p=0.0002, Table 2). Serum IgG4 was 
significantly higher in patients with AIP than in all other groups (p<0.001, Table 1). In particular, 
IgG4 was significantly higher in the AIP group compared to patients with pancreatic carcinoma. 
Levels of bilirubin did not differ between AIP and malignancy. After adjustment for IgG4 and 
bilirubin, Ca 19-9 remained an independent predictor of AIP against pancreatic carcinoma 
(OR=0.28; 95%CI(0.13-0.59), p=0.0001). IgG4 was strongly associated with AIP, while bilirubin 
was not significantly associated with AIP (all p-values > 0.17, results not shown).
Ca 19-9 in subgroups of AIP patients
In addition to the analysis above, the distribution of Ca 19-9 within specific subgroups of AIP 
patients was studied. In AIP patients, Ca 19-9 levels were not significantly different between 
Table 1. Patient characteristics
AIP
Pancreatic 
carcinoma
Cholangio-
carcinoma
Chronic 
pancreatitis PsC
sjögren’s 
syndrome p-overall
Number 33 53 32 52 30 31
Age (yr) 65 (55-73) 66 (60-71) 66 (57-73) 52 (44-60) 46 (40-53) n.a. <0.0011
Male (n,%) 28 (85%) 27 (51%) 15 (47%) 36 (69%) 23 (77%) 3 (10%) <0.0012
Ca 19-9 
(U/ml)
26(12-108) 349(63-1588)* 247(41-2175)* 10(6-24) 59(23-154) 6(4-15)* <0.0011
IgG4
(g/L)
4.7(1.8-10.5) 0.5(0.2-1.1)* 0.6(0.3-1.7)* 0.6(0.3-1.1)* 0.5(0.2-0.9)* 0.2(0.1-0.5)* <0.0011
Bilirubin 
(µmol/L)
10(8-34) 15(9-57) 23(8-57) 7(5-11) 38(15-109) 0(0-1) <0.0011
Elevated 
bilirubin (n,%)
12 (36%) 22 (42%) 17 (53%) 5 (10%) 21 (70%) 0 (0%) <0.0012
Age and laboratory tests in median (interquartile range). AIP: autoimmune pancreatitis; PSC: primary sclerosing 
cholangitis; n.a.: not available. 
1One way analysis of variance to detect differences between groups, with * p<0.05 between AIP and group (post 
hoc paired test with correction for multiple testing). 2Fisher’s exact test.
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* p = 0.009
* p < 0.001
* p < 0.001
Figure 1. Ca19-9 level in pancreatobiliary diseases and Sjögren’s syndrome. Levels of Ca 19-9 are expressed 
in U/ml, as grey boxes (interquartile range) with median (horizontal line within box) and whiskers (range 
that contains 95% of observations). AIP: autoimmune pancreatitis; PAC: pancreatic adenocarcinoma; 
CC: cholangiocarcinoma; CP: chronic pancreatitis; PSC: primary sclerosing cholangitis; SS: Sjögren’s 
syndrome. *p<0.05 between AIP and group.
Table 2. Logistic regression analysis assessing the effect of Ca 19-9, in the total cohort of AIP patients and 
3 different subgroups, as predictor for AIP, unadjusted and adjusted for IgG4 and bilirubin
Unadjusted effect Adjusted for IgG4 and bilirubin
Or (95% CI) p value Or (95% CI) p value
Total AIP 0.42 (0.25-0.70) 0.0002 0.28 (0.13-0.59) 0.0001
AIP with mass 0.32 (0.15-0.67) 0.0006 0.07 (0.01-0.51) <0.0001
AIP steroid naïve 0.50 (0.29-0.85) 0.0066 0.21 (0.07-0.62) 0.0006
AIP proximal biliary involvement 
excluded
0.41 (0.22-0.78) 0.0030 0.27 (0.11-0.68) 0.0010
Sensitivity analysis (logistic regression analysis) was performed for the total cohort of AIP patients, patients 
presenting with a mass lesion, those who were steroid naïve and those without proximal biliary involvement. 
OR: odds ratio; CI: confidence interval.
patients with or without mass presentation (p=0.24), steroid use (p=0.88) or proximal biliary 
involvement (p=0.17) (Table 3). IgG4 and bilirubin levels differed significantly in subgroups with 
or without steroids (p=0.047 and p=0.002). Furthermore, a sensitivity analysis of Ca 19-9 as 
predictor for AIP was performed in these subgroups. Results of the unadjusted effects (Ca 19-9 
only) as well as the adjusted effects (adjusted for IgG4 and bilirubin) in the different subgroups 
supported the overall findings. 
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Diagnostic characteristics of Ca 19-9 and IgG4
The optimal cut-off point for distinction between pancreatic carcinoma and AIP was assessed 
by ROC analysis, as shown in Figure 2. The area under the curve for Ca 19-9 as predictor for the 
presence of pancreatic carcinoma was 0.77 (0.66-0.87). The optimal cut-off level was 74 U/ml, 
yielding a sensitivity of 76% and specificity of 75%, with LR+ of 2.94 and LR- of 0.35. The optimal 
cut-off for IgG4 was 2.6 g/L, yielding a sensitivity of 70% and specificity of 100%, with LR+ ∞ 
(infinite) and LR- 0.3. 
Table 3. Subgroups of AIP patients: characteristics and relation to Ca 19-9, bilirubin and IgG4
subgroups Present Absent p-level1
Mass Number, n (%) 12 (38%) 20 (63%)
Ca 19-9 (U/ml), median (IQR) 16 (8-56) 34 (12-225) 0.236
Bilirubin (µmol/l), median (IQR) 9 (7-19) 12 (8-55) 0.224
IgG4 (g/l), median (IQR) 2.9 (1.4-7.5) 5.0 (2.3-11.7) 0.373
Steroid therapy Number, n (%) 9 (28 %) 23 (72%)
Ca 19-9 (U/ml), median (IQR) 37(13-67) 26 (12-234) 0.881
Bilirubin (µmol/l), median (IQR) 9 (7-11) 14 (8-61) 0.047*
IgG4 (g/l), median (IQR) 1.8 (0.7-4.0) 5.4 (3.4-13.6) 0.002*
Proximal biliary involvement2 Number, n (%) 13 (50%) 13 (50%) 
Ca 19-9 (U/ml), median (IQR) 74 (13-251) 25 (6-58) 0.168
Bilirubin (µmol/l), median (IQR) 20 (10-62) 10 (9-20) 0.264
IgG4 (g/l), median (IQR) 5.08 (2.6-15.9) 1.89 (1.3-4.9) 0.060
* p < 0.05; 1 Mann-Whitney U Test; 2 Biliary involvement other than intrapancreatic part of common bile duct
AUC 0.77
Figure 2. Receiver operating curve for Ca 19-9. The area under the curve (AUC) for the diagnosis of 
pancreatic carcinoma by means of Ca 19-9 levels was 0.77
46
Chapter 3
The diagnostic performance of Ca 19-9 and IgG4, single and in combination, is shown in 
Table 4 and Figure 3. Ca 19-9 as a single marker had moderate sensitivity (73%), and specificity 
Table 4. Diagnostic performance of Ca 19-9 and IgG4, single and combined, to differentiate AIP from 
pancreatic carcinoma
Ca 19-9 ≤ 74 IgG4 > 1.4 IgG4 > 2.6
Ca 19-9 ≤ 74 &  
1.0 < IgG4 ≤ 2.6
or IgG4 > 2.6
Ca 19-9 ≤ 74 &  
1.4 < IgG4 ≤ 2.6
or IgG4 > 2.6
True positive (n) 24 28 23 29 26
Sensitivity (%) 72.7 84.8 69.7 93.5 83.9
Specificity (%) 73.6 81.1 100 100 100
PPV (%) 63.2 73.7 100 100 100
NPV (%) 81.2 89.6 84.1 96.4 91.4
LR + 2.8 4.5 ∞ ∞ ∞
LR - 0.4 0.2 0.3 0.1 0.2
AUC
(95% c.i.)
0.77
(0.66-0.87)
0.91
(0.83-0.99)
0.91
(0.83-0.99)
0.97
(0.92-1.00)
0.92
(0.84-1.00)
PPV: positive predictive value; NPV: negative predictive value; LR: likelihood ratio of + positive or - negative  test; 
AUC: area under the receiver operating curve, CI: confidence interval. Value of Ca 19-9 in U/ml, IgG4 in g/L.
Sens 84%
Spec 100%
Sens 94%
Spec 100%
Figure 3. Combination of Ca19-9 and IgG4 to differentiate AIP from pancreatic carcinoma. Circles 
represent patients with pancreatic carcinoma, dots represent AIP patients. If low levels of Ca 19-9 
(<74 U/ml) were combined with IgG4, specificity rose to 100% with a sensitivity of 84% if 1.4<IgG4≤2.6 or 
IgG4 > 2.6 (grey area) and a sensitivity of 94% if 1.0<IgG4≤2.6 or IgG4>2.6 (diagonally striped area). 
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(74%). IgG4 levels higher than 1.4 g/L were more sensitive (85%) but moderately specific (81%). 
Raising the cut-off to 2.6 g/L improved specificity to 100%, at the cost of lowering sensitivity to 
70%. However, if low levels of Ca 19-9 (<74 U/ml) were combined with IgG4, specificity rose to 
100% and sensitivity improved to 84% if IgG4>1.4  and 94% if IgG4>1.0 g/L.
DIsCUssION
In this study we found that low levels of Ca 19-9 were an independent predictor of AIP after 
adjustment for IgG4, thus Ca 19-9 appears to provide additional information to distinguish 
between AIP and pancreatic carcinoma. As a single test, both Ca 19-9 and IgG4 were not optimal 
for identification of AIP. The most accurate identification of AIP from pancreatic carcinoma 
was achieved with the combination of low levels of Ca 19-9 (<74 U/ml) and high levels of IgG4 
(>1.0 g/L), which shows sensitivity of 94% and specificity of 100%. Our findings hold true for 
subgroups of AIP patients.
In contrast to previous reports, high levels of Ca 19-9 were not diagnostically helpful. The 
marked overlap of values in AIP and cancer limit the value of Ca 19-9 in clinical decision making. 
We observed very high Ca 19-9 levels ranging from 5000-23000 U/ml in several AIP patients, 
as was reported previously29. Previous studies found elevated Ca 19-9 levels in about 25% of 
AIP cases18,20,22 as compared to 58% in the present series. In another study addressing the role 
of Ca 19-9 in differentiating pancreatic carcinoma from AIP, investigators found a sensitivity 
of 62% and specificity of 92% for values higher than 150 U/ml. The authors concluded that Ca 
19-9 levels higher than 150 U/ml are highly specific for pancreatic carcinoma and thus may be 
useful in differential diagnosis. The different result of the present study may be attributable to 
differences in patient selection as illustrated by the higher frequency and also higher values 
of elevated Ca 19-9 in our cohort. This might be explained by differences in proximal biliary 
involvement, which was more frequent in our AIP patients (50% versus 31-34%17,18). However, 
median levels of bilirubin were not different in patients with or without proximal biliary 
involvement and bilirubin was not a confounding variable. 
In general, the interpretation of elevated Ca 19-9 levels is difficult for several reasons. First, 
Ca 19-9 is a sialylated Lewis antigen. Seven to 10% of Caucasians (increasing to 22% in Africans) 
are Lewis negative and are unable to synthesize Ca 19-930. Second, Ca 19-9 can also be elevated 
in benign pancreatic diseases, which often coexist with pancreatic carcinoma. Third, Ca 19-9 
undergoes some degree of biliary excretion and is produced by biliary epithelial cells. Therefore 
in cholestasis, levels are frequently elevated even in benign conditions31,32. Treatment of these 
conditions may result in normalization14-16. In our study, low Ca 19-9 was a strong predictor of 
AIP, even after adjustment for bilirubin. 
For the clinically highly relevant question how to differentiate pancreatic carcinoma from 
AIP, a test with very high sensitivity and specificity is needed. In this patient group however, 
the importance of a high sensitivity outweighs a high specificity. A positive test may prompt 
the decision to perform surgery. In this case clinicians are more willing to accept false 
positivity (lower specificity) than false negativity (lower sensitivity). The former will lead to 
a resection with postoperative benign histology (which is generally observed in 5-11% of 
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pancreatoduodenectomies 1,33-38), the latter means that patients are deprived of the only chance 
for cure in the case of true carcinoma. 
As single tests to detect AIP, Ca 19-9 (<74 U/ml) and IgG4 (>2.6 g/L) would entail 27% and 30% 
of AIP patients misclassified as cancer while having AIP (sensitivity 73% and 70%) respectively. 
This means that one quarter to one third of patients undergoing resection would be erroneously 
exposed to a surgical procedure with substantial morbidity (46%) and mortality (though in a 
large volume centers less than 5%) 35,39. Ca 19-9<74 U.ml as a single test corresponds with 26% 
false positive rate (specificity of 74%), that means one quarter of patients with cancer would be 
erroneously treated with prednisone and potentially deprived of a curative surgical resection. 
IgG4 levels of >2.6 g/L are 100% specific, thus raising the normal cut-off (1.4 g/L) to this level 
would protect AIP patients from unnecessary surgery. For comparison, in large cohorts of AIP 
patients, 16-30% underwent resection17,20,22,24,40. This optimal cut-off level of IgG4 is in line with 
previous observations, which suggested a level of 2.8 g/L (twice the upper limit of normal)4,6. In 
our study, IgG4 levels higher than 1.4 g/L were fairly sensitive for AIP (85%) but not very specific 
(81%). Interestingly, if low levels of Ca 19-9 (<74 U/ml) were combined with IgG4, specificity rose 
to 100% and sensitivity improved to 84% if IgG4>1.4 and 94% if IgG4>1.0. Thus, low levels of Ca 
19-9 improve both the moderate specificity of intermediate IgG4 levels, as the poor sensitivity 
of high IgG4 levels. 
To determine the quality of a diagnostic test in clinical practice, most studies report 
predictive values. In diseases with low prevalence however, this might cause overestimation of 
the quality of the test. The likelihood ratio of positive (LR+) and negative result (LR-), are the 
stable characteristics of a test, independent of prevalence41. In our study, LR+ of IgG4 > 2.6, or 
intermediate levels of IgG4 in combination with Ca 19-9 < 74 U/ml, were infinite. That means that 
these levels definitely rule in diagnosis of AIP. Values of these markers outside this range have 
less capacity to rule out AIP as reflected by their LR-. 
Although the use of Ca 19-9 is advocated in several diagnostic algorithms for AIP, as  far as 
we are aware, this is the first study addressing the combination of both markers to improve the 
diagnostic power in discrimination between AIP and pancreatic cancer. The strengths of our 
study include the diversity of the control groups and the careful selection of patients. Malignancy 
was always confirmed with histology, and chronic pancreatitis patients were excluded if they 
scored positive on diagnostic criteria systems for AIP. Furthermore, we believe that expressing 
the value of this test in terms of likelihood ratios gives a more accurate reflection of its use in 
daily practice than the commonly reported sensitivity, specificity and predictive values. 
Two possible sources of misclassification bias are present in this study. For diagnosing AIP we 
used generally accepted diagnostic criteria systems as gold standard. This might, but does not 
always, include histological proof. In theory, some of these patients could have been wrongly 
classified as AIP while having malignancy. However, all patients in our cohort were observed 
at least two years, which virtually rules out cancer. In patients with cholangiocarcinoma, 
several patients with underlying PSC were included. We cannot rule out the possibility of occult 
malignancy in PSC patients. Our study was not designed to address this particular issue. This 
renders any conclusion regarding the Ca19-9 values in PSC in relation to cholangiocarcinoma 
less reliable. 
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In conclusion, the present study showed that low levels of Ca 19-9 independently predict 
AIP against pancreatic carcinoma. Both Ca 19-9 and IgG4 are not optimal as single markers. The 
most accurate identification of AIP patients was achieved with the combination of Ca 19-9 (<74 
U/ml) and IgG4 (>1.0 g/L), which showed sensitivity of 94% and specificity of 100%.
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ABsTrACT
Background
Type 1 autoimmune pancreatitis (AIP) is the pancreatic manifestation of a systemic IgG4-related 
fibroinflammatory disorder. Differentiating AIP from other forms of acute pancreatitis (AP) and 
chronic pancreatitis (CP) can be challenging. We evaluated the prevalence of elevated levels of 
total IgG, its subclasses, and IgE in patients with type 1 AIP, AP and CP.
methods
Sera of patients with AIP and CP were obtained between March 2007 and May 2011, from 
consecutive cases presented to our tertiary referral center. Sera from patients with (AP) were 
derived from a tissue bank, created between March 2004 and March 2007. In all samples, IgG, 
its subclasses, and IgE levels were determined.
results
A total of 174 patients were included; 32 AIP, 90 AP, and 52 CP patients. Elevated IgG4 levels 
(upper limit of normal [ULN] 1.4 g/L) were found in 27 AIP patients (84%), but also in 7 AP (8%) 
and 9 CP (17%) patients (p<0.001). IgG4 levels >2 times the ULN were found in 19 AIP patients 
(63%), in nil AP and 3 CP patients (6%; p<0.001). In patients with a serum IgG4 between 1 and 2 
times the ULN, the PPV was just 12%. In this subgroup, applying the IgG4/IgG2 ratio improved 
the PPV from 12 to 75%. 
Conclusions
Elevated serum IgG4 levels are frequently present in patients with AP and CP, and therefore 
must be interpreted with caution. However, levels above twice the upper limit of normal are 
rare in AP and CP, and suggest AIP. In mildly elevated IgG4 (1-2x ULN), the IgG4/IgG2 ratio can 
substantially improve the positive predictive value. 
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INTrODUCTION
Autoimmune pancreatitis (AIP) is a rare form of pancreatitis that responds dramatically to 
steroid therapy and typically affects men older than 55 years 1. Two subtypes are distinguished 2,3. 
Type 1 represents the pancreatic manifestation of IgG4-related systemic disease (IgG4-RD) and 
may involve other organs, such as the biliary tree, kidneys, and salivary glands 4. Type 2 is rare, 
pancreas-specific, and not associated with IgG4 5. 
AIP patients generally present with obstructive jaundice, weight loss, and diabetes. 
Therefore, the primary diagnostic consideration is often pancreatic cancer. In addition, it can 
also be challenging to distinguish AIP from other types of pancreatitis. Sah et al. reported that 
24% of AIP patients have features of acute pancreatitis (AP); severe abdominal pain, elevated 
lipase levels, or an oedematous pancreas with peripancreatic stranding 6. Also, in a more 
advanced stage, AIP may have characteristics of chronic pancreatitis (CP), such as pancreatic 
atrophy, ductal stricturing, and functional impairment 7,8. 
IgG4, a subclass of the immunoglobulin G (IgG), is often used as a diagnostic tool in this 
setting. It accounts for less than 5% of total serum IgG and, although the normal value varies, it 
is stable in healthy individuals 9-11. In 2001, elevated serum IgG4 levels were first observed in AIP 
patients 12. Nowadays, it is the mainstay of establishing the diagnosis of type 1 AIP 13,14. 
However, particular caution is needed in interpreting elevated levels of IgG4, since they 
are also encountered in other disorders, including chronic pancreatitis and primary sclerosing 
cholangitis 12,15,16. Very little data are available regarding IgG4 levels in AP of non-immune 
aetiology. Previous studies have shown that combined serum IgG4 and IgG1 measurement can 
be helpful to distinguish IgG4-associated cholangitis from primary sclerosing cholangitis  17. 
So far, combining different IgG subclasses to differentiate AIP from AP and CP has not been 
investigated. Furthermore, IgE may also be of value, as several studies have reported this 
immunoglobulin to be elevated in AIP 18-20. Therefore, the aim of this study was to evaluate 
serum levels of IgG, its subclasses, and IgE in patients with either type 1 AIP or acute and chronic 
pancreatitis of non-immune aetiology.
meTHODs
Patients
The study was approved by the Institutional Review Board of the Erasmus University Medical 
Center. For AIP and CP, serum samples were obtained (after written informed consent) from 
consecutive patients, presenting to our tertiary referral center between March 2007 and May 
2011. Sera from patients with acute biliary, alcoholic or idiopathic pancreatitis were derived 
from a series of 732 samples that had been collected between March 2000 and March 2007, in 
the course of a prospective trial that ran within the Dutch Pancreatitis Study Group 21. Samples 
were matched for age and gender. 
To allow a diagnosis of AIP, patients had to fulfil either the HISORt criteria (Histology, 
Imaging, Serology, Other organ involvement, and Response to steroid therapy) or the 
International Consensus Diagnostic Criteria (ICDC) 13,14. AP was defined as abdominal pain with 
an at least three-fold elevation of serum amylase or lipase levels. CP was diagnosed, based on 
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clinical symptoms, combined with morphological features (calcifications and ductal changes) 
and/or pancreatic functional insufficiency. 
Laboratory analysis and normal values
Serum samples were either processed immediately or stored at -80°C. IgG levels were 
determined by routine automated turbidimetry with a Cobas 8000 modular analyser (Roche, 
Almere, The Netherlands). The upper limit of normal, provided by the manufacturer, is 16.0 g/L. 
IgG subclasses were determined using the Peliclass IgG subclass nephelometry kit (Sanquin, 
Amsterdam, The Netherlands), with an Immage 800 Analyzer (Beckman Coulter, Mijdrecht, 
The Netherlands). The upper limits of normal of IgG1 to 4 are; 11.4, 6.4, 1.1, and 1.4 g/L, 
respectively. Total IgE was determined by the ImmunoCAP 250 system (Phadia, Nieuwegein, 
The Netherlands). For IgE, no upper limit of normal is defined. 
statistical analysis
Data were analyzed using SPSS Statistics 20.0 Software (IBM, New York, USA). Serum levels are 
presented as median values with interquartile ranges (IQR). To detect differences between 
groups, the Mann-Whitney U Test (for continuous data) or the Fisher’s Exact Test (for 
categorical data) were used. The Kruskal-Wallis test was used to detect differences between 
the three groups. Furthermore, IgG4/subclass ratios were determined. Sensitivity, specificity, 
positive predictive value (PPV), negative predictive value (NPV), and receiver operating 
characteristic (ROC) curves were used to assess the diagnostic utility of serum IgG, IgG 
subclasses, IgG4/subclass ratios, and IgE in AIP. Logistic regression analysis was performed to 
study the differences in occurrence of elevated levels of IgG, IgG1, IgG4, IgG3, and IgE between 
the three groups. P-values <0.05 were considered to be statistically significant. 
resULTs
Patients
In total, samples from 174 patients were evaluated; 32 with AIP, 90 with AP and 52 with CP. Patient 
and disease characteristics are shown in Table 1. Among the AIP patients, 24 (75%) presented 
with obstructive jaundice, 29 (91%) with weight loss, and 17 (53%) with (mild) abdominal pain. 
Other organs were involved in 23 patients (72%), most frequently extra-pancreatic cholangitis 
(19 patients, 61%). In eight patients (25%), more than one extra-pancreatic manifestation 
was observed. AIP patients were older and more often male, as compared to AP and CP 
patients (p<0.001). Nine AIP patients were receiving steroid treatment at the time of blood 
sampling (28%). 
IgG4 levels
Elevated IgG4 levels were observed in 25 (75%) of the AIP patients, but also in seven (8%) AP 
patients and in nine (17%) CP patients (Table 2, Figure 1). However, compared with AIP, AP and 
CP patients were less likely to have serum IgG4 levels more than twice the upper limit of normal 
(ULN) (63% vs 0%, p<0.001; 63% vs 6%, p<0.001). 
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Table 1. Demographics of patients with AIP, AP, and CP.
Characteristic AIP (n=32) AP (n=90) CP (n=52) p-value
Age in years¥ - median (IQR) 66 (54-73) 56 (43-69) 52 (44-60) 0.0031,*
male sex – no. (%) 28 (88) 45 (50) 36 (69) <0.0011,*
Disease specifics – no. (%) Location
Diffuse: 20 (65)
Focal: 6 (19)
Cause
Alcoholic: 28 (31)
Idiopathic: 30 (33)
Biliary: 32 (36)
Cause
Alcoholic: 29 (56)
Idiopathic: 14 (27)
Other¥: 9 (17)
-
¥ Age when sample was taken;  * p < 0.05; 1P-value corresponds with differences between the 3 groups; 1Kruskal-
Wallis Test; 2Fisher’s Exact Test
AIP = autoimmune pancreatitis; CP = chronic pancreatitis; AP = acute pancreatitis; IQR = inter quartile range. 
¥Other causes of chronic pancreatitis: pancreas divisum, iatrogenic, hereditary.
Table 2. Serum IgG, IgG subclasses and IgE in patients with AIP, AP, and CP. 
Characteristic
AIP
(n=32)
AP
(n=90)
CP
(n=52)
AIP vs AP
p-value
AIP vs CP
p-value
Total IgG – g/L¶     
      >16.0 – no. (%)
12.7 (10.5-21.7)
13 (41)
9.5 (7.7-11.1)
3 (3)
10.5 (8.9-12.6)
1 (2)
< 0.0011,*
< 0.0012,*
0.0051,*
< 0.0012,*
IgG4 – g/L¶
      range
      >1.4 – no. (%)
      >2.8 – no. (%)
4.5 (1.7-7.7)
0.1-17.2
25 (83)
19 (63)
0.4 (0.2-0.9)
0.1-1.85
7 (8)
0 (0)
0.6 (0.3-1.1)
0.1-4.1
9 (17)
3 (6)
< 0.0011,*
< 0.0012,*
< 0.0012,*
< 0.0011,*
< 0.0012,*
< 0.0012,*
IgG1 – g/L¶
      >11.4 – no. (%)
7.7 (5.9-11.9)
8 (25)
5.4 (4.3-6.9)
3 (3)
6.2 (5.3-7.9)
1 (2)
< 0.0011,*
0.0012,*
0.0281
< 0.0012,*
IgG2 – g/L¶
       >6.4 – no. (%)
3.1 (2.1-5.1)
2 (6)
2.9 (2.1-4.3)
5 (6)
3.5 (2.6-5.1)
6 (12)
0.5051
0.9992
0.4071
0.7042
IgG3 – g/L¶
      >1.1 – no. (%)
0.6 (0.4-1.0)
5 (16)
0.4 (0.3-0.7)
5 (6)
0.4 (0.3-0.6)
0 (0)
0.0251
0.1262
0.0011,*
0.0072,*
Ige – g/L¶
      >100 – no. (%)
302 (50-978)
15 (65)
38 (16-104)
23 (26)
47 (19-102)
13 (26)
< 0.0011,*
0.0012,*
0.0011,*
0.0022,*
 ¶Given values are medians with inter quartile range (IQR); *p < 0.05; 1 Mann-Whitney U Test; 2 Fisher’s Exact Test
The upper limits of normal (ULN) were 16.0 g/L (IgG), 11.40 (IgG1), 6.40 (IgG2), 1.10 (IgG3) and 1.40 (IgG4) g/L. 
For IgE, no ULN is available. AIP = autoimmune pancreatitis; CP = chronic pancreatitis; AP = acute pancreatitis. 
Other immunoglobulin levels
Univariate analysis revealed that elevated levels of total IgG and IgG1 were more prevalent in 
the AIP group, as compared to the AP group (p<0.001 and p=0.001, respectively). The same 
conclusion was drawn for IgG, IgG1 and IgG3 for AIP versus CP patients (p<0.001, p<0.001, 
p=0.007, respectively).
Furthermore, IgE was also significantly higher in AIP patients (p<0.001 and p=0.001; Table 2, 
Figure 2). However, none of these markers had a better diagnostic performance than serum 
IgG4 (Table 3). There were no significant differences in immunoglobulin levels between AP and 
CP patients and, therefore, in further analyses, the results for AP and CP patients were combined.
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Figure 1. Scatterplot of serum IgG4 in AIP, AP and CP patients. The upper limit of normal (ULN) and 2xULN 
are represented by different shades of grey. The bar across each column represents the median value. 
Figure 2. Boxplots of serum IgE in acute, chronic and autoimmune pancreatitis.
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IgG4 cut-off value 
The discriminative value of IgG4 varied according to the cut-off value. At a value of 1.40 mg/dL 
(ULN), the sensitivity and specificity were 83% and 89%, respectively (Table 3). The matching 
PPV was 61% and the NPV 96%. Raising the cut-off value to 2.8 mg/dL (twice the ULN), decreased 
the sensitivity to 63%, but improved the specificity to 98%. The PPV increased substantially to 
86%, whereas the NPV hardly fell (from 96% to 93%). Raising the cut-off value even further, to 
4x the ULN, resulted in a drastic decline in sensitivity, down to 30% (95% CI: 14-46). 
IgG4/subclass ratios
Interestingly, when comparing IgG4/subclass ratios between AIP and non-AIP patients, all 
ratios were higher in AIP patients (Table 4). The IgG4/IgG2 ratio showed the highest area under 
the curve (AUC). At a cut-off value of 0.97, it harbored the optimal combination of sensitivity 
(76%; 95% CI: 59-93) and specificity (88%; 71-100), with a PPV of 90% (79-100) and a NPV of 70% 
(50-90) (Figure 3). 
Table 3. Univariate performance of Immunoglobulins IgG, IgG subclasses and IgE in distinguishing 
autoimmune pancreatitis from acute pancreatitis and chronic pancreatitis.
sensitivity, %  
(95% CI)
specificity, %  
(95% CI)
PPV, % 
(95% CI)
NPV, % 
(95% CI)
IgG4 > 1.4 g/L 83 (70-97) 89 (84-94) 61 (45-77) 96 (93-100)
IgG4 > 2.8 g/L 63 (46-81) 98 (96-100) 86 (71-100) 93 (88-97)
IgG4 > 5.6 g/L 30 (14-46) 100 (100-100) 100 (100-100) 87 (82-92)
Total IgG > 16 g/L 41 (24-58) 97 (95-100) 77 (54-99) 88 (83-93)
IgG1 > 11.4 g/L 25 (10-40) 97 (95-100) 67 (35-98) 85 (80-91)
IgG2 > 6.4 g/L 6 (-2-15) 92 (88-97) 15 (38-100) 81 (75-87)
IgG3 > 1.1 g/L 16 (3-28) 97 (93-100) 50 (12-88) 84 (78-89)
Ige > 100 g/L 67 (48-86) 57 (51-63) 29 (16-42) 93 (88-98)
The upper limits of normal (ULN); 16.0 g/L (IgG), 11.40 (IgG1), 6.40 (IgG2), 1.10 (IgG3), and 1.40 (IgG4). For IgE, 
no ULN is available.
Table 4. Serum IgG4 ratio analysis in patients with elevated IgG4.
subclass ratio, 
median (IQr) AIP 
Non-AIP;
AP + CP p-value AUC (95% CI)
IgG4/IgG 0.30 (0.26-0.53) 0.17 (0.15-0.20) 0.001 0.81 (0.67-0.95)
IgG4/IgG1 0.60 (0.41-0.92) 0.29 (0.23-0.37) 0.001 0.82 (0.68-0.95)
IgG4/IgG2 1.75 (0.94-2.65) 0.53 (0.33-0.91) <0.001 0.85 (0.73-0.97)
IgG4/IgG3 8.27 (4.85-10.34) 4.04 (2.81-8.03) 0.035 0.70 (0.52-0.88)
IgG4/Ige 0.02 (0.01-0.08) 0.03 (0.01-0.07) 0.730 0.47 (0.27-0.66)
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Our previously described results, showed that most non-AIP patients with elevated IgG4 
had values in the range of 1.4 to 2.8 (Figure 1), which correspond with a PPV of only 12%. When 
the IgG4/IgG2 ratio was applied, the PPV for this group improved to 75% (95% CI: 33-100), with 
a NPV of 80% (95% CI: 60-100). 
DIsCUssION
Our results show that elevated IgG4 levels occur in almost one out of ten AP patients and one 
out of five CP patients. However, in AP and CP, IgG4 levels rarely exceed twice the upper limit 
of normal. Thus, the PPV for AIP in patients with mildly elevated IgG4 is rather low, but can be 
substantially improved by applying the IgG4/IgG2 ratio. 
In line with our findings, previous studies have shown that elevated serum IgG4 does not 
preclude other forms of pancreatitis 15,16. In the subgroup with mildly elevated IgG4, the risk of 
misdiagnosis and mistreatment is apparent. However, a markedly elevated IgG4 is a reliable 
marker for AIP. Our study, with a large number of individuals from different, well-characterized 
patient populations, confirm earlier reports, to raise the cut-off value to twice the ULN to 
improve the diagnostic value 16,22. 
We found that none of the other IgG subclasses could compete with IgG4 as individual 
predictor of AIP. However, applying the IgG4/IgG2 ratio has additional benefit. A previous study 
found that the IgG4/IgG1 ratio improved the ability to differentiate IgG4-associated cholangitis 
Figure 3. ROC curve evaluating diagnostic value of IgG4/IgG2 ratio in AIP versus AP and CP with elevated 
IgG4. 
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from primary sclerosing cholangitis 17. In our cohort, the IgG4/IgG1 ratio was also higher in AIP 
patients, but the diagnostic performance of the IgG4/IgG2 ratio was slightly superior. 
For cholangitis, these differences in IgG4 ratios were explained by the fact that 23-30% of the 
primary sclerosing cholangitis patients showed generalized hypergammaglobulinemia, with 
elevation of all IgG subtypes, and may be induced by a nonspecific activation of the immune 
system 17,23.  In contrast, IgG4-associated cholangitis patients had an isolated elevation of IgG4, 
leading to elevated IgG4 ratios. However, this explanation does not apply for our cohort of 
AP and CP patients, as they did not have hypergammaglobulinemia. Elevated ratios in our AIP 
patients might therefore be solely explained by the marked elevation of IgG4 in AIP patients, 
compared to the usually mild elevation in AP and CP. The use of serum IgG4/subclass ratios in 
distinguishing AIP from AP and CP has not been described before. 
Boonstra et al designed a diagnostic algorithm to differentiate between the various bile 
duct disorders, which was evaluated in a validation cohort. In analogy, the diagnostic algorithm 
depicted in figure 4 is based on the current data. With IgG4 testing alone, 16 AP and CP patients 
would have been misclassified as AIP. With the proposed algorithm, 14 of these patients (88%) 
would have been diagnosed correctly. Obviously, this algorithm requires validation in other 
patient cohorts.
We also found IgE levels to be higher in AIP, compared to AP and CP patients. This is not 
an uncommon finding, as both IgG4 and IgE are considered to be part of an Th2 immune 
response 9. Furthermore, elevated IgE levels were previously reported in patients with IgG4-
related tubulointerstitial nephritis 24. Also, AIP patients showed significantly higher IgE levels, 
compared to pancreatic cancer patients, in a pilot study 18. A larger study should confirm 
whether this is a true predictor of AIP. 
The pathophysiology of AIP and IgG4-RD is still unclear, and both autoimmune and allergic 
responses have been postulated as underlying mechanisms 25,26. Elevated IgE levels, which 
have been described before, support the theory of an allergic response 18,27. Recently, an 
autoimmune response to occupational antigen exposure has been suggested to play a role 28. 
Chronic antigen stimulation by solvents, oils, or industrial dusts during a career in a blue-collar 
profession, similar to reported elevated IgG4 serum levels in beekeepers 29, is hypothesized to 
be a potential trigger of IgG4-related disease in susceptible individuals. 
Our study is the first to investigate combined immunoglobulin testing in a large group 
of AIP, AP and CP patients. Furthermore, we evaluated the value of IgG4/IgG subclass ratios, 
to provide more reliable differential diagnostic tools. However, there are several limitations 
AP/CP, DD AIP? IgG4>1.4 <2.8 g/L PPV AIP = 12% 
IgG4<1.4 g/L PPV AIP = 4%  
IgG4>2.8 g/L PPV AIP = 86%
AP or CP 
Serum IgG2 
Corticosteroids 
IgG4/IgG2 ratio < 0.97  
PPV AIP = 20%
IgG4/IgG2 ratio > 0.97  
PPV AIP = 75%
AP or CP 
Corticosteroids 
Figure 4. Diagnostic algorithm for distinguishing AIP from AP or CP using serum IgG4 and IgG4/IgG2 ratio 
analysis.
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to our study. For one, we did not possess the long-term clinical outcome data of all patients. 
In addition, serum samples were not obtained at the same time in the disease course (e.g. at 
presentation, when a patient first developed symptoms) and some AIP patients already had 
had steroids. 
In conclusion, we showed that mildly elevated IgG4 levels not only occur in AIP, but also 
in AP and CP patients and must therefore be interpreted with caution. However, IgG4 levels 
above twice the upper limit of normal do not occur in AP patients and are rare in CP patients. 
Therefore, to establish a diagnosis of AIP, increasing the IgG4 cut-off value seems inevitable. We 
also recommend combining IgG4 with IgG2 testing, to improve diagnostic accuracy. 
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ABsTrACT
Objectives
Autoimmune pancreatitis (AIP) is a rare form of chronic pancreatitis, clinically mimicking 
pancreatic cancer. In 2009, a serological marker for AIP, anti-PBP antibodies, was identified, with 
an outstanding sensitivity and specificity (NEJM 361:135). We aimed to validate the usefulness of 
serum antibodies against AKEERRY in identifying patients with type 1 AIP.
methods
Between March 2007 and May 2011 sera were collected from consecutive patients presenting 
with type 1 AIP, pancreatic adenocarcinoma (PAC), chronic pancreatitis (CP), primary sclerosing 
cholangitis (PSC), and healthy controls (HC) with or without antibodies against Helicobacter 
pylori. Serum antibody binding to synthetic PBP peptide was quantified by enzyme-linked 
immunosorbent assay (ELISA), using standard curves of custom-made PBP rabbit polyclonal 
antibodies. A synthetic FLAG-peptide (DYKDDDK), to which no antibodies are found in human 
serum, was included as negative control.
results
High sensitivity of AKEERRY peptide recognition was demonstrated by  selective binding of 
PBP peptide over Flag-peptide by PBP-immunized rabbit serum. Competition assays with PBP 
peptide validated the selectivity for antibodies recognizing this antigen. A total of 114 patients 
were subsequently tested; 34 AIP, 29 PAC, 17 CP, 16 PSC, and 18 HC’s (9 positive and 9 negative 
for H. pylori). No significant differences in detection of antibodies against the PBP peptide were 
found between different patient groups and healthy controls. 
Conclusions
Using a sensitive and selective ELISA-based assay, we did not find increased serum antibodies 
against the PBP peptide AKEERRY in AIP patients. PBP serum antibodies are therefore not a 
useful diagnostic tool to diagnose AIP.
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INTrODUCTION
Autoimmune pancreatitis (AIP) is a distinct type of pancreatitis, often part of a systemic IgG4-
related disease (IgG4-RD). This fibro-inflammatory disorder may also involve other organs, 
such as the biliary tree, kidneys, and salivary glands 1. Unlike other types of pancreatitis, AIP 
responds extremely well to steroid therapy 2. Clinically, AIP may mimic pancreatic cancer (PAC), 
with jaundice and weight loss as most common symptoms, and differentiation can be difficult. 
As serum IgG4 lacks diagnostic accuracy with a sensitivity of 76% and specificity of 93%, a 
number of other serological markers have been proposed 3-16. However, most were reported in 
a single publication only and none could be validated in a Western population 17. 
In 2009, Frulloni et al identified a novel serological marker by screening a random peptide 
library with pooled IgG obtained from 20 AIP patients 18. The identified peptide showed high 
homology with plasminogen-binding protein (PBP) from Helicobacter pylori as well as the 
human ubiquitin-protein ligase E3 component n-recognin 2 (UBR2), which is expressed in 
pancreatic acinar cells. In 94% of AIP patients and only 5% of PAC patients, IgG antibodies 
against PBP peptide (amino acid sequence AKEERRY) were subsequently observed, resulting in 
a diagnostic tool with an outstanding sensitivity and specificity of 94% and 95%, respectively. 
However, the promising results of this study have not been confirmed. 
The aim of the present study was to validate the usefulness of serum IgG antibodies against 
PBP peptide in discriminating type 1 AIP from PAC, chronic pancreatitis (CP), and primary 
sclerosing cholangitis (PSC). 
meTHODs
Patients
Between March 2007 and May 2011, sera were obtained from consecutive patients presenting 
with AIP, pancreatic carcinoma (PAC), chronic pancreatitis (CP) and primary sclerosing 
cholangitis (PSC). Furthermore, samples of healthy controls, with and without antibodies 
against H.pylori, were collected. Sera were stored at -80°C until use. The study was approved 
by the Institutional Review Board of the Erasmus MC University Medical Center (MEC-2013-581). 
Baseline characteristics of the different patient groups are summarized in Table 1. Patients 
with AIP were included if they fulfilled the ICDC or HISORt diagnostic criteria for AIP19,20. All AIP 
patients were of type 1 and 26 had extrapancreatic manifestations (77%). Twenty-four of the 
samples were collected at diagnosis (71%) and 10 after initiation of steroid treatment (29%). 
To prevent misdiagnosis, any chronic pancreatitis patients that fulfilled the AIP criteria were 
excluded.
All cases with pancreatic cancer were histologically proven and PSC patients were diagnosed 
according to accepted criteria 21. Serum samples of healthy controls were obtained from 
randomly selected blood donors and evaluated for H.pylori specific antibodies by a commercial 
ELISA kit (Pyloriset EIA-G-III, Orion diagnostics, Renkum, the Netherlands). At a positive cut off 
titre of ≥20, this test achieved a sensitivity of 100% (95% CI 95.6-100%) and a specificity of 94,3% 
(95% CI 88.6-97.7%). 
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Peptide synthesis
The amino acid sequence of plasminogen-binding protein (PBP) of Helicobacter pylori, as 
described by Frulloni et al 18 (AKEERRY), was manually synthesized with the standard method 
of Fmoc solid-phase peptide synthesis (Mimotopes, Melbourne, Australia). Total peptide 
sequence was Biotin-SGSGAKEERRY-NH2. Biotin was included to facilitate binding of the 
peptide to neutravidin-coated immunoplates (Pierce, Thermo Fisher Scientific, Rockford, IL.), 
as we observed low binding of unbiotinilated peptide to uncoated plates in standard carbonate 
buffer; and to ensure equal binding of peptide (at saturating levels) in all wells. The linker 
sequence was added as per manufacturers’ recommendation.  
Initial experiments using a variety of plastics and blocking agents showed high background 
levels, due to aspecific binding of human immunoglobulins. We therefore included a synthetic 
control peptide (FLAG-peptide, sequence Biotin-SGSGDYKDDDDK-NH2) to which no natural 
antibodies occur in human serum, which served as negative control.
rabbit antiserum production
Custom polyclonal rabbit antibodies against the AKEERRY sequence were generated by 
Eurogentec (Maastricht, the Netherlands), using the Speedy mini protocol. As small peptides 
are generally less immunogenic, the immunisation peptide used was AKEERRYAKEERRY. In 
silico analysis showed that this peptide was highly immunogenic across the whole sequence, 
and post-immunization serum specifically recognized the AKEERRY sequence. 
Assessment of antibody binding
Antibody binding was evaluated by means of a modified enzyme-linked immunosorbent 
assay (ELISA). Pre-blocked Neutravidin-coated plates (Thermo Fisher Scientific, Rockford, IL) 
were coated with 10 µl/ml peptide in phosphate-buffered saline (PBS) containing 0.1% bovine 
serum albumin (BSA), resulting in peptide binding at saturating levels (not shown). Plates were 
incubated at room temperature for one hour and unbound peptide was removed by washing 
four times with wash-buffer (PBS with 0.05% Tween-20). Plates were incubated overnight 
at 4 ºC with serum samples, diluted 1:50 in PBS/2% BSA. Plates were washed four times with 
Table 1. Baseline characteristics of all included patients (n=114)
Diagnosis No. of patients median age (IQr), y male gender, no. (%)
Autoimmune pancreatitis 34 66 (56-72) 29 (85)
Pancreatic carcinoma 29 65 (61-70) 17 (59)
Chronic pancreatitis 17 57 (49-62) 10 (59)
Primary sclerosing cholangitis 16 46 (39-54) 12 (75)
Healthy controls:  
H.pylori - serological status
9 62 (62-65) 6 (67)
Healthy controls:  
H.pylori + serological status
9 63 (59-65) 7 (78)
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wash-buffer and incubated with peroxidase-labeled antihuman IgG antiserum (Jackson 
ImmunoResearch, 1:1600 in PBS/2% BSA). Plates were then washed five times with wash-
buffer, followed by incubation with 3,3’,5,5’-Tetramethylbenzidine (TMB) substrate solution 
(eBioscience). The reaction was stopped by addition of 2N H2SO4 and plates were read on 
a Bio-Rad 680 XR microplate reader. The data were analysed with the software provided by 
the manufacturer. 
In each individual experiment, standard curves were performed using serial dilutions 
of custom-made rabbit polyclonal antibodies against PBP. Each serum sample was tested in 
triplicate for reactivity against AKEERRY peptide and the non-physiological FLAG-peptide. The 
latter values were subtracted as negative control. Anti-Flag antibodies (Signalway antibody, 
College Park, MD) were used to confirm saturated binding of the Flag-peptide. 
statistical analysis
Statistical analyses were performed using Graphpad Prism 5.0 and SPSS Statistics 20.0 Software. 
The nonparametric Kruskal-Wallis test was used to detect differences between groups. P-values 
<0.05 were considered to be statistically significant. 
resULTs 
In order to test whether the presence of antibodies against the H.pylori PBP peptide could 
distinguish between AIP and PAC  patients, we set up an ELISA assay, which sensitively and reliably 
measures reactivity against the AKEERRY peptide sequence in serum. Rabbit immunization 
with a tandem repeat of the AKEERRY protein resulted in the production of rabbit polyclonal 
antibodies specifically detecting the PBP, but not Flag-peptide by ELISA (Figure 1A). Serial 
dilutions showed that PBP peptide could be reliably measured above background, with serum 
diluted up to 50,000 times (Figure 1B), equivalent with purified antibodies up to 20 ng/mL. To 
further demonstrate specificity of the assay, we performed a competition assay, which showed 
selective inhibition of serum antibody binding to the helicobacter peptide, when serum was 
pre-mixed with PBP peptide, but not when Flag peptide was added (Figure 1C).  
Patients
Having optimized our assay to detect serum PBP antibodies, we subsequently tested a total 
of 114 patients; 34 patients with AIP, 29 with PAC, 17 with CP, 16 with PSC, 9 H.pylori negative 
healthy controls, and 9 H.pylori positive healthy controls. Considerable variation in antibody 
binding was observed between patients (examples shown in Figure 2A). However, no significant 
difference in detection of antibodies against the PBP peptide was found among the different 
patient groups or healthy controls (Figure 2B). In addition, sera from H. pylori positive controls 
did not show higher reactivity towards the PBP peptide than H. pylori negative sera (73.05±33.47 
vs 38.85±12.67, p=0.18; Figure 2B). 
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Figure 1. An assay to selectively and sensitively measure anti-PBP antibodies. 
(A) Neutravidin-plates were coated with biotin-PBP (PBP) or biotin-Flag (Flag) peptide, and wells were incubated 
with rabbit pre-immunisation blood serum (PIB), final bleed serum (SAB) or purified antibodies. No positive 
signal is detected in rabbit serum before immunization with AKEERRY tandem peptide, but specific reactivity 
against PBP, but not Flag, is detected after two rounds of immunization. 
(B) Serial dilutions of rabbit post-immunization serum (SAB) were performed on PBP-peptide or Flag-peptide-
coated Neutravidin plates, showing excellent sensitivity of PBP-peptide detection over a-specific binding.
(C) A 1:20,000 dilution of SAB serum was incubated on PBP-peptide-coated Neutravidin plates. Preincubation 
of sera with increasing concentration of PBP peptide resulted in increasing competition for antibody binding to 
the plates. In contrast, addition of Flag peptide to the sera did not inhibit antibody binding to PBP coated plates, 
demonstrating the specificity of the PBP-peptide:PBP-antibody interaction.
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DIsCUssION
In 2009, Frulloni et al identified a novel serological marker for AIP, by screening a random 
peptide library 18. This peptide showed homology with plasminogen-binding protein (PBP) of 
Helicobacter pylori as well as the pancreatic enzyme UBR2. These findings potentially provided 
a link between H.pylori infection and AIP. They would support the theory of microbial exposure 
and antigenic mimicry as a pathogenic mechanism in AIP – i.e. antibodies directed against 
bacterial components which resemble physiological proteins subsequently harm the body 
in an autoimmune response. H.pylori is associated with several autoimmune conditions like 
primary biliary cirrhosis, Sjögren syndrome, and autoimmune hepatitis, and molecular mimicry 
has been proposed as underlying basis for these diseases as well. The same relation is now 
suggested for autoimmune pancreatitis 22-24. Serum antibodies recognising a synthesized 
Figure 2. No difference in anti-PBP reactivity between AIP and other patient groups. 
(A) Raw ELISA results of a selection of serum samples of individual patients; reactivity against PBP and Flag 
peptide is shown, indicating patient variability. 
(B) ELISA results were compared to standard curves and specific PBP reactivity is shown for all individual 
patients. Patient group mean±SEM is indicated. H. Pylori-positive healthy controls are indicated by grey 
circles. SAB indicates PBP-immunized rabbit serum; Pur Ab purified antibodies; AIP autoimmune pancreatitis; CP 
chronic pancreatitis; PAC pancreatic adenocarcinoma; HC healthy control; PSC primary sclerosing cholangitis.
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bacterial peptide (PBP peptide AKEERRY) were shown to have a sensitivity of 94% and specificity 
of 95% in identifying AIP patients from PAC patients. While promising, these results have not yet 
been confirmed by others and this test has not found wide spread implementation in the clinic. 
In the present study, using a sensitive and selective ELISA-based assay, we did not find increased 
serum antibodies against the PBP peptide AKEERRY in AIP patients. 
Implementation of a novel diagnostic tool requires a reproducible assay, which can be 
performed in multiple labs world-wide with comparable results. While the previous study 
used Delphia technology to sensitively measure anti-PBP antibodies, this technology is not 
available in many facilities, including ours. We therefore aimed to set up an assay that could 
find a wider application. As small peptides are notoriously poor at binding to plastic surfaces, 
and since binding differences between wells as well as experiments and facilities may hamper 
reproducibility, we employed biotin-labelled peptide to coat Neutravidin-plates at saturating 
levels. This method allows quantitative measurement of nanograms of anti-PBP antibodies. 
While we did find positivity in some serum samples, we did not observe differences between AIP 
and PAC patients, or H.pylori positive and negative healthy donors. Unfortunately, we were not 
able to cross-test serum samples from the two studies with the two different methods. While 
it is theoretically possible that we have included mainly H. Pylori-negative AIP patients, this 
seems unlikely, given the known prevalences in our country25. Based on these prevalences in 
the healthy population, at least 46% of AIP patients would be expected to be H. pylori-positive, 
which would still be lower than the 83% reported in by Frulloni et al. However, in the latter study 
there was not a one-on-one correlation between H. Pylori positivity and serum positivity for 
PBP peptide.
As our results do not point towards a diagnostic role for PBP-antibodies in AIP, the search 
for other biomarkers continues. Recently, another type of chronic antigen exposure has been 
described, which would plead for an antigen-driven immune process26. High rates of potential 
chronic occupational antigen exposure to solvents or industrial or metal dusts were found in 
two independent AIP cohorts who proved to be composed mainly of blue collar workers. The 
investigators suggest that this exposure may play a role in the initiation and/or maintenance 
of IgG4-RD in susceptible individuals. These findings could provide an interesting insight into 
the unknown pathophysiology of AIP or IgG4-related disease, and suggest that while disease 
epitopes may be diverse (hampering the identification of novel markers for a diagnostic tool), 
the search for these epitopes should potentially focus on environmental antigens.  
In conclusion, we could not confirm  detection of serum anti-PBP antibodies  as a potential 
useful diagnostic tool in AIP.
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Objective
To evaluate the occurrence and histopathological characteristics of IgG4-related prostatic 
involvement in patients diagnosed with AIP.
methods
Nine cases of IgG4-related prostatitis were identified among 117 males in the autoimmune 
pancreatitis and IgG4-associated cholangitis patient databases in two tertiary hospitals. Clinical 
information was retrieved and available prostatic tissue samples and 18 prostatitis control 
samples were evaluated for characteristic IgG4-related disease (IgG4-RD) features: maximum 
number of IgG4+ cells/HPF; dense lymphoplasmacytic infiltrate; fibrosis, arranged at least 
focally in a storiform pattern; phlebitis with or without obliteration of the lumen; and increased 
number of eosinophils. 
results
The aspecific sign of urine retention was commonly present in IgG4-RD patients with prostatic 
involvement. In these patients with IgG4-related prostatitis, the median number of IgG4+ cells in 
prostatic tissue was 150 (IQR20-150) per high power field, compared with a median of 3 (IQR1-11) 
in control patients (p=0.008). Dense lymphoplasmacytic infiltrate was observed in the majority 
(86% in cases and 72% in control patients) of tissue samples independent of the underlying 
cause of prostatitis. Fibrosis in at least a focally storiform pattern was seen rarely in both groups 
and (obliterative) phlebitis was absent in all patients. Furthermore, eosinophil numbers were 
more often elevated in patients with IgG4-RD compared to controls (p<0.001). In two cases 
amelioration of the prostatitis symptoms upon corticosteroid treatment was documented.
Conclusion
Prostatic involvement may not be rare in patients with pancreatic and/or biliary IgG4-RD. 
Clinicians should consider this disease entity in patients with IgG4-RD and prostatic symptoms.
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INTrODUCTION
Prostatitis may be due to infectious and non-infectious causes, of which chronic abacterial 
prostatitis, or chronic pelvic pain syndrome, is by far the most common1. IgG4-RD is a rare 
systemic disorder that is best known for its manifestations in the pancreas (autoimmune 
pancreatitis, AIP) and biliary tree (IgG4-associated cholangitis, IAC)2,3. However, several 
other organs may be involved, including the kidney and prostate (Supplementary table 1)4-7. 
Most patients with IgG4-RD have elevated serum levels of IgG4 and increased numbers of 
IgG4-positive plasma cells in tissue8. Disease activity can usually be adequately repressed by 
corticosteroid therapy2. 
The diagnosis of the disease, which in most affected organs closely mimics malignant 
disease, can be extremely challenging, both due to the absence of an adequately sensitive 
and specific test and to limited insight in the clinical phenotype. This certainly holds true 
for the prostate manifestation of IgG4-RD, first published in 2006, which in many cases may 
remain undetected. Based on prostate imaging, it is not possible to distinguish IgG4-related 
prostatitis from other types of prostatitis.  As IgG4-RD typically responds well to corticosteroid 
treatment9,10, recognition of IgG4-related prostatitis may enable adequate treatment in these 
patients and could thus avoid unnecessary (surgical) interventions. 
An initial case of what appeared to be IgG4-related prostatitis in one of our patients focused 
our attention to this disease entity. As it is known that IgG4-RD can often simultaneously affect 
multiple organs in a single patient, we reasoned that we might be able to detect prostate 
localizations of IgG4-RD in our cohort of patients with pancreatic and/or biliary manifestations 
of the disease. We thus aimed to investigate in a larger cohort of patients with IgG4-RD the 
occurrence and histopathological characteristics of IgG4-related prostatitis. 
mATerIAL AND meTHODs
Patients and controls
Identification of cases with IgG4-RD prostatitis
The index case (case 1) was identified based on non-prostate imaging and remarkable response 
to therapy.  A cross search for patients with prostatitis symptoms mentioned in the patient 
files was then performed in the AIP and IAC patient registry of two tertiary centers in The 
Netherlands, containing a total of 117 patients diagnosed with either disease between 1992 to 
2012. As controls, prostatic biopsies of patients with prostatitis with or without benign prostatic 
hyperplasia but without a history of IgG4-RD of any organ were used. The study was approved 
by the Institutional Review Board of the Erasmus MC University Medical Center.
Histopathological examination
Hematoxylin-eosin-stained prostatic tissue of case and control patients was evaluated for the 
following characteristic features, as described by Desphande et al8: (dense) lymphoplasmacytic 
infiltrate; fibrosis, arranged at least focally in a storiform pattern; phlebitis with or without 
obliteration of the lumen; and increased number of eosinophils. Routine IgG4 immunostaining 
was performed using monoclonal IgG4 antibody on formaline-fixed, paraffin-embedded 
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tissue. All cases were evaluated by 4 investigators blinded to the patient’s diagnosis and led 
by two senior pathologists, of whom one is the national expert on pathology of IgG4-RD and 
one is specialized in prostate histology. In case of opposing views, consensus was reached 
by discussion.
statistical analysis
Comparison of categorical data between cases and controls was performed using the Fisher’s 
exact test. For continuous variables, comparisons were made using the Kruskal-Wallis test.
resULTs
Case presentation 
To illustrate the clinical presentation of IgG4-related prostatic disease we here present one of 
our patients in more detail.
A 39-year old man was referred to the urological outpatient clinic in 2007 with symptoms of 
urinary hesitancy. Urine sediment, culture and flowmetry did not reveal any abnormalities and 
serum PSA was 0.2 ng/mL. Since his symptoms were mild, no specific therapy was instituted. 
In 2008, he presented at the outpatient clinic of gastroenterology with upper abdominal 
pain, loss of appetite and 8 kg weight loss. A diagnosis of AIP was suspected, based on a 
diffuse pancreatic enlargement with rim enhancement on computed tomography imaging, an 
elevated serum IgG4 level of 1400 mg/dL (normal<140 mg/dL). Furthermore, his obstructive 
urinary symptoms had markedly increased in severity and computed tomography (CT) of the 
abdomen (Figure 1) revealed an enlarged, homogenous prostate with ascites in the small pelvic 
region. 
Treatment with prednisolone 40 mg/day was instituted; the patient reported total 
disappearance of his urinary problems within 4 days and of his other symptoms within 3 weeks. 
Abdominal CT after 2 months showed significantly decreased prostate and pancreatic swelling 
and complete disappearance of ascites in the small pelvic region (Figure 1). The prednisolone 
dose was gradually tapered and stopped after one year.  In the following three years his medical 
condition remained stable and he was free of urinary or other complaints.
Case series
A total of nine cases of prostatic IgG4-RD were identified, based on histology, non-prostate 
imaging, or response to therapy. Clinical findings are summarized in Table 1. The patients 
were males (age 39-74), with 4/9 (44%) patients  previously diagnosed with autoimmune 
pancreatitis or cholangitis as a manifestation of IgG4-RD, presenting with severe symptoms of 
urine retention. In 5/9 (56%) patients IgG4-related autoimmune pancreatitis or cholangitis was 
preceded by obstructive urinary symptoms in the foregoing 3 years. Serum PSA was elevated in 
two patients (22%), serum IgG4 in 7/9 (78%) patients. 
Four out of 9 (56%) patients underwent transurethral resection of the prostate (TURP) and 
one suprapubic prostatectomy (SPP) for release of obstructive symptoms. In two patients (22%) 
needle biopsies were taken for exclusion of prostate adenocarcinoma. The majority of these 
9 patients were retrospectively diagnosed with IgG4-prostatitis, based on histopathological 
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Figure 1. Contrast enhanced abdominal CT in a 39-year old man before and after steroid treatment 2 
months later. (A) Sausage-shaped pancreatic body (*) with subtle hypodense capsular rim. The pancreatic 
tail (short white arrow) is relatively atrophic. (B) Enlarged prostate (51 x 49 x 49 mm) of homogeneously low 
density. (C) After steroid treatment the pancreatic body (*) has decreased to normal size, although still with 
loss of normal lobularity. Note irregular and slight pancreatic duct dilatation in atrophic tail (short white arrow). 
(D) Decrease of prostate enlargement (45 x 47 x 44 mm) and return of zonal distinction after steroid treatment.
Table 1. Clinical characteristics of patients with IgG4-related prostatitis
Case
Age
(years) LUTs
Interval between AIP 
and prostatitis
serum IgG4  
(mg/dL) †
serum PsA 
(ng/mL) ‡
specimen 
type
response to 
prednisolone
1 39 yes 9 mo* 1400 0.2 none yes
2 67 yes 2 y 1320 2.3 none yes
3 69 yes 3 y 5 4.2 TURP not treated
4 64 yes 2 y* 570 7.4 TURP not treated
5 74 yes 3 y* 613 54 SPP not treated
6 67 yes 1 mo 1830 0.56 TURP not treated
7 63 yes 3 mo 90 0.5 NB not treated
8 74 yes 2 mo* 832 1.23 TURP not treated
9 72 yes 2.5 y* 733 6.6 NB not treated
† Normal value, 8-140 mg/dL; ‡ normal value, <2.5 ng/mL in males aged 40-49 y, <3.5 ng/mL if 50-59 y, 
<4.5 ng/mL if 60-69 y, < 6.5 ng/mL if 70-79; 
* Prostatitis before the diagnosis of AIP.
LUTS indicates lower urinary tract symptoms; AIP, autoimmune pancreatitis;  
N, normal value; NA, data not available; 
TURP, transurethral resection of the prostate; SPP, suprapubic prostatectomy; NB, needle biopsy;
A C
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findings. Therefore, no steroid therapy was instituted specifically aimed to reduce prostatic 
complaints. However, steroid therapy leading to improvement of obstructive symptoms 
is described in the case presented above. A second patient developed severe urinary tract 
symptoms, which he himself ascribed to the discontinuation of steroid treatment because the 
symptoms arose within a few days of steroid cessation. There was no suspicion of prostatic 
cancer according to the attending urologist based amongst others on digital rectal examination, 
so there was no need to obtain tissue. After several drugs were instituted without result, the 
patient requested restart of steroid treatment and within days his lower urinary tract symptoms 
(LUTS) resolved (Table 1).
Histopathological results
An overview of the results of histopathological examination of prostatic tissue is presented in 
Table 2. Dense lymphoplasmacytic infiltrate was present in 6/7 (86%) cases and 13/18 (72%) control 
patients. Fibrosis in a storiform pattern was seen in one patient in both groups and phlebitis in 
none of the patients. An increased number of eosinophils was seen in 6/7 cases and 0/18 control 
patients (p<0.001). Significant differences were found in the number of IgG4-positive cells/HPF, 
with a median of 150 (IQR 20-150) in the cases and 3 (IQR 1-11) in the control patients (p=0.008).
Table 2. Histopathological characteristics of prostatic tissue of cases and controls (total n=25)
Cases Control patients p-Value
Number of patients 7 18
Tissue obtained by: 0.9992
     Resection, no (%) 5 (71%) 12 (67%)
     Biopsies, no (%) 2 (29%) 6 (33%)
IgG4 staining of tissue:
     Number of IgG4+ cells/HPF, median (IQR) 150 (20-150) 3 (1-11) 0.008*,3
IgG4-rD histopathological features observed in prostate tissue:
     Dense lymphoplasmacytic infiltration, no (%) 6 (86%) 13 (72%) 0.6372
     Fibrosis, at least focally in a storiform pattern, no (%) 1 (14%) 1 (6%) 0.4902
     Phlebitis, with or without obliteration of the lumen, no (%) 0 (0%) 0 (0%) N.A.
     Increased number of eosinophils1, no (%) 6 (86%) 0 (0%) <0.001*,2
1 Increased number of eosinophils: > 10/HPF; 2 Fisher’s exact test; 3 Mann-Whitney test; * p-Value < 0.05; NA: not 
applicable
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Figure 2. Trans urethral resection of the prostate (TURP) showing IgG4-related prostatitis. 40x and 200x 
magnification showing patchy lymphoplasmacytic infiltrations with increased number of eosinophils (A, 
B). 100x and 200x magnification with immunohistochemical stain for IgG4 shows many (>40/HPF) IgG4-
positive cells (C,D).
COmmeNT
We here describe, to our knowledge, the largest series of cases with prostatic involvement in 
patients with IgG4-RD. Although the study design did not allow for the identification of any 
urological symptoms specific for IgG4-related prostatitis, we did find 9 patients with suspected 
prostatic involvement among a total of 117 patients with IgG4-related pancreaticobiliary 
disease. We observed marked differences between the prostate tissue of patients with 
IgG4-RD and control prostatitis patients: tissue infiltration with IgG4-positive plasma/B cells 
and eosinophils were characteristic histological features in patients with prostatitis associated 
with IgG4-RD. Our findings show that the prostate represents an organ more often affected by 
IgG4-RD than previously assumed and these data may help physicians that treat patients with 
systemic IgG4-RD to recognize prostatic involvement. Furthermore, our case series stresses 
that urological symptoms may precede other organ manifestations, and detection of IgG4-
related prostatitis in these cases could speed up the diagnostic and therapeutic process in 
these patients.
A B
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Little is known on IgG4-related prostatitis. Until now a total of ten patients have been 
reported in the literature (Supplementary Table 1)4-7. Our case series shows that the clinical 
phenotype, serological and pathological features among these nine patients are comparable 
to the previous reported cases, strengthening the concept of IgG4-related prostatitis as a 
clinical entity. 
Diagnosing IgG4-RD in all cases relies on the combined approach of excluding other causes 
for the observed disease pattern and the application of positive criteria for the presence of 
IgG4-RD, of which the HISORt-criteria11,12 are most widely applied in the US and Europe. In 
the pancreas and biliary tree it is well-documented that IgG4-RD lesions may strongly mimic 
malignant processes and this appears to be the case as well in the prostate13,14. Up to now, serum 
IgG4 is the best single test to diagnose IgG4-RD. However, sensitivity and specificity are limited 
with elevated serum IgG4 levels present even in malignant disease15-18. Clinicians thus need 
to fully exclude other causes for the disease and furthermore gather pieces of evidence that 
support the diagnosis of IgG4-RD19. A careful history taking or IgG4 immunohistochemistry on 
historic biopsy specimens may reveal earlier episodes suggestive of IgG4-RD in the same or 
other organs.
The histological interpretation of tissues affected by IgG4-RD remains challenging. Using 
the most widely accepted criteria as defined by Deshpande et al.20 we observed that the 
prostate lesions in IgG4-RD patients showed elevated numbers of IgG4-positive plasma/B 
cells and eosinophils per HPF, in line with earlier descriptions in other organs affected by 
IgG4-RD. The cut-off value of 20 IgG4-positive cells per HPF that is used in the pancreas seems 
adequate for the prostate. It should be noted that sampling issues regularly are a problem in the 
histological evaluation of IgG4-RD tissue due to the patchy distribution of the IgG4-positive B/
plasmacellular infiltrate. In our study, many resection specimens were available, which may not 
always be the case in clinical practice.
Storiform fibrosis, once considered a hallmark of IgG4-RD pathology, was not found to be 
significantly present, as it has earlier been reported to be absent in organs like lymph node21, 
lung22, or lacrimal glands23. These differences are in line with our earlier observations in other 
tissues and with the reported variability across the different organs12,24,25.  Pathologists should 
thus be aware of IgG4-RD in the prostate, when conspicuous infiltration of lymphocytes and 
plasma cells together with eosinophils is observed. 
In line with the earlier published cases of IgG4-prostatitis we have documented several 
patients in which steroid therapy did improve symptoms. As we detected most patients in 
a retrospective fashion, though, the bulk of patients did not receive immunosuppressants 
targeted at the urological symptoms, making it impossible to draw conclusions regarding the 
efficacy of treatment to normalize prostate functioning. Ideally, this should be investigated in 
a prospective way.
Furthermore, one of the main characteristics of IgG4-related disease is the dramatic 
response to steroid therapy2. It seems unlikely that IgG4-related prostatitis will be an exception 
in this context. Therefore, in patients with a suspicion of IgG4-related prostatitis and not 
responding to steroid therapy, this diagnosis should be reconsidered.
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This case series could imply that a proportion of patients currently diagnosed with chronic 
prostatitis or chronic pelvic pain syndrome may in fact suffer from a monosymptomatic disease 
manifestation of IgG4-related prostatitis. Especially in patients with well-established IgG4-RD 
presenting with LUTS, prostatic involvement should be considered to avoid ineffective medical 
or unnecessary surgical treatment.  As we have in this study identified patients with prostate 
involvement in our cohorts of IgG4-RD of the pancreas and/or biliary tree, it would equally be 
interesting to investigate the prevalence of suspected IgG4-related prostatitis among a large 
cohort of patients with not otherwise explained prostatitis. 
We can only speculate upon the mechanisms that underlie the striking range of organs that 
have been reported as localizations of IgG4-RD. Chronic antigenic exposure could underlie a 
IgG4-dominant response26, potentially directed against a self-antigen, but the IgG4 response 
could also be reactive to chronic immune activation, as was recently shown in malignant 
melanoma where IgG4 suppresses the IgG1-mediated chronic antitumor-response18. 
CONCLUsIONs
In conclusion, we here present the largest case series of patients with prostate involvement of 
IgG4-related systemic disease. Our case series shows that the association is not rare and stresses 
the need for both urologists and pathologists to consider IgG4-RD as a possible cause for 
prostatic symptoms as well as for physicians treating patients with other organ manifestations 
of IgG4-RD to be aware of the possibility that the prostate can also be affected by IgG4-RD.
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supplementary Table 1. Clinical features of earlier reported patients with IgG4-related prostatitis
reference
Age
(years) LUTs AIP
serum IgG4  
(g/L) †
serum PsA 
(µg/L) ‡ Procedure
response 
to steroids
Yoshimura  
et al 1
65 yes yes 3.79 N TURP yes
Nishimori  
et al 2
40 yes yes 10.30 NA NB yes
Nishimori  
et al 2
49 yes no 4.73 1.62 TURP not treated
Uehara  
et al 3
66 yes yes 15.50 5.5 RP not treated
Uehara  
et al 3
73 yes yes 14.35 7.2 NB not treated
Uehara  
et al 3
71 yes yes 4.99 1.57 NB yes
Uehara  
et al 3
55 yes yes 14.40 0.38 NB yes
Uehara  
et al 3
73 yes yes 11.60 5.84 NB not treated
Uehara  
et al 3
66 yes yes 13.00 0.1 NB yes
Hart et al4 55 yes yes 10.00 0.67 NB yes
† Normal value, 0.08-1.40 g/L; ‡ normal value, <2.5 µg/L in males aged 40-49 y, <3.5 µg/L if 50-59 y, <4.5 µg/L if 
60-69 y, < 6.5µg/L if 70-79;  
LUTS indicates lower urinary tract symptoms; AIP, autoimmune pancreatitis; N, normal value; NA, data not 
available; TURP, transurethral resection of the prostate; RP, radical prostatectomy; NB, needle biopsy;
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ABsTrACT
Objective 
The objective of this study was to compare efficacy of high versus low doses of prednisone for 
induction of remission in autoimmune pancreatitis (AIP).
methods
This is a retrospective, multicenter study including patients diagnosed with AIP between May 
1992 and August 2011. Clinical, laboratory and imaging findings were assessed before treatment 
and at 1, 3, and 6 months after starting treatment. 
results
A total of 65 patients (57 males; median age, 63 years) were treated with an initial low dose 
(10-20 mg/d, n = 14), a medium dose (30 mg/d, n = 15) or a high dose (40-60 mg/d, n = 36) 
of prednisone. There were no significant differences in baseline characteristics between 
the treatment groups including age, presenting symptoms and laboratory results. During a 
follow-up period of 6 months, in nearly all patients symptoms ( jaundice, weight loss) resolved 
completely. After 6 months, treatment response with respect to symptomatic, radiological and 
laboratory improvement was comparable for the different dosage groups. 
Conclusions
Response to therapy was comparable for AIP patients treated with doses of prednisone in the 
range of 10 to 60 mg/d.  A prospective trial should be conducted to confirm efficacy of lower-
dose prednisone treatment.
95
LOW-DOSE STEROIDS IN AIP
7
INTrODUCTION
Autoimmune pancreatitis (AIP) is a distinct type of chronic pancreatitis, predominantly affecting 
males in their fifth and sixth decade. Frequently AIP represents the pancreatic manifestation of 
immunoglobulin G4 (IgG4)-related disease, a systemic disorder that may involve not only the 
pancreas but also almost any other organ. Patients frequently present with obstructive jaundice, 
weight loss, steatorrhea, and diabetes mellitus. Characteristic radiological features include 
diffuse enlargement of the pancreas and irregular narrowing of the main pancreatic duct.
Laboratory tests often reveal elevated serum levels of IgG and/or IgG41. Histologically, AIP 
is frequently associated with a lymphoplasmacytic infiltration rich of IgG4-positive plasma cells 
and fibrosis of the pancreatic parenchyma2.
Unlike other types of pancreatitis, AIP responds dramatically to steroid therapy3-7. The 
usually recommended dosage of prednisone (or equivalent dosage of prednisolone) for 
remission induction is 0.6 mg/kg per day, resulting in daily starting doses of 30 to 40 mg8-10. 
This recommended dosage is largely based on empirical data but lacks a solid scientific basis. 
Corticosteroid treatment, in particular when high doses are used, is potentially associated with 
significant side effects11-14. These negative treatment effects may even be more important in 
patients presenting with AIP because this is a population characterized by relatively advanced 
age, (de novo) diabetes mellitus, and obstructive jaundice. 
Furthermore, the rationale for high-dose treatment could be questioned considering the 
well-established sensitivity of AIP to corticosteroids. We therefore investigated the efficacy of 
treatment in AIP patients using low (≤20 mg), medium (30 mg), and high (≥40 mg) daily doses 
of prednisone therapy for induction of remission.
meTHODs
Patients and treatment
A retrospective, multicenter study was conducted among patients diagnosed with AIP between 
May 1992 and March 2012 in 4 centers in the Netherlands. Data were retrieved from electronic 
medical record systems and by reviewing paper hospital charts.  
Patients were included if they fulfilled the International Consensus Diagnostic Criteria, 
Asian or HISORt (Histology, Imaging, Serology, Other organ involvement and Response to 
therapy) diagnostic criteria for AIP, or if diagnosis could be based on post-surgery histology, a 
combination of unexplained pancreatic disease, biliary disease/extrapancreatic manifestations 
and either response to steroids or IgG4-positive serology, and had been treated with prednisone 
therapy for induction of remission7, 15, 16.
All patients were treated with oral prednisone, not  according to a particular multicentre 
protocol but at the discretion of the treating physician. In patients treated with 10 or 15 mg per 
day, this dose was maintained for at least 6 months. In 3 other centers, patients were generally 
treated with 30 to 40 mg prednisone per day during 2 to 4 weeks after which the dose was 
tapered, usually with 5 mg per 1 to 2 weeks. 
Patients were excluded when (1) essential data with respect to the dose and duration of 
treatment and the evolution of symptoms, radiological abnormalities, and laboratory findings 
96
Chapter 7
were not available; (2) they had previously been treated with corticosteroids for the same 
condition; (3) concurrent initial treatment with azathioprine or other immunomodulating 
agents was instituted during the first three months because this was considered to hamper 
interpretation of the results; (4) when biliary stents were still in place 6 months following the 
start of treatment, to exclude confounding by biliary drainage on clinical and biochemical 
response (Figure 1).
65 patients enrolled
21 excluded: no prednisone treatment
28 excluded:
- 17 missing data
- 9 combination of prednisone and 
azathioprine for remission induction
- 2 biliary stent in situ at endpoint (=6 months)
114 potential study participants
93 treated with prednisone for 
remission induction
Data regarding induction of remission by steroid treatment were collected immediately 
before starting treatment (maximal allowed period 4 weeks) and subsequently after 1, 3, and 
6 months.
In addition, data on concurrent biliary drainage, timing of stent removal, and other 
immunosuppressive drugs, which were initiated during the follow-up period, were analyzed. 
Symptomatic response was defined as the disappearance of the initial clinical symptoms. 
Radiological response was defined as marked improvement or resolution of the pancreatic 
and/or extrapancreatic manifestations on imaging studies, particularly pancreatic swelling 
and pancreatic and biliary duct strictures. Relapse was defined as recurrence of disease after 
discontinuation of steroid therapy.
Laboratory evaluation
The following laboratory parameters were analyzed: serum levels of IgG4, IgG, total bilirubin, 
alkaline phosphatase (ALP), aspartate aminotransferase (ASAT), and alanine aminotransferase 
(ALAT).  
Imaging
Initially patients were examined by contrast-enhanced computed tomography (CT), magnetic 
resonance imaging (MRI), and/or endoscopic retrograde cholangiopancreatography (ERCP). 
Morphological changes after steroid therapy were studied with CT and MRI or ERCP. 
Figure 1. Study enrollment and exclusion.
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Complete remission
We used the following criteria to evaluate complete remission in the different dosage groups: 
disappearance of clinical symptoms and resolution of pancreatic abnormalities on imaging 
studies.
statistical analysis
Data were analyzed in several ways. First, we analyzed data with prednisone as a continuous 
variable. We also analyzed data with patients categorized into 2 prednisone dosage groups 
(≤20  and >20 mg/d). Finally, data were analyzed with patients categorized into 3 prednisone 
dosage groups (low dose: 10-20 mg/d, medium dose: 30 mg/d and high dose: 40-60 mg/d). 
Results are presented with patients categorized into 3 dosage groups (low, medium, and high).
Statistical analysis was performed using Fisher exact test and Kruskall-Wallis test using 
SPSS 17.0 to compare baseline characteristics between patients treated with different doses of 
prednisone. 
Differences in symptomatic and radiologic response between groups treated with different 
initial doses of prednisone were compared using Fisher exact test. Differences in biochemical 
response between the treatment groups were compared in a repeated measurement model 
with a random intercept and random decline from baseline to month 1 and a random linear 
decline from month 1 and onwards to month 6. This broken stick model was used to describe 
the observed changes in the 2 described periods. The random intercept allows for adjustment 
of the individual baseline biochemical values.
To correct for multiple testing, P < 0.01 was considered statistically significant. 
medical ethical concerns
The study was approved by the Institutional Review Board of the Erasmus University Medical 
Center, Rotterdam, the Netherlands.
resULTs
Patients
A total of 65 patients with AIP (57 men and 8 women with a median age of 63 years) were 
included (Figure 1). A recent onset of diabetes mellitus (<1 year) was seen in 24 (38%) of 
65 patients. Extrapancreatic manifestations were observed in 48 (74%) of 65 patients, including 
IgG4-related sclerosing cholangitis in 38 (59%) of 65 cases. Table 1 provides a further overview 
of demographic data and clinical symptoms. 
No patients were lost to follow-up during the six months’ study period. Five patients were 
treated with an initial dose of prednisone of 10 mg/d, 2 patients with 15 mg/d, 7 patients with 
20 mg/d, 15 patients with 30 mg/d, 34 patients with 40 mg/d, and 2 patients with 60 mg/d. 
The mean prednisone induction dosage in the low dose group (10-20 mg) was 0.22 mg/kg per 
day, in the medium dose group (30 mg) was 0.41 mg/kg per day and in the high dose group 
(40-60 mg) was 0.55 mg/kg per day.
There were no significant differences in baseline characteristics including gender, age, 
presenting symptoms, laboratory, and imaging results between the treatment groups (Table 1).
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In general, the initial dose was administered for 2 to 4 weeks and gradually tapered by 
5  mg every 2 weeks. In patients treated with 10 to 20 mg/d, the initial dose was maintained 
for a longer period. During the follow-up period, the dose of prednisone was not raised in the 
low-dose group.
At the time when prednisone was started, 28 (43%) of 65 patients were treated for distal 
biliary obstruction by endoscopic insertion of plastic endoprotheses: 6 (43%) of 14 patients in the 
Table 1. Baseline patient characteristics
AIP patients 
(n = 65)
Low Dose
(n = 14)
medium Dose
(n = 15)
High Dose
(n = 36)
Dose 
Categorized:
Low-medium-
High
(P)
Male, n (%) 57 (88) 13 (93) 12 (80) 32 (89) 0.60*
Age at onset, median (IQR), y 63 (53-71) 67 (62-74) 59 (49-66) 62 (44-72) 0.02†
Weight, median (IQR), kg 74 (70-83) 72 (58-84) 74 (67-79) 74 (70-87) 0.42†
Initial symptoms, n (%)
Jaundice 47 (73) 11 (79) 11 (73) 25 (71) 0.93*
Weight loss 55 (87) 13 (93) 12 (80) 30 (88) 0.68*
Recent-onset diabetes
mellitus
24 (38) 6 (43) 5 (33) 13 (37) 0.89*
Steatorrhea 40 (69) 12 (86) 12 (80) 16 (55) 0.10*
Abdominal discomfort 34 (53) 6 (43) 7 (47) 21 (60) 0.50*
Laboratory tests, median (IQR)
IgG4, g/L (n ≤ 1.40) 5.4 (1.7-11.0) 8.6 (5.4-20.6) 3.3 (0.6-8.0) 5.0 (1.0-9.6) 0.02†
Elevated IgG4, n (%) 41 (77) 11 (100) 7 (70) 23 (72) 0.11*
IgG, g/L (n ≤ 16.0) 16.1 (11.5-20.8) 20.0 (14.4-28.1) 21 (8.7-28.6) 14.5 (11.3-17.4) 0.04†
Total bilirubin, µmol/L 
(n ≤ 16)
49 (14-151) 42 (17-150) 79 (18-182) 49 (13-138) 0.78†
ALP, U/L (n ≤ 114) 425 (235-618) 564 (309-768) 468 (333-794) 379 (203-590) 0.20†
ASAT, U/L (n ≤ 34) 126 (55-186) 139 (77-168) 146 (72-176) 93 (38-223) 0.63†
ALAT, U/L (n ≤ 44) 129 (67-306) 130 (65-213) 137 (112-461) 127 (49-337) 0.53†
Radiology, n (%) 
Pancreatic enlargement
Diffuse
Focal
34 (58)
16 (27)
6 (46)
4 (31)
6 (50)
4 (33)
22 (65)
8 (24)
0.68*
Diffuse narrowing 
pancreatic duct
22 (54) 4 (80) 4 (44) 14 (52) 0.55*
Extrapancreatic lesions, n (%)
IgG4-related sclerosing 
cholangitis, n (%)
48 (74)
38 (58)
12 (86)
9 (64)
11 (73)
10 (67)
25 (69)
19 (54)
0.55*
0.54*
* Exact test
† Kruskal-Wallis test
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low-dose group, 5 (33%) of 15 in the medium-dose group and 17 (47%) of 36 in the high-dose group. 
These stents were removed after a median of 10 weeks (interquartile range [IQR], 5-15) weeks.
During the follow-up period of 6 months, azathioprine was added to steroid therapy in 12 
(18%) of 65 patients: 6 of 14, 1 of 15, and 5 of 29 in the low-, medium- and high-dose group, 
respectively. The shortest interval between initiation of steroid treatment and introduction of 
azathioprine was 4 months. Seven (58%) of the 12 patients who were treated with azathioprine 
took this drug during at least 2 months. The number of patients treated with azathioprine 
during the 6 months follow-up period did not differ between the treatment groups (P = 0.038). 
Clinical response
During a clinical follow-up period of 6 months, 59 (92%) of 65 patients achieved complete 
clinical response, whereas in 5 (8%), the response was partial. The regression of clinical 
symptoms after 6 months of treatment was not associated with the dosage of prednisone 
(P = 0.999) (Figure 2). 
During the 6-month follow-up period, all patients in the low-dose group continued prednisone 
treatment in contrast to 12 of 15 and 20 of 36 in the medium- and high-dose group, respectively (P = 
0.003). No relapses were observed in those patients in whom prednisone was discontinued. 
We also analyzed data with prednisone dosage as a continuous variable and categorized into 
2 prednisone dosage groups (≤20 and >20 mg/d). No dose-response correlation or significant 
differences were found. 
Biochemical response 
Before steroid therapy was started, elevated levels of serum IgG (>18 g/L) and IgG4 (>1.4 g/L) 
were observed in 42% and 77%, respectively. After start of treatment, IgG4 showed a rapid 
Figure 2. Symptomatic response after 6 months of prednisone therapy for induction of remission. Results 
were categorized in 3 treatment groups, low dose (10-20 mg/d), medium dose (30 mg/d) and high dose 
(40-60 mg/d) prednisone. 
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Figure 3. Biochemical mean response during 6 months of prednisone therapy for induction of remission: 
IgG4 (A), IgG total (B), Total Bilirubin (C), Alkaline Phosphatase (D), ASAT (e), ALAT (F). — low dose 
(10-20 mg/d), −− medium dose (30 mg/d) and ∙∙∙∙ high dose (40-60 mg/d) prednisone. Cutoff levels are 
indicated by the horizontal lines.  
decline in the majority of patients, but levels remained elevated in 76% (Figure 3A). IgG 
normalized in all patients (Figure 3B). At baseline, the majority of patients had abnormal 
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serum liver tests. In conjunction with clinical improvement, in all patients, rapid declines 
in total bilirubin, ALP, ASAT, and ALAT were observed, which persisted after stent removal 
(Figure  3C-F). After 6 months, we found that bilirubin completely normalized in 85% of the 
patients, ALP in 57%, ASAT in 61%, and ALAT in 67%. No significant differences were detected 
between the 3 treatment groups.
Treatment response as assessed by biochemical parameters was not associated with doses 
of prednisone (Table 2). Although the quantitative decrease in IgG and IgG4 levels in the 
low-dose group was more pronounced, no significant differences were observed at 6 months 
(P = 0.131, P = 0.234).
Data regarding biochemical response were also analyzed with prednisone as a continuous 
variable and categorized into 2 groups (≤20 and >20 mg/d). However, these analyses revealed 
no dose-response correlation or significant differences.
radiological response
Before treatment, diffuse pancreatic enlargement was observed in 37 (59%) of 63 patients and 
focal pancreatic enlargement in 18 (29%) of 63 patients. In 22 (71%) of 31 patients, ERCP or MRI 
showed diffuse narrowing of the main pancreatic duct (MPD), whereas in 3 (10%) of 31 patients, 
segmental narrowing of the MDP was observed. 
After 6 months of steroids, all patients showed partial (19 patients, 42%) or complete 
(26 patients, 58%) resolution of pancreatic or biliary abnormalities on imaging studies (Figure 4). 
Radiological response was analyzed with prednisone dosage as a continuous variable and 
Table 2. Response to treatment during 6 months of treatment.
Biochemical  
response
Low medium High
P
0-1 mo (95% CI)
1-6 mo (95% CI)
0-1 mo (95% CI)
1-6 mo (95% CI)
0-1 mo (95% CI)
1-6 mo (95% CI)
IgG4, g/L -4.28 (-7.34 to -1.22)
-0.58 (-0.90 to -0.25)
-3.30 (-6.87 to 0.27)
0.22 (-0.30 to 0.73)
-3.49 (-5.44 to -1.53)
-0.05 (-0.35 to 0.25)
0.85
0.03
IgG, g/L -8.15 (-11.29 to -5.00)
-0.74 (-1.14 to -0.35)
-7.17 (-11.97 to -3.36)
0.03 (-0.43 to 0.49)
-5.48 (-7.68 to -3.28)
0.13 (-0.29 to 0.54)
0.34
0.01
Total bilirubin, µmol/L -84.8 (141.5 to -28.2)
-1.21 (-3.19 to 0.77)
-91.0(-147.6 to -34.4)
-2.10 (-4.20 to 0.01)
-73.1 (-109.0 to -37.2)
-1.60 (-3.07 to -0.14)
0.84
0.82
ALP, U/L -363 (-491 to -234)
-16.5 (-30.3 to -2.58)
-294 (-422 to -166)
-15.4 (-30.8 to -0.02)
-263 (-345 to -181)
-11.4 (-22.0 to -0.81)
0.42
0.82
ASAT, U/L -101.6 (-167.8 to -35.4)
-2.49 (-7.52 to 2.54)
-87.4 (-149.6 to -25.2)
-0.57 (-5.92 to 4.77)
-106.7 (-146.8 to -66.6)
0.85 (-3.13 to 4.83)
0.87
0.57
ALAT, U/L -117.1 (-235.9 to 1.73)
-5.16 (-14.09 to 3.76)
-160.0 (-279.5 to -40.3)
-5.71 (-15.57 to 4.15)
-158.2 (-234.1 to -82.4)
-6.18 (-13.09 to 0.72)
0.82
0.98
Estimated mean decline the first month and from month 1 to month 6 by dosage. 
Decline adjusted for baseline biochemical values in a repeated measurement model with a random intercept and 
random decline from baseline to month 1 and a random linear decline from month 1 and onwards to month 6 
[broken stick model y= a + b * t + c (t – 1), where t = months y = lab value]. 
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categorized into 2 groups (≤20 and >20 mg/d) as well. These analyses did not result in a dose-
response correlation or significant differences.
Complete remission
Furthermore, we analyzed the capability for the different dosage groups to achieve complete 
remission. The rate of complete remission was 71% (10/14) in the low-dose group, 40% (6/15) in 
the medium-dose group, and 72% (26/36) in the high-dose group.
DIsCUssION
This study shows comparable therapeutic efficacy  of low-dose (10-20 mg/d) prednisone as 
compared to high-dose (40-60 mg/d) prednisone for induction of remission in AIP. 
The therapeutic efficacy of corticosteroid in AIP has been well documented3-7, but we 
are not aware of previous studies specifically addressing different corticosteroid remission 
induction regimens. In a number of studies not primarily aimed to evaluate dose-response 
relationships, comparable outcomes were reported for patients treated with medium to high 
doses of prednisone, ranging from 25 to 50 mg/d9, 17-19. Reports on corticosteroid induction 
doses lower than 15 mg/d are scarce. One case report described successful treatment with 
prednisolone 5 mg/d20.
Although worsening of glycaemic control is a known side effect in the elderly diabetic 
AIP patient, steroid therapy has been reported to improve endocrine pancreatic function 
in approximately half of the patients. Yet this beneficial effect is counterbalanced by newly 
developed diabetes or worsening of diabetic control in a substantial subset of patients6, 18, 21, 22.
Figure 4. Radiological response after 6 months of prednisone therapy for induction of remission. Results 
were categorized into 3 treatment groups: low dose (10-20 mg/d), medium dose (30 mg/d), and high 
dose (40-60 mg/d) prednisone. 
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High-dose steroid therapy, especially during an extended period (>1 week), poses a 
substantial risk for significant side effects11-14, 23. Frequently observed important side-effects in 
elderly populations are inducing, or worsening of pre-existing, diabetes mellitus. Other possible 
risks include weight gain, increased bone loss, opportunistic infections, and psychological 
disturbances. 
Diabetes mellitus or worsening of glycaemic control is frequent in individuals presenting 
with AIP4, 19, 21, 24. In a cohort of 114 Dutch patients, 35% of patients had recent-onset diabetes 
at presentation (unpublished data). Corticosteroids, in particular high doses, obviously have 
the potential to further impair glucose tolerance and glycaemic control. In series of elderly 
patients with rheumatoid arthritis and chronic kidney disease, 9 to 40% developed diabetes 
mellitus upon treatment with steroids. Older age and obesity were identified as independent 
risk factors12, 13. In addition, Gurwitz et al14 demonstrated with prednisone therapy a dose-related 
risk of developing hyperglycaemia requiring therapy with oral glucocorticoid use. The odds 
ratio for starting an oral hypoglycaemic agent or insulin ranged from 1.77 for patients treated 
with a hydrocortisone equivalent dose of 1 to 39 mg/d, to 3.02 for 40 to 70 mg/d and to 5.82 for 
80 to 119 mg/d. 
Furthermore, high-dose steroids result in a greater risk of complicated glucocorticoid 
withdrawal and require longer periods of drug tapering. Any patient treated with at least 20 mg/d 
prednisone for more than 5 days is at risk of hypothalamic-pituitary-adrenal suppression25. 
Our study has a number of limitations. This study had a retrospective, uncontrolled nature 
and had a limited number of patients treated with low initial doses of prednisone. Importantly, 
individual patient characteristics or disease manifestations might have influenced the treating 
physician to choose a particular corticosteroid dose. Nevertheless, as shown in Table 1, there 
were no significant differences in these baseline characteristics between the treatment 
groups. It is important to stress that patients included in this series were not treated according 
to a particular protocol but at the discretion of the treating physician. Most patients in the 
low-dose group were recently treated by a single physician who believed, based on preliminary 
observations, that low-dose prednisone could be as effective as higher doses in the initial 
treatment of the disease. In another center, however, the standard regimen was 30 or 40 mg 
prednisone per day throughout the study period. Because of the retrospective design of this 
study, we were not able to retrieve sufficient and/or reliable data for assessing potential adverse 
treatment effects, for example, on glucose tolerance, body weight, and blood pressure. 
Concurrent biliary drainage and azathioprine therapy are of concern in interpreting the results 
of this study. 
Pancreaticobiliary imaging after 2 weeks, using CT and/or ERCP, has been recommended 
to evaluate the response to corticosteroid treatment, in particular when this information is 
considered part of the diagnostic process26. Because AIP often responds well to steroids, biliary 
stents are often removed at an early stage. Nevertheless, in clinical practice, the timing of stent 
removal varies substantially, as illustrated by the markedly variable period of stenting in our 
study. This implies that the observed response to treatment in the first 3 months was due to the 
combination of steroid treatment and biliary drainage. 
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The percentage of patients treated with stents and the time to stent removal did not differ 
between the groups, and all patients were free of biliary stents after 6 months. Therefore it 
seems unlikely that our main conclusions are invalidated by concurrent endoscopic treatment. 
Steroid therapy is frequently combined with other types of immunosuppressive drugs. Following 
relapse or unsuccessful tapering of prednisone, azathioprine is often used in combination with 
steroids to maintain remission or as a corticoid-sparing immunosuppressant. We excluded 
patients initially treated with a combination of immunosuppressive drugs. Patients were not 
excluded when azathioprine treatment was introduced subsequently. Azathioprine was used 
in a minority of patients and usually after 3 to 4 months of prednisone treatment. Nonetheless, 
since the effect of azathioprine is assumed to start after 2 to 3 months, it cannot be excluded 
that azathioprine influenced the observed 6-month treatment response.
The number of patients treated with azathioprine during the follow-up period did not differ 
between the treatment groups (P = 0.038). Further studies are needed to study the effect of 
azathioprine on long-term outcome. 
In conclusion, in this retrospective series, response to therapy was comparable for AIP patients 
treated with doses of prednisone in the range of 10 to 60 mg/d. These preliminary data 
suggest that low-dose (<20 mg/d) prednisone may be effective for induction of remission of 
AIP,  with possibly avoiding the risks of high dose steroid treatment. However, these results 
await confirmation, ideally by controlled trials comparing the efficacy and tolerance of low- and 
high-dose induction corticosteroid therapy, before this can be generally recommended.   
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ABsTrACT
Objective
To evaluate the long-term outcome of autoimmune pancreatitis (AIP).
methods
Patients with at least 2 years of follow-up were included. Information was collected regarding 
disease characteristics, treatment outcome, diagnosed malignancies, and mortality. In addition, 
pancreatic function and quality of life (QoL) were assessed prospectively.
results
Hundred-seven patients were included (87% male, 90% type 1), with a median follow-up of 
74 months (IQR 49-108). One third was operated for suspected pancreatic cancer (32%). Most 
patients were (successfully) treated with steroids (83%), but relapses were common (52%), for 
which no risk factors could be identified. Pancreatic carcinoma was not observed.
Prospective data were obtained from 64%, as 17% had died, 7% were lost to follow-
up, and 13% refused to participate. After a median of 75 months (IQR 50-106), 46% still used 
active treatment. Exocrine and endocrine insufficiency were highly prevalent (82 and 57%, 
respectively). QoL and survival were not impaired, as compared to a reference population.
Conclusions
Despite an excellent initial treatment response, relapses are common, even in type 2, and 
almost half of the patients require maintenance therapy. Pancreatic insufficiency is highly 
prevalent, which calls for active screening. Pancreatic cancer was not observed and QoL and 
survival is not impaired.
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INTrODUCTION
Autoimmune pancreatitis (AIP) is a unique form of pancreatitis with a dramatic response to 
steroids. Two subtypes are distinguished.1,2 Type 1 is the classical form, histologically described 
as ‘lymphoplasmacytic sclerosing pancreatitis’ (LPSP). It is part of a systemic IgG4-related 
disease (IgG4-RD), which can involve multiple organs (i.e. biliary tract, kidneys, and salivary 
glands) and relapses frequently.3,4 Type 2, or ‘idiopathic duct-centric pancreatitis’ (IDCP), is 
histologically characterized by granulocyte epithelial lesions, with few or no IgG4-positive 
cells.5 This type is more rare, pancreas-specific, not associated with elevated serum IgG4, and 
relapses seem to be less common. AIP is increasingly being recognized and several diagnostic 
criteria have been proposed, including the HISORt criteria (Histology, Imaging, serology, Other 
organ involvement, and response to steroids) and the International Consensus Diagnostic 
Criteria (ICDC).1,2
Little is known about the long-term consequences of AIP. Establishing the diagnosis can 
be difficult and patients are often wrongly suspected of pancreatic cancer. This may result in 
invasive (diagnostic) procedures and even major surgery. The impact of such events on quality 
of life was never investigated. Furthermore, a delayed diagnosis may lead to pancreatic function 
loss, because prolonged inflammation causes fibrosis and pancreatic acinar and islet cell loss. 
Another late complication may be the development of cancer. Other forms of pancreatitis 
harbour an increased risk for pancreatic cancer, and the same association has been reported 
for AIP.6,7 
With this study we set out to investigate the long-term outcome of patients with type 1 and 
type 2 AIP, in terms of treatment response, pancreatic function, quality of life, risk of pancreatic 
cancer, and mortality.
mATerIAL AND meTHODs
Inclusion criteria
This study was approved by the Institutional Review Board of the Erasmus University Medical 
Center. Patients registered in our prospectively maintained AIP database for at least 2 years, 
were enrolled.8 Type 1 AIP patients had to fulfil either the HISORt criteria or the ICDC, based on 
their complementarity, as we described previously.1,2,8 Patients with type 2 AIP were diagnosed as 
proposed by Maire et al, who added criteria for ‘probable type 2 AIP’, to allow a diagnosis in the 
absence of histology.9,10 Definitive type 2 AIP was defined as histologically confirmed idiopathic 
duct-centric pancreatitis. The diagnosis of probable type 2 AIP was based on a combination of 
unexplained pancreatic disease, suggestive imaging (a diffusely enlarged pancreas, irregular 
pancreatic duct), normal serum IgG4 levels, and a positive response to steroids. 
Treatment
There was no formal treatment protocol. The induction regimen most frequently used, 
consisted of prednisolone 30-40 mg/day for 2-4 weeks, after which steroids were tapered off 
in 2-3 months. Every 3-6 weeks patients were clinically and biochemically evaluated. Imaging 
studies were performed to document response to therapy and whenever clinically indicated. 
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For relapses, steroids were restarted, often in combination with azathioprine. Patients who 
were unable to taper steroids usually received azathioprine as well.
Data collection
Information regarding patient and disease characteristics, treatment, response, and relapses 
were retrieved from the database. In addition, the incidence of pancreatic and other 
malignancies were evaluated. Malignancies, diagnosed within one year of the AIP diagnosis 
were excluded, to preclude any paraneoplastic phenomenon or misdiagnosis. If data were 
incomplete, we prospectively collected any missing information by reviewing medical records 
or contacting treating physicians and/or patients by telephone. 
Subsequently, all living patients were invited to participate in the prospective part of the 
study. If informed consent was obtained, pancreatic function and quality of life were assessed 
between December 2012 and May 2013. To evaluate the exocrine function, a fecal elastase test 
was performed (enzyme-linked immunosorbent assay, ScheBo-Tech, Wettenberg, Germany). 
The endocrine function was assessed by measuring fasting serum glucose levels and glycated 
hemoglobin levels, and by collecting data on medication use. The quality of life was assessed 
using the European Organization for Research and Treatment of Cancer (EORTC) Quality of Life 
Questionnaire C30 (QLQ-C30), and the Short Form-36 (SF-36).11-13
Definitions
The assay used to measure serum IgG4 varied among the different hospitals, but the upper 
limit of normal was uniformly set on 140 mg/dl. IgG4-associated cholangitis (IAC) was defined 
as biliary involvement, either intrahepatic or proximal to the pancreatic head. Distal biliary 
narrowing was excluded, as it is impossible to distinguish cholangitis from ductal compression 
at this site. 
Treatment response was defined as the disappearance of initial symptoms, in addition to 
a marked improvement or resolution of pancreatic and/or extrapancreatic manifestations 
on imaging studies. A relapse was defined as the recurrence of symptoms, together with a 
reappearance of pancreatic and/or extrapancreatic imaging abnormalities.10 
Exocrine insufficiency was defined as an elastase-1 value below 0.200 µg/gr feces. Endocrine 
insufficiency was considered to be present when the fasting glucose level was above 6.9 mmol/l, 
the HbA1c level was more than 46 mmol/mol (6.4%), or if patients used oral antiglycemic agents 
or insulin.14 Quality of life, the occurrence of malignancies, and mortality were compared to an 
age- and sex-matched Dutch reference population.
statistical analysis
Outcome measures are presented as medians with an interquartile range (IQR). Patients with 
type 1 and 2 AIP were compared with the Mann-Whitney U Test for continuous data and the 
Fisher’s Exact Test for categorical data. Survival, cancer free survival, and relapse free survival 
were calculated using life tables (Kaplan-Meier method). Cox proportional hazards regression 
was used for univariate analysis of predictors of disease relapse. 
Exact logistic regression analysis was performed to determine risk factors for endo- and 
exocrine insufficiency, adjusted for length of follow-up. QoL scores were compared to a 
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reference population with a One-sample t-test. A p-value <0.05 was considered statistically 
significant. To evaluate the cancer risk in AIP patients, we compared the observed cancer 
frequency to the expected frequency, based on the Dutch population-based cancer incidence 
rates from 1989-2011 (http://www.iknl.nl). The life expectancy of the general Dutch population, 
matched for age and sex, was obtained from the online database of the Dutch Central Bureau 
of Statistics (www.cbs.nl). 
resULTs
Baseline characteristics 
A total of 107 patients were included (93 male; median age 71 years (IQR 61-78); Figure 1), with 
a median follow-up of 74 months (IQR 49-108). Patient characteristics are shown in Table 1. 
Patients had been diagnosed between May 1992 and August 2011. The median diagnostic 
delay was 5 months (IQR: 2-19). Presenting symptoms were weight loss in 92  patients 
(89%), obstructive jaundice in 82 (78%) and abdominal discomfort in 61 (57%). At diagnosis, 
72 patients (75%) had symptoms of steatorrhea and 38 patients (36%) were treated for 
diabetes mellitus.
Imaging studies revealed a pancreatic mass in 21 patients (20%) and diffuse pancreatic 
enlargement in 62 (59%). In 54 patients a pancreatogram was obtained, which showed 
irregular narrowing of the pancreatic duct in 46 (85%). Other organs were involved in 
72 patients (67%), most frequently IgG4-associated cholangitis of the extrapancreatic, usually 
intrahepatic, biliary tree (58%). In 24 patients, more than one extra-pancreatic manifestation 
was observed (33%).
Figure 1. Study enrollment 
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AIP type
Ninety-six patients were diagnosed with type 1 AIP (90%) and 11 patients with type 2 (10%; 
3 definitive, 8 probable). Elevated serum IgG4 was found in 81 patients (84% of all patients, 
90% of type 1 AIP). Thirty-four patients were operated for suspected pancreatic cancer (32%), 
of which 18 underwent a pancreatic resection (17%). Pancreatic histology was obtained in 29 
patients (27%), either surgically (n=24) or by biopsy during endoscopic ultrasonography (n=5). 
Lymphoplasmacytic sclerosing pancreatitis (type 1 AIP) was found in 23 patients and idiopathic 
duct-centric pancreatitis (type 2) in three. As compared to type 1, the type 2 AIP group 
was younger (p<0.001), with less male predominance (p=0.036). Surprisingly, other organ 
involvement was not only found in type 1, but also in type 2 patients (70% and 45%, respectively). 
An association with inflammatory bowel disease was only observed in type 2 patients (36%). 
AIP treatment and response
Steroid therapy was instituted in 89/107 patients (83%), all of which responded favourably. 
Sixty-five patients were treated with an initial dose of 30-40 mg prednisolone daily (78%). Three 
patients received a higher dose of 45-60 mg (3%) and 16 a low dose of 10-20 mg per day (18%). 
In 16 patients, azathioprine was added as (steroid sparing) maintenance therapy. 
Fifty-five patients experienced a relapse (52%; Figure 2); 22 a single relapse (21%) and 34 
multiple relapses (34%). Of note, relapses not only occurred in type 1 patients (55%), but also 
in 27% of type 2 patients. However, in type 2 disease, relapses never occurred more than once. 
Table 1. Patient characteristics of entire cohort
Demographics
AIP patients 
(n=107)
Type 1 AIP
(n=96, 90%)
Type 2 AIP
(n=11, 10%) p-value
Age in years - median (IQR)¥ 71 (61-78) 72 (65-78) 48 (32-61) <0.0012,*
Male sex - no. (%) 93 (87) 86 (90) 7 (64) 0.0361,*
Elevated serum IgG4 – no. (%)¶ 81 (84) 81 (84) 0 (0) <0.0011,*
Other organ involvement, no. (%) 73 (68) 67 (70) 6 (55) 0.3211
Inflammatory bowel disease - no. (%) 4 (4) 0 (0) 4 (36) <0.0011,*
Initial treatment:
     Surgery for suspected malignancy - no. (%) 34 (32) 31 (32) 3 (27) 0.9991
Pancreatic resection 18 (17) -
          - Diagnostic laparotomy/laparoscopy 14 (13) -
          - Combined gastric and biliary bypass 2 (2) -
     Steroid therapy - no. (%) 89 (83) 81 (84) 8 (73) -
          Relapse 55 (52) 52 (55) 3 (27) 0.1141
          Azathioprine addition 44 (42) -
Follow-up in months – median (IQR) 74 (49-108) 75 (50-114) 52 (50-106) 0.2612
Death - no. (%) 18 (17) 16 (17) 2 (18) 0.9991
¥ Age at the time of the present study; ¶ At presentation; * p < 0.01; 1Fisher’s Exact Test; 2Mann-Whitney U Test
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The first relapse occurred a median of 31 months (IQR 11-85) after diagnosis and most frequently 
involved the pancreas or biliary tract (55 and 67%, respectively; Figure 3). Furthermore, almost 
80% of the relapses occurred within 2 years after diagnosis. All relapses were successfully 
treated with a restart of steroid therapy and in 28 patients, azathioprine was added. None of the 
evaluated items was associated with relapse (age, gender, presenting symptoms, other organ 
involvement, AIP type, serum IgG4 levels, diffuse pancreatic enlargement, steroid therapy or 
dosing, and pancreatic resection). 
survival
In total, 18 patients had died after a median of 70 months (IQR 47-120). Five of these patients 
died from complications of IgG4-RD, a median of 5 years after diagnosis (IQR 4-10; Figure 1). 
Two of these patients had declined steroid therapy, resulting in end-stage liver cirrhosis. 
The other three patients had a substantial diagnostic delay (median 4 years), and developed 
irreversible liver (n=2) or renal failure (n=1). Another patient with a substantial diagnostic delay 
also developed liver and renal organ failure, but this patient survived after a combined liver-
kidney transplant. There was no significant difference in survival of AIP patients, as compared 
to an age- and sex-matched Dutch reference population (Figure 4). 
Prospective outcome data
Of the 82 living patients, 68 agreed to participate (83%), 62 with type 1 AIP and 6 with type 2 
(91% and 9%, respectively). Due to the small number of type 2 AIP patients, we were not able 
         AIP patients at risk
        106         63       43                 30                17                8         4        3  
Figure 2. Relapse-free survival in AIP patients. 
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     P=0.932
AIP patients
Dutch population
   AIP patients at risk
   107        97         75  51    37       18         11 11   9
Figure 3. Distribution of organs involved in first relapse (n=55). Other organs included salivary glands (3), 
retroperitoneal fibrosis (4), prostate (1), kidney (1) and IBD (2). Simultaneous relapses in pancreas and bile 
duct occurred in 16 patients; in pancreas, bile duct and salivary glands in 1 patient; and in bile duct and 
retroperitoneum in 1 patient.
Figure 4. Survival of AIP patients, compared to an age- and sex-matched Dutch reference population. 
Log-rank test P value is reported.
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to perform a statistical analysis comparing type 1 and 2 AIP. The median follow-up of this group 
was 75 months (IQR 50-106). There were no significant differences in baseline characteristics 
between the patients who did and did not agree to participate (data not shown). Due to the 
small number of type 2 patients, statistical analysis, comparing the two AIP types, could not be 
performed. Thirty-one patients still received active treatment for AIP (46%); 11 prednisolone 
(35%), eight azathioprine (26%), 11 a combination of the two (35%), and one mercaptopurine 
(3%). During the study period, none of the patients developed pancreatic cancer. Eight patients 
developed some other type of cancer (8%); prostate (n=2), esophagus, colon, bladder, and 
lung cancer, leukemia and non-Hodgkin lymphoma. However, the general cancer risk of AIP 
patients was not different from an age- and sex-matched Dutch reference population (Figure 5). 
Fifty-six patients were found to be exocrine insufficient (82%), of which only 32 had been 
diagnosed prior to the study and were already treated with enzyme supplementation (57%, 
Table 2). Exact logistic regression analysis revealed older age to be the only associated risk 
factor (Table 3; OR: 1.05 (95%CI: 1.0-1.1)). Endocrine insufficiency was present in 37 patients 
(57%), of which 6 were newly diagnosed by tests carried out as part of the study protocol 
(16%). Risk factors, associated with endocrine insufficiency, were a longer follow-up period 
(OR: 1.36 (95% CI: 1.11-1.68)) and older age (OR: 1.06 (95% CI: 1.01-1.11)). Importantly, there was 
no difference in pancreatic function for patients, who did and did not receive steroid therapy. 
               P=0.133
 
        AIP patients
        Dutch population
    AIP patients at risk
    100      89          65      47            32         13     10   10         7
Figure 5. Cancer-free survival of AIP patients, compared to an age- and sex-matched Dutch reference 
population. Log-rank test P value is reported. 
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Table 2. Prospective outcome; pancreatic endocrine and exocrine function status
 Variable (n=68)
Exocrine insufficiency¥ – no. (%) 56 (82)
     Feces elastase in µg/gram feces – median (IQR) 0.015 (0.015-0.104)
Pancreatic enzyme suppletion – no. (%) 32 (57)
Endocrine insufficiencyҰ – no. (%) 37 (57) †
     Fasting glucose in mmol/L – median (IQR) 5.6 (5.1-6.4)
     HbA1c in mmol/mol Hb – median (IQR) 40 (37-44)
Medication use for endocrine insufficiency – no. (%) 31 (70)
     Insulin 19 (61)
     Oral medication 17 (55)
Ұ Endocrine insufficiency defined as fasting glucose level >7.0 mmol/L, HbA1c level >42 mmol/mol (6.0%), or 
using prescribed antidiabetic medication
¥ Exocrine insufficiency defined as fecal elastase level of <200 µg/gram feces
† The denominator differs, because serum samples were not available in 2/68 patients (3%). 
Table 3. Multivariate logistic regression analysis for factors associated with exocrine and endocrine 
pancreatic insufficiency
Variables
exocrine insufficiency,  
Or (95% CI) p-value
endocrine insufficiency, 
Or (95% CI) p-value
Length of follow-up 1.24 (0.97-1.58) 0.08 1.36 (1.11-1.68) 0.003*
Age at onset¥¶ 1.05 (1.01-1.09) 0.03* 1.06 (1.01-1.11) 0.02*
Male sex¥ 3.41 (0.08-14.94) 0.10 1.66 (0.39-7.14) 0.49
Type 1 AIP¥ 5.47 (0.92-32.66) 0.06 5.84 (0.70-48.85) 0.10
Pancreatic resection¥ 5.50 (0.28-108.11) 0.26 3.09 (0.59-16.16) 0.18
¥Adjusted for length of follow-up; ¶ 1-year increment; *Significant at p<0.05 level.
Table 4 shows the mean QoL scores, as compared to age- and sex-matched general population 
norms. None of the SF-36 component scores or QLQ-C30 subscales was lower in AIP patients. 
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DIsCUssION
This study is the first to evaluate the full range of long-term consequences of autoimmune 
pancreatitis, with a unique follow-up of more than 6 years. The results show that, despite a 
successful primary treatment response, more than half of the patients developed one or more 
relapses, and almost half of the patients required chronic maintenance therapy. None of the AIP 
patients developed pancreatic cancer during the study period, but most became both exo- and 
endocrine insufficient. Remarkably, AIP did not have a negative impact on quality of life or survival. 
In this cohort, the vast majority of patients became both endocrine and exocrine insufficient 
over the years. Therefore, we recommend active screening for pancreatic insufficiency in AIP, 
especially in older patients, as age was identified as a risk factor. The observed prevalences 
correspond with reports from Japan, but are higher than numbers found in a European 
cohort.10,15-17 This difference may be explained by the prospective nature of the present study, 
because a significant number of patients were diagnosed by tests performed as part of the study 
protocol. In addition, the long follow-up time (exceeding 6 years) might have contributed, as 
duration of follow-up was found to be a predictive factor for the development of pancreatic 
endocrine insufficiency. 
Several studies have reported improvement of the pancreatic function after steroid 
therapy.15,17-19 However, our data do not indicate that treatment can preserve the pancreatic 
function on the longer term. Prospective studies are needed to show if long-term maintenance 
therapy influences pancreatic insufficiency rates. 
Table 4. Prospective outcome; Quality of life scores, as compared to age- and sex-matched general 
population norms
AIP patients 
(n=67)
General  
Population Norms p-Value†
sF-36¶ 
     Physical health component 48 ± 9 46 0.04*
     Mental health component 53 ± 9 51 0.09
QoL QLQ-C30#
     Global health status 78 ± 17 77 0.61
     Physical functioning 85 ± 17 88 0.21
     Role functioning 87 ± 20 88 0.64
     Emotional functioning 85 ± 20 90 0.06
     Cognitive functioning 91 ± 12 90 0.65
     Social functioning 91 ± 19 93 0.29
*p-value < 0.05, †One-Sample T-test
¶The scores of the SF-36 component scores range from 0 to 100, with higher scores indicating better quality of 
life. Linear transformations were performed to standardize the scores to a mean score ± standard deviation of 
50 ± 10 in a general Dutch population.
#Scores of the QLQ-C30 are linearly transformed to a scale of 0 to 100, with higher score indicating better 
functioning or global QoL.
120
Chapter 8
To our knowledge, the impact of AIP on quality of life was never studied before. Given 
the diagnostic difficulties and confusion with pancreatic cancer, it seemed reasonable to 
assume that AIP might have a negative long-term influence. However, in this cohort, the 
long-term quality of life was not impaired, even though almost half of the patients still used 
immunosuppressive therapy and most suffered from some form of pancreatic insufficiency. 
Again, the long follow-up period might have played a role, with the negative impact of AIP-
related events waning over time.  Also, conversion from the life-threatening diagnosis of 
pancreatic cancer to a benign and treatable disease may have resulted in a lasting sense of 
relief. Finally, in patients who experience a serious and possible life-threatening disorder, the 
response shift phenomenon is known to occur, meaning that changes in health status alter the 
internal standards of quality of life.20
All patients in this study responded favorably to steroid treatment. These excellent 
response rates have been reported many times before.10,21-24 This implies that in patients who 
do not respond to steroid therapy, the diagnosis of AIP should be reconsidered. The value of 
steroid treatment is emphasized by the six patients who developed end-stage organ failure (of 
whom five died). None received steroid treatment (in time). Therefore, their uniform negative 
outcome may be seen as evidence of an unfavorable natural disease course. Previously, Sah et al 
described that AIP does not affect the long-term survival and we conclude the same.25 However, 
our data show that this only holds true for patients, diagnosed and treated in a timely fashion, 
and that AIP is a potentially life-threatening disorder when patients are deprived of steroids. 
Relapses were frequently observed, similar to previous reports.22,24,25 We could not identify 
any risk factors for disease relapse. Importantly, we found no differences in relapse rate 
between patients, initially treated with a low or a high dose of prednisolone. However, only 
a small group of patients received a low dose, so further studies are needed to confirm these 
findings.26 Interestingly, almost all relapses occurred in the first 2 years after diagnosis. This 
implies that clinicians should observe patients carefully in the first years after tapering steroids.
At follow-up, almost half of the patients still required treatment for AIP. This shows that, 
despite a successful initial treatment response, recurrences are common and many patients are 
unable to cease immunosuppressive therapy. Low-dose steroids are often used for maintenance. 
However, long-term steroid treatment may result in significant side effects, especially in 
an elderly population. As an alternative, immunomodulators, such as azathioprine, can be 
prescribed. Although some studies reported treatment-limiting side effects, others describe 
successful use, without serious complications, which is in line with our experience.10,21,27-29
Future studies are required to further define the role of azathioprine. Recently, rituximab 
has been suggested as an effective alternative for patients with difficult-to-treat, relapsing AIP, 
but this requires further investigation.27 
The observed clinical profiles of type 1 and 2 disease were in correspondence with earlier 
findings, with two exceptions; First, in contrast to previous studies, we found other organ 
involvement to be quite common in type 2 patients.10,24,25 In addition, previous studies reported 
a lower relapse rate in type 2 AIP patients, but in this study population, relapse rates were 
similar, although type 2 patients never relapsed more than once.24,25 Perhaps, the much longer 
follow-up period of the present study allowed more time for relapses to develop, even in the 
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type 2 group. Unfortunately, a formal comparison between the two AIP types was impossible, 
due to the small number of type 2 patients. Of note, the proportion of type 2 patients in our 
cohort is similar to others.10,24 
Several case reports suggested an increased risk of pancreatic cancer in AIP, similar to other 
forms of pancreatitis.30-33 This was also suggested by Gupta et al., who examined histological 
specimens of operated patients with AIP and chronic pancreatitis, and concluded that pre-
neoplastic ductal lesions were highly prevalent in both groups.7 In contrast, in the present 
study, none of the patients developed pancreatic cancer. This corresponds with findings 
from another international cohort, which showed that the occurrence of pancreatic cancer 
following AIP was rare.24 Given this conflicting evidence, additional prospective studies are 
needed to clarify this issue. 
Our study comprises one of the largest AIP cohorts, especially in comparison to other 
European studies, and is the first to prospectively assess the pancreatic function and quality of 
life. Furthermore, the long follow-up period is unique and offers new insights in the long-term 
outcome of AIP. However, the study also has limitations. Some of the outcome data were 
collected retrospectively. Also, not all patients agreed to participate in the prospective part of 
the study. However, a selection bias is unlikely, given the size and characteristics of this group. 
In addition, patients were not treated according to a standard treatment protocol, as validated 
guidelines on this topic are lacking. 
Ideally, only one criteria scoring system would have been used, preferably the recently 
proposed ICDC.2 These criteria are a first step towards uniform diagnostic criteria for AIP, 
replacing national criteria, like the HISORt criteria. However, a previous study, focusing on the 
diagnostic performance of the AIP scoring systems, showed their complementary rather than 
overlapping use.8 For type 1 AIP patients, when imaging is not available or shows no pancreatic 
abnormalities, the HISORt criteria are the only criteria that can establish an AIP diagnosis, based 
on positive serology and response to steroids. On the other hand, if IgG4 levels are normal, 
AIP cannot be diagnosed by the HISORt criteria. In type 2 AIP patients, it is nearly impossible 
to establish a diagnosis non-histologically, mainly because of the less-known clinical features 
of type 2 patients and the lack of a serological marker, as described by Ikeura.9 In our view, this 
might lead to the misclassification of type 2 as type 1 patients. Therefore, we chose to use the 
system proposed by Maire et al.10 
In summary, in this large cohort of AIP patients we show that recurrences are common, 
despite a successful initial treatment response (even in type 2 patients), and almost half of 
the patients require long-term maintenance therapy. Pancreatic cancer was not observed, 
but pancreatic insufficiency was extremely common. Therefore, regular evaluation of the 
pancreatic function is highly recommended, especially in older patients. Long-term quality of 
life and (cancer free) survival are not impaired.
122
Chapter 8
reFereNCes
1. Chari ST, Smyrk TC, Levy MJ, et al. Diagnosis of autoimmune pancreatitis: the Mayo Clinic experience. 
Clin Gastroenterol Hepatol 2006;4:1010-6; quiz 934.
2. Shimosegawa T, Chari ST, Frulloni L, et al. International consensus diagnostic criteria for autoimmune 
pancreatitis: guidelines of the International Association of Pancreatology. Pancreas 2011;40:352-8.
3. Stone JH, Zen Y, Deshpande V. IgG4-related disease. N Engl J Med 2012;366:539-51.
4. Buijs J, Maillette de Buy Wenniger L, van Leenders G, et al. Immunoglobulin G4-related Prostatitis: A 
Case-control Study Focusing on Clinical and Pathologic Characteristics. Urology 2014;83:521-7.
5. Sugumar A, Kloppel G, Chari ST. Autoimmune pancreatitis: pathologic subtypes and their implications 
for its diagnosis. Am J Gastroenterol 2009;104:2308-10; quiz 11.
6. Bracci PM, Wang F, Hassan MM, et al. Pancreatitis and pancreatic cancer in two large pooled case-
control studies. Cancer Causes Control 2009;20:1723-31.
7. Gupta R, Khosroshahi A, Shinagare S, et al. Does autoimmune pancreatitis increase the risk of pancreatic 
carcinoma?: a retrospective analysis of pancreatic resections. Pancreas 2013;42:506-10.
8. van Heerde MJ, Buijs J, Rauws EA, et al. A comparative study of diagnostic scoring systems for 
autoimmune pancreatitis. Pancreas 2014;43:559-64.
9. Ikeura T, Detlefsen S, Zamboni G, et al. Retrospective comparison between preoperative diagnosis 
by International Consensus Diagnostic Criteria and histological diagnosis in patients with focal 
autoimmune pancreatitis who underwent surgery with suspicion of cancer. Pancreas 2014;43:698-703.
10. Maire F, Le Baleur Y, Rebours V, et al. Outcome of patients with type 1 or 2 autoimmune pancreatitis. Am 
J Gastroenterol 2011;106:151-6.
11. Aaronson NK, Ahmedzai S, Bergman B, et al. The European Organization for Research and Treatment 
of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl 
Cancer Inst 1993;85:365-76.
12. van de Poll-Franse LV, Mols F, Gundy CM, et al. Normative data for the EORTC QLQ-C30 and EORTC-
sexuality items in the general Dutch population. Eur J Cancer 2011;47:667-75.
13. Aaronson NK, Muller M, Cohen PD, et al. Translation, validation, and norming of the Dutch language 
version of the SF-36 Health Survey in community and chronic disease populations. J Clin Epidemiol 
1998;51:1055-68.
14. American Diabetes A. Standards of medical care in diabetes--2013. Diabetes care 2013;36 Suppl 1:S11-66.
15. Kamisawa T, Egawa N, Inokuma S, et al. Pancreatic endocrine and exocrine function and salivary gland 
function in autoimmune pancreatitis before and after steroid therapy. Pancreas 2003;27:235-8.
16. Nishino T, Toki F, Oyama H, et al. Long-term outcome of autoimmune pancreatitis after oral 
prednisolone therapy. Intern Med 2006;45:497-501.
17. Nishimori I, Tamakoshi A, Kawa S, et al. Influence of steroid therapy on the course of diabetes mellitus 
in patients with autoimmune pancreatitis: findings from a nationwide survey in Japan. Pancreas 
2006;32:244-8.
18. Ito T, Kawabe K, Arita Y, et al. Evaluation of pancreatic endocrine and exocrine function in patients with 
autoimmune pancreatitis. Pancreas 2007;34:254-9.
19. Frulloni L, Scattolini C, Katsotourchi AM, et al. Exocrine and endocrine pancreatic function in 21 
patients suffering from autoimmune pancreatitis before and after steroid treatment. Pancreatology 
2010;10:129-33.
20. Schwartz CE, Bode R, Repucci N, et al. The clinical significance of adaptation to changing health: a 
meta-analysis of response shift. Qual Life Res 2006;15:1533-50.
21. Church NI, Pereira SP, Deheragoda MG, et al. Autoimmune pancreatitis: clinical and radiological 
features and objective response to steroid therapy in a UK series. Am J Gastroenterol 2007;102:2417-25.
22. Kamisawa T, Shimosegawa T, Okazaki K, et al. Standard steroid treatment for autoimmune pancreatitis. 
Gut 2009;58:1504-7.
23. Hirano K, Tada M, Isayama H, et al. Long-term prognosis of autoimmune pancreatitis with and without 
corticosteroid treatment. Gut 2007;56:1719-24.
123
Long-term outcome of AIP
8
24. Hart PA, Kamisawa T, Brugge WR, et al. Long-term outcomes of autoimmune pancreatitis: a multicentre, 
international analysis. Gut 2013;62:1771-6.
25. Sah RP, Chari ST, Pannala R, et al. Differences in clinical profile and relapse rate of type 1 versus type 2 
autoimmune pancreatitis. Gastroenterology 2010;139:140-8; quiz e12-3.
26. Buijs J, van Heerde MJ, Rauws EA, et al. Comparable efficacy of low- versus high-dose induction 
corticosteroid treatment in autoimmune pancreatitis. Pancreas 2014;43:261-7.
27. Hart PA, Topazian MD, Witzig TE, et al. Treatment of relapsing autoimmune pancreatitis with 
immunomodulators and rituximab: the Mayo Clinic experience. Gut 2012.
28. Sandanayake NS, Church NI, Chapman MH, et al. Presentation and management of post-treatment 
relapse in autoimmune pancreatitis/immunoglobulin G4-associated cholangitis. Clin Gastroenterol 
Hepatol 2009;7:1089-96.
29. Matsushita M, Ikeura T, Fukui T, et al. Refractory autoimmune pancreatitis: azathioprine or steroid 
pulse therapy? Am J Gastroenterol 2008;103:1834; author reply -5.
30. Inoue H, Miyatani H, Sawada Y, et al. A case of pancreas cancer with autoimmune pancreatitis. Pancreas 
2006;33:208-9.
31. Fukui T, Mitsuyama T, Takaoka M, et al. Pancreatic cancer associated with autoimmune pancreatitis in 
remission. Intern Med 2008;47:151-5.
32. Loos M, Esposito I, Hedderich DM, et al. Autoimmune pancreatitis complicated by carcinoma of the 
pancreatobiliary system: a case report and review of the literature. Pancreas 2011;40:151-4.
33. Pezzilli R, Vecchiarelli S, Di Marco MC, et al. Pancreatic ductal adenocarcinoma associated with 
autoimmune pancreatitis. Case Rep Gastroenterol 2011;5:378-85.

sUmmArY AND GeNerAL DIsCUssION
C H A P T E R  9

127
Summary and general diScuSSion
9
INTrODUCTION
Autoimmune pancreatitis (AIP) is a novel type of chronic pancreatitis, which is increasingly 
being recognized. There are two different subtypes. Type 1 represents the pancreatic 
manifestation of a systemic, IgG4-related disease (IgG4-RD), which can involve other 
organ systems. It is the most common form and relapses are frequently observed. Type 2 
is pancreas-specific, not associated with elevated serum IgG4, and rarely causes relapses. 
Clinically, AIP mimics pancreatic cancer, with painless obstructive jaundice and weight loss 
as most common symptoms. Unlike other types of pancreatitis, AIP responds dramatically to 
steroid therapy. A timely diagnosis is of utmost importance, to provide proper treatment and 
avoid unnecessary interventions and complications. 
Chapter 1 provides an introduction. Here, we discuss the clinical profile of AIP and give an 
overview on current treatment options. Furthermore, we present the aims and outline of this 
thesis; to study the diagnostic process, treatment, and outcome of this disease.
mAIN FINDINGs
AIP cohort
To do so, in chapter 2, we describe the characteristics of a group of 114 AIP patients, retrieved 
from a prospectively maintained database that was established by three tertiary referral centers 
(Rotterdam, Amsterdam, Utrecht), in cooperation with several other hospitals. The median age 
of these patients was 62 years and 87% were men. The most common presenting symptoms 
were obstructive jaundice (76%) and weight loss (88%). Furthermore, mild abdominal pain 
(54%) and signs of endocrine and exocrine pancreatic insufficiency (35% and 75%, respectively) 
were reported frequently.
Diagnostic scoring systems
As the clinical presentation of AIP resembles pancreatic carcinoma, establishing the diagnosis 
can be challenging. Several diagnostic scoring systems have been proposed that combine 
radiological, histological, and serological evidence of AIP, other organ involvement, and 
response to therapy1-3. The most commonly used are scoring systems from the United States 
(HISORt) and Asia (Asian criteria). Recently, an international panel of experts developed a new 
set of criteria, the International Consensus Diagnostic Criteria (ICDC), which combines features 
from the HISORt and Asian criteria. 
In chapter 2, we evaluate the performance of these three diagnostic scoring systems in our 
AIP cohort. These scoring systems were applied retrospectively, using data obtained during the 
original diagnostic phase, to mimic clinical practice. Although the majority of patients fulfilled 
the requirements of one or more scoring systems, 21 (18%) did not, even though these patients 
had an unchallenged diagnosis of AIP. The systems proved to be complementary, rather than 
overlapping. In accordance with previous reports, the best result was achieved by the ICDC, 
with 68% of patients fulfilling the requirements, followed by the HISORt (52%) and Asian 
criteria (33%)4-6. 
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The ICDC are the only criteria distinguishing type 1 and 2 AIP. However, as the definition 
of type 2 is based solely on histology, which is not always available, this can lead to under-
recognition of type 2. Furthermore, their clinical applicability is limited, due to their complexity. 
Based on these facts, we primarily recommend the use of the HISORt criteria, and advice to use 
the Asian criteria, if a pancreatogram is available. If the diagnosis cannot be confirmed by either 
of these systems, the ICDC can be used. Further studies should evaluate the specificity of the 
diagnostic criteria, to assess the risk for false-positivity.
Diagnostic markers
As AIP is difficult to distinguish from pancreatic cancer, reliable diagnostic markers are 
desperately needed. In chapter 3, we report the diagnostic value of the tumor marker Ca19-9, in 
differentiating AIP from other pancreatobiliary disorders. We compared serum samples from 33 
patients with AIP, 53 with pancreatic carcinoma, and 145 with other pancreatobiliary disorders. 
Indeed, we found that patients with AIP have lower levels of Ca 19-9 and higher levels of IgG4 
than those with pancreatic carcinoma. However, the diagnostic value of Ca19-9 and IgG4 alone 
was limited, because a marked overlap exists between the two disorders. 
Our study showed that high levels of Ca19-9 (ranging from 5000-23000 U/ml) did not rule 
out AIP. Furthermore, elevated Ca19-9 levels were almost twice as common in AIP patients than 
previously reported. Although, individually, neither test was accurate enough to distinguish AIP 
from pancreatic cancer, the two tests combined reached a sensitivity of 94% and a specificity 
of 100%. This emphasizes the importance of combined Ca19-9 and IgG4 testing, when AIP is 
considered. Currently, the IgG4 upper limit of normal is set on 1.4 g/L, even though our data 
(in line with other reports) show that only levels above 2.6 g/L are 100% specific for AIP7. To 
prevent pancreatic carcinoma patients with mildly elevated IgG4 levels to be misdiagnosed as 
AIP, we suggest raising this upper limit of normal.
Elevated serum IgG4 is one of the main characteristics of AIP and is incorporated in all 
diagnostic scoring systems. However, particular caution is warranted in interpreting elevated 
levels of IgG4, since they are also encountered in other disorders, including chronic pancreatitis 
and primary sclerosing cholangitis. In chapter 4, we compared serum IgG4 levels in patients 
with acute, chronic, and autoimmune pancreatitis. In total, samples from 174 patients were 
evaluated; 32 with AIP, 90 with acute pancreatitis (AP) and 52 with chronic pancreatitis (CP). 
Our results showed that elevated IgG4 levels occurred in almost one out of ten AP patients 
and one out of five CP patients. However, in AP and CP, IgG4 levels rarely exceeded twice 
the upper limit of normal. Therefore, this study emphasizes increasing the cut-off value to 
diagnose AIP as well. We found that none of the other IgG subclasses could compete with IgG4 
as individual predictor of AIP. However, in mildly elevated IgG4 (1-2x ULN), the IgG4/IgG2 ratio 
can substantially improve the positive predictive value.
In 2009, an Italian study identified a novel serologic marker, anti-PBP antibodies, with an 
outstanding sensitivity and specificity for diagnosing AIP, described in the New England Journal 
of Medicine8.  We aimed to validate these results in our own cohort of AIP patients in chapter 5. 
To do so, we set up an ELISA assay, which sensitively and reliably measured reactivity against the 
AKEERRY peptide. Subsequently, we tested 34 patients with AIP, 29 with pancreatic carcinoma, 
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17 with CP, 16 with primary sclerosing cholangitis, 9 H.pylori negative healthy controls and 9 
H.pylori positive healthy controls. However, no significant difference in detection of antibodies 
against the PBP peptide was found among the different patient groups or healthy controls. 
Therefore, we concluded that this is not a useful diagnostic tool to diagnose AIP.
IgG4-related disease and its pathogenesis
Type 1 AIP represents the pancreatic manifestation of a systemic, IgG4-related disease. Other 
organs are involved in approximately half of the patients and, up to now, a wide range of 
organ-localizations has been reported, from biliary to prostatic involvement. Other organ 
involvement can precede, coincide or follow the presence of pancreatitis. In contrast to other 
autoimmune disorders, patients with IgG4-RD are typically male and over 50 years old. Mostly, 
IgG4-RD has a subclinical presentation with mild symptoms, and is diagnosed coincidentally by 
the radiologist. However, it may cause severe symptoms and even organ failure9,10.
In our AIP cohort, we identified nine patients with IgG4-related prostatitis. In chapter 6, we 
described their clinical and histological characteristics, and compared the presence of IgG4-RD 
features in prostatic tissue with 18 prostatitis control patients. This showed that infiltration of 
IgG4 positive plasma cells and an increased number of eosinophils were indicative for IgG4-
related prostatitis. In two patients, prostatic symptoms improved after steroid therapy, which 
was given for AIP. Therefore, we advise to actively look for these features, to identify a subgroup 
of prostatitis patients, for whom steroid therapy may be beneficial. 
The pathogenesis of IgG4-RD is still poorly understood and is most likely multifactorial. 
Given the infiltration of plasma cells in the affected tissue, and the excellent response to steroid 
therapy, an immune-mediated disorder was soon considered. A likely mechanism is that the 
disease develops in genetic susceptible persons, after exposure to certain triggers. 
Whether serum IgG4 is pathogenic or an innocent bystander of the inflammatory response 
in IgG4-RD remains unknown. There is no linear association between symptoms and the 
level of serum IgG4. Also, serum IgG4 may remain elevated after therapy and resolution of 
symptoms, which suggests only a secondary role of IgG4. Furthermore, there are other clinical 
conditions associated with elevated serum IgG4, in which a protective effect is suspected, such 
as maintenance of food tolerance in atopic individuals and patients who underwent bee-venom 
immunotherapy11,12. 
However, a recent study from Amsterdam demonstrated that in patients with IgG4-related 
autoimmune cholangitis (IAC), IgG4-positive B-cell clones are abundantly present in both 
serum and inflamed tissue, compared to healthy and disease controls13. This suggested an 
antigen-driven immune response. In search for a causative agent leading to chronic antigenic 
stimulation, they noticed that the majority of their cohort had a history of blue collar work, which 
was validated in a second, independent cohort14. Chronic exposure to toxic dusts, industrial oils 
and paint for example could therefore provide an environmental trigger. Further support for 
the role of B-cells in the pathogenesis of IgG4-RD, is the swift improvement of symptoms after 
B-cell depletion therapy with rituximab in patients refractory to steroid therapy15.
Furthermore, in a recent British study, serum IgG4 antibodies in patients with melanoma 
have been described to promote tumour progression, by contributing to a defective anti-
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tumour immune response16. Chronic exposure to tumor antigens is suggested to induce this 
extensive IgG4 antibody production by B-cells, and elevated levels of serum IgG4 appear to 
be a negative predictor of progression-free and overall survival in these patients17. The authors 
further suggest that this knowledge might contribute to improved patient stratification and 
optimal personalized therapies.
Treatment
The first therapeutic step in AIP is to induce clinical remission with steroids. Patients with AIP 
show a dramatic response to steroid therapy, with response rates of nearly 100%. Currently, the 
recommended induction dosage is 30-40mg/day, however, this is largely based on empirical 
data and lacks a scientific basis. Whether a lower dose would evoke the same response is 
unclear, but could potentially prevent patients from the well-known side effects of high dose 
steroids. Therefore, in chapter 7, we retrospectively compared the efficacy of dosages ranging 
from 10 to 60 mg/day. Surprisingly, we found clinical, biochemical, and radiological responses 
to be comparable. These results await confirmation, ideally by controlled trials comparing the 
efficacy and tolerance of low- and high-dose induction corticosteroid therapy, although such a 
study would be difficult to perform. 
Although remission induction is easy in AIP, treatment may be complicated, because 
recurrences are common and maintenance therapy may be necessary in some patients. After 
the first relapse, azathioprine is often added, after which steroids are tapered. However, some 
patients report treatment-limiting side effects and further studies are needed to define the 
role of azathioprine as maintenance therapy. Recently, rituximab has been suggested as an 
effective alternative for patients with difficult-to-treat, relapsing AIP, but this requires further 
investigation18.
Long-term outcome
Since AIP is a newly recognized disease entity, little is known about the long-term consequences. 
In chapter 8, we study the long-term outcome of AIP, in terms of of treatment response, 
pancreatic function, quality of life, risk of pancreatic cancer, and mortality. We found that, 
despite an initial excellent treatment response, recurrences were common and almost half of 
AIP patients required long-term maintenance therapy. 
Furthermore, the prevalence of exocrine and endocrine insufficiency in our cohort was 
striking, 82% and 57%, respectively. Pancreatic insufficiency in AIP patients has been described 
before, but our prevalences were much higher than earlier reported19,20. This might be explained 
by the prospective nature of our study, as a significant number of patients was diagnosed by 
tests carried out as part of the study protocol. This suggests that pancreatic insufficiency is 
significantly under-diagnosed in AIP patients. We therefore recommend active screening for 
pancreatic insufficiency, as this can result in severe complications. 
Surprisingly, AIP did not have a negative impact on the quality of life. Given the diagnostic 
difficulties and confusion with pancreatic cancer, it seemed reasonable to assume that AIP 
might have a negative long-term influence. However, although almost half of the patients 
still used immunosuppressive therapy and most suffered from pancreatic insufficiency, the 
long-term quality of life was not impaired. 
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Finally, we also evaluated the risk for pancreatic cancer and the impact on mortality. 
Other forms of pancreatitis harbour an increased risk for pancreatic cancer, and the same 
association has been reported for AIP27,28. However, none of the patients in our cohort 
developed pancreatic cancer and the general cancer risk was not different from an age- and 
sex-matched Dutch reference population. Possibly related, survival of AIP patients, compared 
to a reference population, was not impaired either. Future follow-up studies are needed to 
confirm our findings.
CONCLUsIONs AND FUTUre PrOsPeCTIVes
Although in the past decade, clinical features and treatment of AIP and IgG4-RD have been 
further elucidated, the pathogenesis remains largely unclear. Different roles for IgG4 have been 
suggested, from pathogenic to that of an innocent bystander. A better understanding of the 
pathogenesis could lead to more targeted therapies. 
Diagnostic markers are still urgently needed, especially to differentiate AIP from pancreatic 
cancer and to prevent redundant investigations or even major surgery. Regarding AIP and 
IgG4-RD treatment strategies, prospective randomized studies are needed to generate 
evidence-based data. However, these studies will be difficult to complete, as this is a rare 
disease and large numbers of patients are needed.  For this reason, international collaborations 
are crucial. 
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Introductie
De alvleesklier (‘pancreas’ in het Latijn) is een worstvormig orgaan dat zich bevindt in de 
buikholte, net achter de maag. Het heeft twee belangrijke functies; het produceren van 
spijsverteringssappen en de regulatie van de bloedsuikerspiegel, door afgifte van hormonen. 
De alvleesklier kan ontstoken raken, hetgeen ‘pancreatitis’ genoemd wordt. Dit proefschrift 
gaat over een zeldzame vorm van alvleesklierontsteking, namelijk autoimmuun pancreatitis 
(afgekort ‘AIP’). Pas de laatste 15 jaar is er meer aandacht gekomen voor dit type pancreatitis, 
waarvan de oorzaak nog onbekend is. 
AIP heeft twee verschillende subtypes: type 1 en type 2. Type 1 komt het meest voor en 
is vaak onderdeel van een systeemziekte, die zich in verschillende organen kan presenteren. 
Deze ziekte wordt ook wel ‘IgG4-related disease’ genoemd, omdat het zich kenmerkt door een 
verhoogd gehalte van het antilichaam IgG4. Type 2 betreft alleen de alvleesklier en gaat niet 
samen met een verhoogd IgG4 gehalte. 
Patiënten met AIP ontwikkelen vaak geelzucht en gewichtsverlies. Deze klachten lijken op 
die van alvleesklierkanker, waardoor het voor artsen lastig is beide ziektebeelden van elkaar te 
onderscheiden. Echter, er is een belangrijk verschil; AIP is goed te behandelen met medicijnen, 
terwijl alvleesklierkanker meestal dodelijk is en alleen kan worden genezen door een operatie. 
Het is daarom extreem belangrijk om onderscheid te maken tussen de twee aandoeningen. 
Bijna alle patiënten met AIP reageren goed en snel op de behandeling met 
ontstekingsremmende medicijnen, ook wel steroïden genoemd. Deze behandeling wordt 
meestal weer gestopt als de ziekteverschijnselen zijn verdwenen. Bij een deel van de 
patiënten (met name met type 1 AIP) komen de klachten echter weer terug, waarvoor een 
onderhoudsbehandeling wordt voorgeschreven. 
Om onderzoek te kunnen doen naar dit ziektebeeld hebben wij een grote hoeveelheid 
gegevens van AIP patiënten verzameld in een database. Hierin zijn allerlei eigenschappen van 
patienten vastgelegd, zoals de klachten waarmee ze zich presenteerden en de afwijkingen die 
zij hadden bij aanvullend onderzoek. Daarnaast hebben we ook de reactie op behandeling en 
de lange termijn gevolgen bijgehouden. 
Belangrijkste resultaten
In hoofdstuk 1 worden de doelen en de inhoud van dit proefschrift besproken. Daarnaast 
wordt een algemeen overzicht gegeven van AIP, met onder andere de symptomen, 
behandelingsmogelijkheden en eventuele onderwerpen voor toekomstig onderzoek. 
Het stellen van de diagnose AIP is moeilijk. Er zijn verschillende combinaties van diagnostische 
criteria bedacht om AIP te kunnen onderscheiden van andere alvleesklieraandoeningen. 
In hoofdstuk 2 vergelijken we de bruikbaarheid van drie van deze samengestelde criteria in 
een cohort van 114 AIP patiënten. Hoewel in 82% de diagnose met één of meerdere systemen 
bevestigd kon worden, gold dit niet voor de overige 18% van de patiënten; zij voldeden aan 
geen van de drie definities. 
Omdat de symptomen van alvleesklierkanker en AIP gelijk zijn, zou een onderscheidende 
test, bij voorkeur een simpele bloedtest (serum marker), heel waardevol zijn. In hoofdstuk 3 
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onderzoeken we twee serum markers: Ca19-9 en IgG4. Ca 19-9 is een tumormarker, die vaker 
verhoogd is bij alvleesklierkanker, en IgG4 is een antilichaam dat vaak verhoogd is bij AIP. 
Zoals we verwachtten, hadden AIP patiënten een hoger IgG4 gehalte en een lager Ca 19-9 
dan patiënten met alvleesklierkanker. Geen van deze tests bleek echter betrouwbaar genoeg 
om AIP te onderscheiden van alvleesklierkanker. Wanneer beide tests gecombineerd werden 
daarentegen, maakten ze wel voldoende onderscheid. 
In hoofdstuk 4 hebben we IgG4 bloedspiegels vergeleken van patiënten met verschillende 
vormen van alvleesklier ontsteking: acute, chronische en autoimmuun pancreatitis. Ondanks 
dat een verhoog IgG4 een belangrijk kenmerk van AIP is, bleek dit ook voor te komen bij 
één op de tien patiënten met acute pancreatitis en één op de vijf patiënten met chronische 
pancreatitis. IgG4 waardes die meer dan 2x verhoogd waren, kwamen maar zelden voor 
bij andere aandoeningen dan AIP. Licht verhoogde IgG4 waardes moeten dus zorgvuldig 
geïnterpreteerd worden om niet de verkeerde diagnose te stellen. Daarnaast zou ons advies 
zijn, om de afkapwaarde van een normale IgG4 waarde te verhogen.
In 2009 werd in een Italiaanse studie een nieuwe marker voor AIP beschreven, anti-PBP 
antilichamen, die zeer nauwkeurig leek te zijn. In hoofdstuk 5 beschrijven we een laboratorium 
opzet, waarmee we betrouwbaar reactiviteit tegen PBP antilichamen meten in ons eigen 
cohort van AIP patiënten. Er werden echter geen verschillen in reactiviteit gevonden 
tussen de verschillende patiënten groepen. Deze test blijkt daarmee onbruikbaar om AIP te 
diagnosticeren. 
In hoofdstuk 6 beschrijven we een reeks patiënten met type 1 AIP, bij wie de systeemziekte 
ook in de prostaat voorkomt. We hebben prostaat weefsel van deze patiënten vergeleken met 
weefsel van een controlegroep met een ander type prostaatontsteking. Wat opviel, is dat een 
aantal kenmerken vaker voorkwam bij AIP patiënten, namelijk IgG4-positieve cellen en een 
verhoogd aantal eosinofielen (een speciaal type witte bloedcellen). 
Patiënten met AIP reageren in het algemeen goed op een behandeling met steroïden. 
Hoewel er geen wetenschappelijk onderzoek gedaan is naar welke dosis het beste werkt, 
wordt in de praktijk meestal 30-40 milligram per dag gegeven. Aangezien steroïden forse 
bijwerkingen kunnen geven, onderzochten wij in hoofdstuk 7 of een lagere dosering net zo 
effectief is. We concludeerden dat de reactie op deze behandelingen vergelijkbaar was.
In hoofdstuk 8 hebben we de gevolgen van AIP op de langere termijn onderzocht. Omdat 
AIP relatief kort geleden als aparte ziekte werd ontdekt, is hierover nog weinig bekend. Wij 
kwamen tot de conclusie dat, ondanks een goede eerste reactie op behandeling, de ziekte 
vaak terugkomt, en bijna de helft van de patiënten een onderhoudsbehandeling nodig heeft. 
In ons cohort heeft niemand alvleesklierkanker ontwikkeld, maar bleek de functie van de 
alvleesklier bij meer dan driekwart van de patiënten sterk verminderd. Hun kwaliteit van leven 
en overleving was echter niet anders dan van de gemiddelde Nederlandse bevolking. 
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